ABSTRACT

There is increasing evidence of an association between cancer and diabetes mellitus. Patients with type II diabetes are at increased risk of malignancy due to shared risk factors between the two conditions, and people with a diagnosis of cancer may develop new onset diabetes or impaired glycemic control, partly as a result of the systemic anti-cancer treatments (SACT) they receive. Many newer targeted anti-cancer treatments can have off-target metabolic toxicities not seen with conventional chemotherapy agents. Early recognition of diabetes or hyperglycemia in people with cancer can improve outcomes. This chapter aims to summarize these associations, provide an overview of how different SACT modalities can impact on glycemic control, and highlight key recommendations for the management of this complex patient group.

INTRODUCTION

Diabetes mellitus (DM) is a rising global public health emergency, with recent estimates suggesting that over 780 million people globally will be affected by 2045 (1). DM is typically classified into broad categories including type 1 (T1DM), type 2 (T2DM), gestational, monogenic, pharmacologically-induced, endocrinopathy-driven and DM due to pancreatic disease/deficiency (sometimes referred to as type 3c) (2, 3). T2DM is regarded as the most common subtype and is reported to account for over 85% of cases (1). All types of DM can lead to multisystem microvascular (nephropathy, retinopathy, neuropathy) and macrovascular (ischemic heart disease, stroke and peripheral vascular disease) complications, with management of these complications placing a strain upon many health services.

People with a diagnosis of DM are also at higher risk for developing several cancers (4), with reasons for this in part due to shared risk factors between the two, including age, obesity, sedentary lifestyle, and diet (5,6). A recent umbrella review of meta-analyses found that risks of developing most cancers were higher in people with DM compared to those without, with the most convincing evidence seen in breast cancer, intrahepatic cholangiocarcinoma, colorectal cancer, and endometrial cancer. One exception in this study was prostate cancer, where the risk appeared lower in individuals with DM (4). In view of this increased cancer risk in people with DM, some groups even advocate that regular screening for underlying cancer should be part of routine DM assessments (7).

It is estimated that approximately 20% of people with cancer have concurrent diabetes (8). Individuals with cancer are also at an increased risk of developing new onset DM or hyperglycemia, independent of an underlying diagnosis of diabetes, whilst cancer patients with concurrent DM often experience worsening glycemic control (9). Reasons for poor glycemic control in these individuals include complications from systemic anticancer treatments (SACT) along with supportive medications to treat treatment side effects, and symptoms of the underlying malignancy. This chapter aims to summarize the complex relationship between malignancy and DM, particularly the effects of SACT on glycemic control and risk of DM, as well as outlining management guidelines for DM in people with cancer.

DIABETES/HYPERGLYCEMIA AND CANCER OUTCOMES                       

A number of observational studies have demonstrated that hyperglycemia is associated with poorer overall survival (OS) and increased risk of disease recurrence in a number of malignancies, solid and hematological (10-17), with a number of individual studies, and larger meta-analyses supporting this. One meta-analysis reviewed 12 studies comprising 9,872 people with a diagnosis of cancer without known diabetes. Individuals with hyperglycemia were found to have significantly worse disease-free survival (DFS) (hazard ratio (HR) 1.98, 95% confidence interval (CI) 1.20-3.27) compared to those without, as well as worse OS (HR 2.05, 95% CI 1.67-2.551) (18). A further meta-analysis of 4,241 patients with pancreatic cancer suggested that those individuals with concurrent DM (1,034) have poorer OS (HR 1.16, 95% CI 1.08-1.25) and a higher risk of on-treatment death than those without concurrent DM (19). Furthermore, in a meta-analysis of 8 studies in breast cancer, concurrent DM was found to confer a greater risk of death, and a later stage at presentation, as well as impact on the treatment given (20). People with DM also have a higher prevalence of oral cancers, as well as a higher mortality from these cancers (21).

In addition to this, a number of preclinical studies have suggested that hyperglycemia may specifically attenuate the efficacy of chemotherapy in people with cancer with or without diabetes, which could in part account for these observations (22). For example, hyperglycemia may attenuate chemotherapy-induced reactive oxygen species (ROS) production, which in-turn can diminish the efficacy of treatment (23). In vivo, there are some small series that have demonstrated an association between hyperglycemia and resistance to chemotherapy. A clinical study of 88 people with estrogen-receptor positive breast cancer demonstrated impaired glucose tolerance significantly correlated with disease progression in those patients receiving chemotherapy (24). Furthermore, high blood glucose levels irrespective of an underlying DM diagnosis, were shown to significantly enhance oxaliplatin resistance in individuals with stage III colorectal cancer receiving adjuvant chemotherapy (22). Studies such as these highlight the importance of adequate glycemic control during treatment for cancer to potentially improve outcomes, although these data are mainly from observational studies, with interventional studies lacking.

EFFECT OF DIABETES OR HYPERGLYCEMIA ON QUALITY OF LIFE IN PEOPLE WITH CANCER

Cancer-related symptoms and SACT side effects, such as fatigue, nausea, anorexia and pain can be debilitating to patients. When confounded by symptoms of hyperglycemia, the impact upon an individuals’ quality of life can be significant (25). Furthermore, the impact of a cancer diagnosis, as well as treatment and cancer-related symptoms can have major negative impacts on diabetes self-care (26), with data suggesting that adherence to glucose lowering drugs often decreases in individuals following a cancer diagnosis (27). A cancer diagnosis can also have financial and social impacts upon individuals, affecting access to healthy food and outpatient diabetes services, resulting in lower quality of life and a higher symptom burden (28). A systematic review of 10 studies, demonstrated poorer patient reported outcomes (PROs) in those diagnosed with both cancer and DM compared to having either one of these diseases alone (29).

DIABETES AND RISK OF TREATMENT RELATED TOXICITY

People with DM are known to be at higher risk from infections, and undergoing SACT can exacerbate this, resulting in higher rates of infection and hospitalization observed in those with cancer and DM (30, 31). This in turn leads to higher rates of chemotherapy dose reductions and early treatment cessation (28, 32-34). A meta-analysis of 10 observational studies involving 8,688 cases found that the likelihood of developing chemotherapy-induced neutropenia was higher amongst individuals with DM/hyperglycemia than those without (odds ratio (OR) 1.32, 95% CI 1.06-1.64) (31). Chemotherapy-induced neutropenia poses a significant risk for infection and hospitalization in all people with cancer, with an associated rate of morbidity and mortality which is higher in those with raised blood glucose levels (30). In addition to severe hematological toxicity, more severe rates of non-hematological toxicity have also been associated with hyperglycemia during chemotherapy in people with prostate cancer and lymphoma (35). A single-center retrospective analysis found that individuals with cancer and DM who had good glycemic control had no increased risk of treatment-related complications compared with individuals without DM (36), suggesting that optimal glycemic control during SACT could improve tolerability, thereby reducing rates of admission and dose-limiting toxicity.

Conceivably, people with DM may be more prone to neuro- and nephrotoxic agents due to their underlying predisposition conferred by the DM. Indeed, a previous report suggested that taxane-based chemotherapy regimens resulted in a significantly higher rates of peripheral neuropathy in those with DM compared to those without (74.4% vs. 58.5%) (37). There are no convincing data to suggest that a concurrent cancer diagnosis accelerates the risk of diabetic nephropathy or retinopathy.

EFFECTS OF SYSTEMIC ANTICANCER THERAPIES ON GLYCEMIA  

Systemic anti-cancer therapies (SACT) encompass a wide range of treatments including cytotoxic chemotherapy, hormone therapy, targeted therapy, and immunotherapy, many of which can impact upon glycemic control directly or as a result of toxicity management or supportive medications which are given alongside treatment. Several anti-cancer agents have been demonstrated to increase the risk of hyperglycemia as summarized in Table 1, and many can do this even in those without a known diagnosis of DM. People receiving SACT are also at risk of developing a new diagnosis of diabetes. One study demonstrated that 11% of people (15/134) undergoing routine chemotherapy met the criteria for a new diagnosis of diabetes (using the diagnostic criteria as per guidelines from the UK National Institute for Clinical and Healthcare Excellence (NICE) and without a previous known diagnosis) based upon HbA_1cmeasurements). The majority of these individuals (73%) had been receiving short course steroids with chemotherapy, and 40% were being treated in the curative/adjuvant setting (38). A second prospective cohort study in 90 people taking glucocorticoids as part of therapy protocols for primary brain tumor or metastases, lymphoma, or for bone marrow transplant, found non-DM range hyperglycemia in 58% and DM-range hyperglycemia in 18.9% (39). These individuals with hyperglycemia are also more likely to present with an emergency admission during cancer therapy than those with normoglycemia (40).

Abbreviations: ADT = androgen deprivation therapy; ALK – anaplastic lymphoma kinase; ATO – arsenic trioxide; CTLA-4 – cytotoxic T-lymphocyte protein-4; EGFR – epidermal growth factor receptor; FLT3 – FMS-like tyrosine kinase-3; ICP – immune checkpoint inhibitor; TKI – tyrosine kinase inhibitor; mTOR – mechanistic target of rapamycin; PI3K – phosphoinositide-3 kinase; PD-1 – programmed cell death protein-1; T1DM – type 1 diabetes mellitus; T2DM – type 2 diabetes mellitus

Cytotoxic Chemotherapy

Hyperglycemia occurs in between 10 and 30% of people undergoing cytotoxic chemotherapy for malignancy (74), and although often transient during treatment, can persist, or even lead to DM in some people. Poor glycemic control can increase the risk of infections and hospitalization (28, 34), as previously discussed, leading to treatment interruptions and dose reductions, as well as significant morbidity, and even mortality (33). A number of cytotoxic chemotherapy regimens are reported to cause hyperglycemia in people without diabetes, including commonly used drugs such as 5-fluorouracil (5-FU), platinum-based drugs (oxaliplatin, carboplatin, cisplatin) and anthracyclines (doxorubicin, epirubicin) (75). In one cohort study of 422 people receiving 5FU-based chemotherapy regimens for the treatment of early or advanced colorectal cancer, 11.6% (42 people) developed diabetes and a further 11.3% developed impaired fasting blood glucose (FBG) levels. Of the 42 people who developed diabetes, 7 required no treatment, 13 received diet control and physiotherapy only, and 22 received antidiabetic medication (75). In a second cohort of 185 people with head and neck cancer treated with platinum-containing regimens, 3.8% developed type 2 DM, with 3 presenting with hyperglycemic crises (DKA, HHS) (65). One possible contributing factor for developing impaired FBG levels and/or type 2 DM is the concurrent use of corticosteroids in highly emetogenic chemotherapy regimens, but an analysis of type 2 DM following anthracycline use in 3,147 lymphoma patients suggested that the use of these drugs independently increases the risk of T2DM, when data was adjusted for corticosteroid use, comorbidities, age, and gender. A threshold doxorubicin dose of 253mg was identified, below which there was no increased risk of developing T2DM (76). Risk of diabetes from cytotoxic chemotherapy may also increase with age, with one pediatric study suggesting that the risk was higher in acute lymphoblastic leukemia (ALL) patients aged > 10, compared with those < 10 years old (77).

Exact mechanisms of how and why some cytotoxic chemotherapies can lead to hyperglycemia or T2DM remain unclear. Proposed mechanisms include the induction of an inflammatory state which predisposes to hyperglycemia (78) or direct metabolic effects on tissues vital to glucose homeostasis such as skeletal muscles (79).

Oral Targeted Anticancer Agents

Many new targeted cancer therapies inhibit various points in the insulin receptor signaling pathway including the commonly used class of tyrosine kinase inhibitors (TKIs) (80). Reported effects of targeted TKIs on blood glucose metabolism range from the development of metabolic syndrome and diabetes via the blocking of insulin signaling (80), as well as erratic glycemic control and even hypoglycemia in those with pre-existing type 1 or type 2 DM49, (81, 82). In contrast some TKIs may improve glycemic control suggesting that management of these individuals needs to be individualized with no one-size-fits-all management algorithm. Reversibility of these effects is also unclear, with reported improvements in glycemic control and HbA1c levels following dose reductions or treatment termination (83).

Inhibitors of mTOR (everolimus, temsirolimus or ridaforolimus) have also been shown to impact glycemic control since mTOR is a protein kinase that plays a key role in regulating cell growth as well as lipid and glucose metabolism (84, 85). Meta-analyses looking into these effects have demonstrated significantly higher rates of hyperglycemia, hypercholesterolemia, and hypertriglyceridemia compared with controls (86, 87) In isolated cases, the effects have been severe enough to precipitate DKA (88). To date, studies have not demonstrated either positive or negative associations between treatment response rates and incidence of metabolic complications (89).

As novel targeted agents continue to be introduced to manage a range of cancers, it is expected that metabolic toxicities continue to be reported given the homeostatic function of many of these druggable targets. Whilst some of these agents will provide meaningful benefit in terms of survival for people with advanced cancers, such as the PI3Kainhibitor alpelisib for PI3KA-mutated metastatic breast cancer (43), glycemic control needs to be at the forefront of the prescriber’s mind at initiation, to ensure adequate management of toxicities.

Hormone Therapy

ANDROGEN DEPRIVATION THERAPY

Androgen deprivation therapy (ADT) is recognized as a risk factor for development of diabetes, metabolic syndrome, and cardiovascular disease (72, 90, 91). In a large observational study of over 35,000 men treated for prostate cancer, ADT in the form of gonadotropin-releasing hormone (GnRH) agonists, oral antiandrogens, a combination of the two, or orchiectomy was associated with a significantly increased risk of diabetes, coronary heart disease, myocardial infarction, and sudden cardiac death (90). These findings are supported by other studies, including a meta-analysis of over 150,000 men with prostate cancer receiving ADT (72), with association observed with all forms of ADT, with the weakest association with anti-androgen therapy alone.

ESTROGEN TARGETED THERAPY

Studies examining the effect of estrogen-targeted therapies on the development of diabetes in women with breast cancer are less clear cut. Whilst one retrospective cohort analysis failed to demonstrate a link between tamoxifen use and the development of DM (92), two large population-based studies demonstrated a significant association between tamoxifen use and the development of diabetes in women diagnosed with breast cancer (73, 93); The first of these studies included almost 15,000 Canadian women aged 65 years or older diagnosed with early breast cancer, whilst the second included over 22,000 women in Taiwan aged 20 years and over. Whilst tamoxifen appears to increase the risk of developing DM, aromatase inhibitor therapy does not, with no link found in any of these three studies.

Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICPi), including cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PDL-1) inhibitors are a sub-class of monoclonal antibody treatments that have revolutionized cancer treatment over the last decade. First approved for use in the treatment of melanoma, ICPi are now recognized as providing a survival benefit across a number of cancers, and are increasingly used in early-stage cancers in the adjuvant setting and also in combination with chemotherapy (94). Whilst clinically effective, ICPi can lead to a spectrum of immune-related adverse events (IRAEs). Endocrine IRAEs include hypophysitis, thyroiditis, adrenalitis and de novo diabetes. The risk of developing de novo diabetes is low, occurring in 0.2-4% of ICPi treated individuals depending on the immunotherapy given (69). The immune checkpoint PD-1 and its ligand PD-L1 have been shown to have an important immune homeostatic function in the pancreas by promoting beta cell maturation and preventing immune-mediated beta cell destruction (95). To date, there is no convincing evidence for a physiological role for CTLA-4 within the pancreas. PD-1 inhibitors, PD-L1 inhibitors, and combination CTLA-4/PD-1 therapy have been demonstrated to precipitate diabetes more commonly than CTLA-4 inhibitors alone. The underlying clinical presentation is akin to type 1 diabetes (70) and believed to be precipitated by inappropriate activation of self-reactive T-cells and destruction of insulin-producing pancreatic islet β-cells. ICP-induced insulin deficiency may lead to new-onset insulin-dependent diabetes or worsening pre-existing type 2 diabetes. Up to 75% of people who develop ICP-induced hyperglycemia/diabetes present with diabetic ketoacidosis (DKA) (96-98). Presentations are frequently acute with a precipitous increase in blood glucose (99). Therefore ICP-induced diabetes can be discriminated from ‘standard’ type 1 diabetes mellitus, by its tendency towards a faster onset, apparently fulminant course, and high degree of antibody negativity (99). The nomenclature of the condition in the published literature varies mainly between ‘type 1 like’ to ‘fulminant’ with there being differences between the presentation of ICPi-induced diabetes and type 1 and fulminant diabetes. Kyriacou and colleagues compared the characteristics of 75 published cases and concluded that there is some overlap with type 1 DM and fulminant DM. However, this was felt to be insufficient overlap for ICPi diabetes to be wholly classified as either type 1 like or fulminant (100). Nevertheless, the recognition that these agents can precipitate rapid beta cell destruction which results in an unusually high number of emergency presentations is key. Treatment of non-endocrine IRAEs is typically with high dose steroids, often for prolonged periods of time. At present, steroids are used in up to a third of people receiving ICPs, further increasing the risk of hyperglycemia, and steroid induced T2DM.

An analysis of the World Health Organizations (WHO) pharmacovigilance database over a 4-year period detected 283 cases of ICP-induced diabetes mellitus, 50.2% of which presented with DKA, and 6% of whom were on concurrent steroids at diagnosis (101). There was a wide variability in duration of ICP treatment, and timing of DM onset, occurring even up to 8 months after cessation of ICP treatment. A systematic review of 90 cases, demonstrated a diagnosis of DM on average after 4.5 cycles of ICP (102). C-peptide levels were usually low or undetectable at diagnosis, islet autoantibodies were positive in 53%, with a predominance of glutamic acid decarboxylase antibodies, and susceptible HLA genotypes present in 65% (102). HbA1c levels were relatively low, consistent with the observed rapid onset of beta cell inflammation. Importantly, an elegant albeit small single-center study, used radiological and biochemical phenotyping to demonstrate that ICPi DM is irreversible (103). This has important clinical implications such that any individual diagnosed with ICPi-induced DM should be counselled around an expected life-long requirement of insulin.

Glucocorticoid (Steroid) Treatment

Glucocorticoids (GC) increase insulin resistance and glucose production and inhibit the production and secretion of insulin by pancreatic beta cells, as well as acting centrally to counteract the appetite-reducing effects of insulin (104). As such they are commonly associated with the development of hyperglycemia and diabetes. GCs have a direct hyperglycemic effect which starts very early after ingestion (105, 106). They typically cause an increase in blood glucose levels 4-8 hours after ingestion leading to a peak blood glucose level between midday meal and evening meal (106, 107). One in ten people not known to have diabetes develop GC-induced diabetes (108) an effect which is dose dependent (109). The incidence of glucocorticoid-induced hyperglycemia has been shown to occur in up to 30% of individuals without diabetes (110), but could be as high as 50%. The consequences of missing it can lead to significant harm, including the development of Hyperosmolar Hyperglycemic State (HHS), hospitalization, and in extreme circumstances, death. In a single center UK prevalence study 12.8% (120/940) of inpatients were found to be on glucocorticoids, however only 20.5% of these individuals (25/120) had their blood glucose levels measured during admission, demonstrating how infrequently glucose is measured in hospital (111). It is important to ensure that if glucocorticoid (steroid) induced hyperglycemia does occur, it is picked up early.

The use of GCs, is common in advanced cancer, to reduce peri-lesional edema, relieve pain, control nausea, combat fatigue, or boost appetite. For oncological emergencies such as cerebral metastases, superior vena-cava obstruction (SVCO), or metastatic spinal cord compression (MSCC), high dose GC treatment is integral to patient management. Furthermore, GC treatments are the backbone of many hematological cancer treatment regimens, and are often used as supportive anti-emetic medications, or to prevent allergic reactions, in many solid tumor regimens (105), and, as discussed above, the main first-line treatment for the management of ICP toxicity. In one study, the incidence of glucocorticoid-induced diabetes was 20% in those with newly diagnosed gastrointestinal cancer following at least 3 cycles of highly or moderately emetogenic chemotherapy, including dexamethasone as a supportive medication. Furthermore, almost 60% of people in the study exhibited signs of insulin resistance and multivariate analysis showed a significant association between the cumulative dose of dexamethasone and the incidence of corticosteroid-induced diabetes (112). In a separate smaller study of 16 women without diabetes with ovarian or endometrial cancer receiving carboplatin/paclitaxel chemotherapy with dexamethasone as supportive care, almost all experienced elevated interstitial glucose levels with diurnal variation during the first five days of treatment (113). For those who receive prednisolone as part of a treatment regimen for hematological malignancies, rates of steroid-induced diabetes and hyperglycemia have been reported to be as high as 32.5% and 47% respectively, highlighting the scale of this issue (114, 115).

Supra-physiological doses of glucocorticoids approximate to a dose of prednisolone greater than 5mg per day – or an equivalent dose of the alternative synthetic GC (Table 2). With increasing dose of GC, the risk of potential hyperglycemia increases, and in people without pre-existing diabetes, a glucocorticoid dose equivalent of >12mg dexamethasone and longer acting steroids are associated with a greater degree of hyperglycemia (116). As duration of GC treatment increases, it becomes increasingly likely that hyperglycemia may not resolve once the GCs are withdrawn, with those groups at particular risk of developing glucocorticoid induced diabetes, shown in Table 3.

HYPOGYCEMIA IN PEOPLE ON SACT

Although anti-cancer therapies and glucocorticoid use lead predominantly to hyperglycemia, there are risks of hypoglycemia that require consideration. People at risk of hypoglycemia should be counselled on the signs and symptoms to be aware of, and of the requirement to inform the driver and vehicle licensing agency should they experience any episodes of hypoglycemia requiring third party assistance.

Poor oral intake and nausea/vomiting from the underlying cancer or treatments put individuals at increased risk of hypoglycemia. Poor glycemic control can cause weight loss and precipitate nutrition impact symptoms (NIS) such as nausea, poor appetite, and altered bowel movements, further increasing the risks of hypoglycemia, particularly when dietary intake has been poor for some time. People with diabetes on an insulin secretagogue (sulfonylureas or meglitinides), or those on insulin, are also at higher risk of hypoglycemia.

In patients with end-stage metastatic disease, and shortened life expectancy, tight glucose control is not indicated, potentially placing individuals at unnecessary risk for hypoglycemia, particularly in those with a poor performance status >2. Individual risk for hypoglycemia and prognosis should be considered and recommended glycemic measurement targets are between 6.0 mmol/L – 15 mmol/L (108 – 225 mg/dl) (117).

People with new onset ICPi-induced insulin deficiency often have labile glucose control (99). More relaxed glucose targets may be required to avoid hypoglycemia wherever possible. Immune checkpoint inhibitors can also induce hypopituitarism leading to secondary adrenal insufficiency. This may lead to hypoglycemia (together with any of the following - hyponatremia, hyperkalemia and hypotension). Adrenalitis leading to primary adrenal insufficiency is very rare. Presentation of adrenal insufficiency ranges from asymptomatic laboratory alterations to the acutely unwell, with management depending on the severity (118). Other causes of adrenal or pituitary deficiency leading to hypoglycemia include metastases at these sites, surgery, irradiation, azole class of anti-fungal medication, and inappropriate abrupt cessation of glucocorticoid medication.

In oncology patients being weaned from long-term steroids, glucose monitoring will need to be continued after glucocorticoid cessation, with doses of anti-diabetic treatments adjusted accordingly, and individuals advised on risks of hypoglycemia. Caution is also required whilst using certain hematological anti-cancer therapies, including lenalidomide (119) and bortezomib (120), which can precipitate hypoglycemia, particularly in people with an underlying diagnosis of diabetes.

All cancer patients at risk from hypoglycemia should receive advice regarding appropriate treatment with 15–20 g of fast-acting carbohydrate, taken immediately (121). Comprehensive guidelines from the Joint British Diabetes Societies for Inpatient Care on the management of hypoglycemia can be found at this reference (122).

MANAGEMENT RECOMMENDATIONS  

Despite the effects of hyper- and hypoglycemia in people with diabetes (PWD) and those without known diabetes in cancer, there is a sparsity of guidance on the specific management considerations of these individuals. To address this, collaborative guidelines have recently been produced by the UK Chemotherapy Board (UKCB) and Joint British Diabetes Society for Inpatient Care (JBDS) (123, 124). The scope of these guidelines are to provide advice for the oncology/hemato-oncology and diabetes multidisciplinary teams to manage people with diabetes, commencing anti-cancer/ steroid therapy, as well as identifying individuals without a known diagnosis of diabetes who are at risk of developing hyperglycemia and new onset diabetes. These guidelines are intended for the outpatient management of people with cancer, particularly in the setting of the oncology/hemato-oncology clinic, and provision of advice for individuals at home, but where necessary, may be applied to inpatients as well. Whilst covering these guidelines in detail is beyond the scope of this chapter, key management considerations are summarized in tables 4-9.

Full management guidelines can be found at the UK Chemotherapy Board (UKCB) and Joint British Diabetes Society for Inpatient Care (JBDS) websites.

ADDITIONAL MANAGEMENT CONSIDERATIONS: CHOICE OF DIABETES THERAPEUTIC AGENT

Special consideration should also be given to the non-glycemic effects of hypoglycemic agents, including specific side effects and the impact on weight. Although weight reduction is associated with improvement in glycemic and metabolic profile in people with type 2 diabetes and is a key consideration in the choice of therapy, significant weight loss would usually be an unwanted effect in the oncology population. Indeed, weight gain is often used as a metric of improving nutritional state, especially in cancer related cachexia. This also has implications when counselling people with cancer about dietary choices when there is an additional cancer diagnosis. It is imperative that personalized advice is offered by healthcare professionals considering the global impact on the individual of any dietary or even lifestyle advice. SGLT2 inhibitors and GLP-1 agonists, for their potential weight reduction effects, are therefore less attractive options in the oncology setting. Insulin and sulfonylureas, on the other hand, offer an anabolic effect and therefore may be more desirable. Gastrointestinal side effects are common among hypoglycemic agents including metformin, DPP4 inhibitors, and GLP-1 agonists, and have the potential to complicate issues with nausea, vomiting, and oral intake from the underlying cancer and its treatment. Similarly, poor oral intake and nephrotoxic effects of certain SACT, added to a potential osmotic diuretic effect of SGLT2

inhibitors, could also increase the risk of acute kidney injury. The associated risk of genital tract infections with SGLT2 inhibitors would also be an additional consideration especially within an immunocompromised population (125). The impact and significance of these non-glycemic effects in the oncology population clearly differ to that of the general population, therefore highlighting the importance of a personalized approach with regular review of patients’ diabetes treatment through their oncology journey. 

CONCLUSIONS

It is common practice in oncology to initiate systemic anti-cancer therapy (including chemotherapy, targeted treatment, immunotherapy and steroids) in people with pre-existing diabetes. Diabetes, or risk of developing diabetes are by no means a contraindication to treatment but treating clinicians should be aware of the risks to patients, and counsel them appropriately. As more sophisticated anti-cancer treatments become licensed for use, the metabolic effects of these treatments will become better understood, and oncology teams should utilize and collaborate with endocrinology and primary care services to minimize the risks to individuals from poor glycemic control and diabetes. The recent publication of specific guidelines should act as a reference aid for clinicians and wider healthcare professionals to aid in risk recognition, diagnostic and screening for treatment induced diabetes, and provide the tools to appropriately manage these individuals and reduce the risks of complications.

REFERENCES

1. International Diabetes Federation. IDF Diabetes Atlas 2021. Available at https://diabetesatlas.org/atlas/tenth-edition/. Accessed Dec 2021.
2. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care [Internet]. 2021; 44(Supplement 1): S15-S33.https://doi.org/10.2337/dc21-S002
3. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1(Suppl 1):S62-9. doi:10.2337/dc10-S062
4. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JPA. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ : British Medical Journal. 2015;350:g7607. doi:10.1136/bmj.g7607
5. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60(4):207-21. doi:10.3322/caac.20078
6. Yan P, Wang Y, Yu X, Liu Y, Zhang ZJ. Type 2 diabetes mellitus and risk of head and neck cancer subtypes: a systematic review and meta-analysis of observational studies. Acta Diabetol. 2021;58(5):549-565. doi:10.1007/s00592-020-01643-0
7. Suh S, Kim KW. Diabetes and Cancer: Cancer should be screened in routine diabetes assessment. Diabetes Metab J. 2019;43(6):733-743. doi:10.4093/dmj.2019.0177
8. Diabetes UK. Diabetes and Cancer. https://wwwdiabetesorguk/diabetes-the-basics/related-conditions/diabetes-and-cancer. Accessed 28th February 2020
9. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300(23):2754-64. doi:10.1001/jama.2008.824
10. Calderillo-Ruiz G, Lopez H, Herrera M, et al. P-149 - Obesity and hyperglycemia as a bad prognosis factor for recurrence and survival in colon cancer. Annals of Oncology. 2019;30:iv40-iv41. doi:https://doi.org/10.1093/annonc/mdz155.148
11. Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, et al. Impact of diabetes and hyperglycemia on survival in advanced breast cancer patients. Exp Diabetes Res. 2012;2012:732027. doi:10.1155/2012/732027
12. Hosokawa T, Kurosaki M, Tsuchiya K, et al. Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy. World journal of gastroenterology. 2013;19(2):249-57. doi:10.3748/wjg.v19.i2.249
13. Wright JL, Plymate SR, Porter MP, et al. Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer. Prostate cancer and prostatic diseases. 2013;16(2):204-8. doi:10.1038/pcan.2013.5
14. Barba M, Sperati F, Stranges S, et al. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Ann Oncol. 2012;23(7):1838-45. doi:10.1093/annonc/mdr540
15. Chen S, Tao M, Zhao L, Zhang X. The association between diabetes/hyperglycemia and the prognosis of cervical cancer patients: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(40):e7981. doi:10.1097/md.0000000000007981
16. Liu H, Liu Z, Jiang B, et al. Prognostic significance of hyperglycemia in patients with brain tumors: a meta-analysis. Mol Neurobiol. 2016;53(3):1654-1660. doi:10.1007/s12035-015-9115-4
17. Ali NA, O'Brien Jr JM, Blum W, et al. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. https://doi.org/10.1002/cncr.22777. Cancer. 2007/07/01 2007;110(1):96-102. doi:https://doi.org/10.1002/cncr.22777
18. Barua R, Templeton AJ, Seruga B, Ocana A, Amir E, Ethier JL. Hyperglycaemia and survival in solid tumours: A systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2018;30(4):215-224. doi:10.1016/j.clon.2018.01.003
19. Ma J, Wang J, Ge L, Long B, Zhang J. The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis. Acta Diabetol. 2019;56(10):1103-1111. doi:10.1007/s00592-019-01337-2
20. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011;29(1):40-6. doi:10.1200/jco.2009.27.3011
21. Ramos-Garcia P, Roca-Rodriguez MDM, Aguilar-Diosdado M, Gonzalez-Moles MA. Diabetes mellitus and oral cancer/oral potentially malignant disorders: A systematic review and meta-analysis. Oral Dis. 2021;27(3):404-421. doi:10.1111/odi.13289
22. Gerards MC, van der Velden DL, Baars JW, et al. Impact of hyperglycemia on the efficacy of chemotherapy—A systematic review of preclinical studies. Critical reviews in oncology/hematology. 2017;113:235-241. doi:https://doi.org/10.1016/j.critrevonc.2017.03.007
23. Garufi A, Traversi G, Gilardini Montani MS, et al. Reduced chemotherapeutic sensitivity in high glucose condition: implication of antioxidant response. Oncotarget. 2019;10(45):4691-4702. doi:10.18632/oncotarget.27087
24. Stebbing J, Sharma A, North B, et al. A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann Oncol. 2012;23(4):860-6. doi:10.1093/annonc/mdr347
25. Hershey DS, Given B, Given C, Von Eye A, You M. Diabetes and cancer: impact on health-related quality of life. Oncol Nurs Forum. 2012;39(5):449-57. doi:10.1188/12.Onf.449-457
26. Hershey DS, Tipton J, Given B, Davis E. Perceived impact of cancer treatment on diabetes self-management. Diabetes Educ. 2012;38(6):779-90. doi:10.1177/0145721712458835
27. Pettit S, Cresta E, Winkley K, Purssell E, Armes J. Glycaemic control in people with type 2 diabetes mellitus during and after cancer treatment: A systematic review and meta-analysis. PLoS One. 2017;12(5):e0176941. doi:10.1371/journal.pone.0176941
28. Hershey DS. Importance of glycemic control in cancer patients with diabetes: treatment through end of life. Asia-Pacific journal of oncology nursing. 2017;4(4):313-318. doi:10.4103/apjon.apjon_40_17
29. Vissers PAJ, Falzon L, van de Poll-Franse LV, Pouwer F, Thong MSY. The impact of having both cancer and diabetes on patient-reported outcomes: a systematic review and directions for future research. J Cancer Surviv. 2016;10(2):406-415. doi:10.1007/s11764-015-0486-3
30. Alenzi EO, Kelley GA. The association of hyperglycemia and diabetes mellitus and the risk of chemotherapy-induced neutropenia among cancer patients: A systematic review with meta-analysis. J Diabetes Complications. Jan 2017;31(1):267-272. doi:10.1016/j.jdiacomp.2016.09.006
31. Chao C, Page JH, Yang SJ, Rodriguez R, Huynh J, Chia VM. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Annals of Oncology. 2014;25(9):1821-1829. doi:10.1093/annonc/mdu203
32. Yang IP, Miao ZF, Huang CW, et al. High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy. Ther Adv Med Oncol. 2019;11:1758835919866964. doi:10.1177/1758835919866964
33. Liu X, Ji J, Sundquist K, Sundquist J, Hemminki K. The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden. Cancer. 2012;118(5):1353-61. doi:10.1002/cncr.26420
34. Park JH, Kim H-Y, Lee H, Yun EK. A retrospective analysis to identify the factors affecting infection in patients undergoing chemotherapy. European Journal of Oncology Nursing. 2015;19(6):597-603. doi:https://doi.org/10.1016/j.ejon.2015.03.006
35. Brunello A, Kapoor R, Extermann M. Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. Am J Clin Oncol. 2011;34(3):292-6. doi:10.1097/COC.0b013e3181e1d0c0
36. Attili V, Bapsy P, Dadhich HK, Batra U, Lokanatha D, Babu KG. Impact of diabetes on cancer chemotherapy outcome: A retrospective analysis. International Journal of Diabetes in Developing Countries. 2007;27(4)122-128
37. de la Morena Barrio P, Conesa M, González-Billalabeitia E, et al. Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes. J Natl Compr Canc Netw. 2015;13(4):417-23. doi:10.6004/jnccn.2015.0057
38. Kim S, Garg A, Raja F. Cancer patients with undiagnosed and poorly managed diabetes mellitus. Journal of Clinical Oncology. 2017;35(15_suppl):e18232-e18232. doi:10.1200/JCO.2017.35.15_suppl.e18232
39. Hamilton A, Todd A, Wallace H, et al. Improving identification and management of steroid-induced hyperglycaemia in day-case chemotherapy patients: Results from a quality improvement project in a regional oncology centre. 2018. (Abstract) Diabetic Medicine 2018;35 (Suppl 1)
40. Zylla D, Gilmore G, Eklund J, Richter S, Carlson A. Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy. J Diabetes Complications. 2019;33(4):335-339. doi:10.1016/j.jdiacomp.2018.12.012
41. Xu KY, Shameem R, Wu S. Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis. Acta Oncol. 2016;55(9-10):1196-1203. doi:10.3109/0284186x.2016.1168939
42. Verges B, Walter T, Cariou B. Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol. 2014;170(2):R43-55. doi:10.1530/EJE-13-0586
43. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. New England Journal of Medicine. 2019;380(20):1929-1940. doi:10.1056/NEJMoa1813904
44. Shariff AI, Syed S, Shelby RA, et al. Novel cancer therapies and their association with diabetes. 2019;62(2):R187. doi:10.1530/jme-18-0002
45. Sullivan I, Planchard D. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience. Therapeutic Advances in Respiratory Disease. 2016;10(6):549-565. doi:10.1177/1753465816670498
46. Wadlow RC, Hezel AF, Abrams TA, et al. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 2012;17(1):14. doi:10.1634/theoncologist.2011-0452
47. Joint Formulary Committee. British National Formulary. Available at: https://bnf.nice.org.uk/drug/panitumumabhtml. 2020;Accessed 3rd March 2020
48. Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. The Lancet Oncology. 2016;17(3):378-388. doi:10.1016/S1470-2045(15)00515-X
49. Agostino NM, Chinchilli VM, Lynch CJ, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract. 2011;17(3):197-202. doi:10.1177/1078155210378913
50. Chang L, An Y, Yang S, Zhang X. Meta-analysis of therapeutic effects and the risks of hypertension and hyperglycemia in patients with renal cell carcinoma who were receiving antiangiogenic drugs. J Cancer Res Ther. 2016;12(Supplement):96-103. doi:10.4103/0973-1482.191614
51. Saglio G, Larson RA, Hughes TP, et al. Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial. Blood. 2010;116(21):3430-3430. doi:10.1182/blood.V116.21.3430.3430
52. Chan O, Talati C, Isenalumhe L, et al. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood advances. 2020;4(3):530-538. doi:10.1182/bloodadvances.2019000268
53. Villadolid J, Ersek JL, Fong MK, Sirianno L, Story ES. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. Transl Lung Cancer Res. 2015;4(5):576-583. doi:10.3978/j.issn.2218-6751.2015.10.01
54. Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840-851. doi:10.1182/blood-2018-08-869453
55. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. New England Journal of Medicine. 2017;377(5):454-464. doi:10.1056/NEJMoa1614359
56. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. New England Journal of Medicine. 2019;381(18):1728-1740. doi:10.1056/NEJMoa1902688
57. US FDA. Mylotarg (gemtuzumab ozogamicin for injection). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021174s020lblpdf. Accessed January 2021;
58. Wolin EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res. 2012;5(5):161-168.
59. Yang J, Jia B, Qiao Y, Chen W, Qi X. Variations of blood glucose in cancer patients during chemotherapy. Original Article. Nigerian Journal of Clinical Practice. 2016 2016;19(6):704-708. doi:10.4103/1119-3077.187323
60. Yang J, Jia B, Yan J, He J. Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer. Niger J Clin Pract. 2017;20(11):1422-1427. doi:10.4103/njcp.njcp_444_16
61. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247-55. doi:10.1016/s1470-2045(12)70063-3
62. Clinical Trials. Pemetrexed and best supportive care versus placebo and best supportive care in non-small cell lung cancer (NSCLC). Available at: https://clinicaltrialsgov/ct2/show/results/NCT00102804. 2014;Accessed 3rd March 2020
63. Ma YY, Zhao M, Liu Y, et al. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis. Hematology. 2019;24(1):507-515. doi:10.1080/16078454.2019.1632407
64. Electronic Medicines Compendium (emc). Busulfan concentrate for infusion. Available at : https://www.medicines.org.uk/emc/product/2160/smpc#gref. Accessed January 2021;
65. Huang CY, Lin YS, Liu YH, Lin SC, Kang BH. Hyperglycemia crisis in head and neck cancer patients with platinum-based chemotherapy. J Chin Med Assoc. 2018;81(12):1060-1064. doi:10.1016/j.jcma.2018.05.008
66. Nan DN, Fernandez-Ayala M, Vega Villegas ME, et al. Diabetes mellitus following cisplatin treatment. Acta Oncol. 2003;42(1):75-8. doi:10.1080/0891060310002276
67. Yang J, Wang Y, Liu K, Yang W, Zhang J. Risk factors for doxorubicin-induced serious hyperglycaemia-related adverse drug reactions. Diabetes Ther. 2019;10(5):1949-1957. doi:10.1007/s13300-019-00677-0
68. Kritharis A, Bradley TP, Budman DR. Association of diabetes mellitus with arsenic trioxide (ATO) evaluated in the treatment of acute promyelocytic leukemia (APL). Journal of Clinical Oncology. 2011;29(15_suppl):e19724-e19724. doi:10.1200/jco.2011.29.15_suppl.e19724
69. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2017;28:iv119-iv142. doi:https://doi.org/10.1093/annonc/mdx225
70. Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Research & Care. 2019;7(1):e000591. doi:10.1136/bmjdrc-2018-000591
71. Lu J, Yang J, Liang Y, Meng H, Zhao J, Zhang X. Incidence of immune checkpoint inhibitor-associated diabetes: A meta-analysis of randomized controlled studies. Systematic Review. Frontiers in Pharmacology. 2019;10(1453)doi:10.3389/fphar.2019.01453
72. Wang H, Sun X, Zhao L, Chen X, Zhao J. Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis. J Diabetes Investig. 2016;7(4):629-636. doi:10.1111/jdi.12472
73. Lipscombe LL, Fischer HD, Yun L, et al. Association between tamoxifen treatment and diabetes: a population-based study. Cancer. 2012;118(10):2615-22. doi:10.1002/cncr.26559
74. Hwangbo Y, Lee EK. Acute hyperglycemia associated with anti-cancer medication. Endocrinol Metab (Seoul). 2017;32(1):23-29. doi:10.3803/EnM.2017.32.1.23
75. Feng JP, Yuan XL, Li M, et al. Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. Colorectal Dis. 2013;15(1):27-33. doi:10.1111/j.1463-1318.2012.03097.x
76. Teng CJ, Chang KH, Tsai IJ, Hwang WL, Hsu CY, Sheu WH. Impact of anthracyclines on diabetes mellitus development in B-cell lymphoma patients: A nationwide population-based study. Clin Drug Investig. 2018;38(7):603-610. doi:10.1007/s40261-018-0645-1
77. Koltin D, Sung L, Naqvi A, Urbach SL. Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics. Support Care Cancer. 2012;20(9):2009-15. doi:10.1007/s00520-011-1307-5
78. van Niekerk G, Engelbrecht AM. Inflammation-induced metabolic derangements or adaptation: An immunometabolic perspective. Cytokine Growth Factor Rev. 2018;43:47-53. doi:10.1016/j.cytogfr.2018.06.003
79. de Lima Junior EA, Yamashita AS, Pimentel GD, et al. Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPk signalling in skeletal muscle. J Cachexia Sarcopenia Muscle. 2016;7(5):615-625. doi:10.1002/jcsm.12104
80. Giovannucci E. The critical need for guidance in managing glycaemic control in patients with cancer. https://doi.org/10.1111/dme.14624. Diabetic Medicine. 2021;e14624. doi:https://doi.org/10.1111/dme.14624
81. Buffier P, Bouillet B, Smati S, Archambeaud F, Cariou B, Verges B. Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors. Ann Endocrinol (Paris). 2018;79(5):574-582. doi:10.1016/j.ando.2018.07.011
82. Romero-Ventosa EY, Otero-Millán L, González-Costas S, et al. Effect of tyrosine kinase inhibitors on the glucose levels in diabetic and nondiabetic patients. Indian journal of cancer. 2017;54(1):136-143. doi:10.4103/ijc.IJC_190_17
83. Sakuma I, Nagano H, Yoshino I, Yokote K, Tanaka T. Ceritinib aggravates glycemic control in insulin-treated patients with diabetes and metastatic ALK-positive lung cancer. Intern Med. 2019;58(6):817-820. doi:10.2169/internalmedicine.1870-18
84. Bouillet B, Buffier P, Smati S, Archambeaud F, Cariou B, Vergès B. Expert opinion on the metabolic complications of mTOR inhibitors. Ann Endocrinol (Paris). 2018;79(5):583-590. doi:10.1016/j.ando.2018.07.010
85. Vergès B. mTOR and cardiovascular diseases: diabetes mellitus. Transplantation. 2018;102(2S Suppl 1):S47-s49. doi:10.1097/tp.0000000000001722
86. Martel S, Bruzzone M, Ceppi M, et al. Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Cancer treatment reviews. 2018;62:123-132. doi:10.1016/j.ctrv.2017.09.009
87. Sivendran S, Agarwal N, Gartrell B, et al. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer treatment reviews. 2014;40(1):190-6. doi:10.1016/j.ctrv.2013.04.005
88. Acharya GK, Hita AG, Yeung SJ, Yeung SJ. Diabetic ketoacidosis and acute pancreatitis: serious adverse effects of everolimus. Ann Emerg Med. 2017;69(5):666-667. doi:10.1016/j.annemergmed.2017.01.002
89. Bono P, Oudard S, Bodrogi I, et al. Outcomes in patients with metastatic renal cell carcinoma who develop everolimus-related hyperglycemia and hypercholesterolemia: combined subgroup analyses of the RECORD-1 and REACT Trials. Clin Genitourin Cancer. 2016;14(5):406-414. doi:10.1016/j.clgc.2016.04.011
90. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39-46. doi:10.1093/jnci/djp404
91. Ng HS, Koczwara B, Roder D, Vitry A. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Prostate cancer and prostatic diseases. 2018;21(3):403-410. doi:10.1038/s41391-018-0036-y
92. Santorelli ML, Hirshfield KM, Steinberg MB, Rhoads GG, Lin Y, Demissie K. Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women. Ann Epidemiol. 2016;26(6):436-40. doi:10.1016/j.annepidem.2016.04.004
93. Sun LM, Chen HJ, Liang JA, Li TC, Kao CH. Association of tamoxifen use and increased diabetes among Asian women diagnosed with breast cancer. Br J Cancer. 2014;111(9):1836-42. doi:10.1038/bjc.2014.488
94. Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. https://doi.org/10.1111/cei.13424. Clinical & Experimental Immunology. 2020;200(2):131-140. doi:https://doi.org/10.1111/cei.13424
95. Falcone M, Fousteri G. Role of the PD-1/PD-L1 dyad in the maintenance of pancreatic immune tolerance for prevention of type 1 diabetes. Review. Frontiers in Endocrinology. 2020;11(569)doi:10.3389/fendo.2020.00569
96. Clotman K, Janssens K, Specenier P, Weets I, De Block CEM. Programmed cell death-1 inhibitor–induced type 1 diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism. 2018;103(9):3144-3154. doi:10.1210/jc.2018-00728
97. Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471-1480. doi:10.2337/dbi18-0002
98. Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. https://doi.org/10.1111/dme.14050. Diabetic Medicine. 2019;36(9):1075-1081. doi:https://doi.org/10.1111/dme.14050
99. Perdigoto AL, Quandt Z, Anderson M, Herold KC. Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome. The Lancet Diabetes & Endocrinology. 2019;7(6):421-423. doi:10.1016/S2213-8587(19)30072-5
100. Kyriacou A, Melson E, Chen W, Kempegowda P. Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus? Clinical Medicine. 2020;20(4):417-423. doi:10.7861/clinmed.2020-0054
101. Wright JJ, Salem J-E, Johnson DB, et al. Increased reporting of immune checkpoint inhibitor–associated diabetes. Diabetes Care. 2018;41(12):e150. doi:10.2337/dc18-1465
102. de Filette JMK, Pen JJ, Decoster L, et al. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. Sep 2019;181(3):363-374. doi:10.1530/eje-19-0291
103. Byun DJ, Braunstein R, Flynn J, et al. Immune checkpoint inhibitor-associated diabetes: A single-institution experience. Diabetes Care. 2020;43(12):3106-3109. doi:10.2337/dc20-0609
104. Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes. 2014;6(1):9-20. doi:10.1111/1753-0407.12090
105. Dunning T, Martin P. Palliative and end of life care of people with diabetes: Issues, challenges and strategies. Diabetes Res Clin Pract. 2018;143:454-463. doi:10.1016/j.diabres.2017.09.018
106. Joint British Diabetes Society (JBDS) for Inpatient Care Group. Steroid use for inpatients with diabetes. Available at: https://abcdcare/resource/steroid-use-inpatients-diabetes. May 202
107. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes. 2015;6(8):1073-1081. doi:10.4239/wjd.v6.i8.1073
108. Pilkey J, Streeter L, Beel A, Hiebert T, Li X. Corticosteroid-induced diabetes in palliative care. J Palliat Med. 2012;15(6):681-9. doi:10.1089/jpm.2011.0513
109. Gannon C, Dando N. Dose-sensitive steroid-induced hyperglycaemia. Palliat Med. 2010;24(7):737-9. doi:10.1177/0269216310377816
110. Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65(4):324-32. doi:10.1159/000365892
111. Narwani V, Swafe L, Stavraka C, Dhatariya K. How frequently are bedside glucose levels measured in hospital inpatients on glucocorticoid treatment? Clin Med (Lond). 2014;14(3):327-328. doi:10.7861/clinmedicine.14-3-326a
112. Jeong Y, Han HS, Lee HD, et al. A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients. Cancer Res Treat. 2016;48(4):1429-1437. doi:10.4143/crt.2015.464
113. Lyall MJ, Thethy I, Steven L, et al. Diurnal profile of interstitial glucose following dexamethasone prophylaxis for chemotherapy treatment of gynaecological cancer. Diabet Med. 2018;35(11):1508-1514. doi:10.1111/dme.13770
114. Lamar ZS, Dothard A, Kennedy L, et al. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma. 2018;59(8):1871-1877. doi:10.1080/10428194.2017.1410889
115. Lee S-y, Kurita N, Yokoyama Y, et al. Glucocorticoid-induced diabetes mellitus in patients with lymphoma treated with CHOP chemotherapy. Supportive Care in Cancer. 2014;22(5):1385-1390. doi:10.1007/s00520-013-2097-8
116. Healy SJ, Nagaraja HN, Alwan D, Dungan KM. Prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies. Endocrine. 2017;56(1):90-97. doi:10.1007/s12020-016-1220-2
117. Roberts A, James J, Dhatariya K. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med. 2018;35(8):1011-1017. doi:10.1111/dme.13675
118. Higham CE, Olsson-Brown A, Carroll P, et al. Society for Endocrinology emergency guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocrine connections. 2018;7(7):G1-G7. doi:10.1530/EC-18-0068
119. Przybylski DJ, Birhiray R, Reeves DJ. Severe Hypoglycemia Caused by Lenalidomide. Pharmacotherapy. 2018;38(1):e1-e6. doi:10.1002/phar.2061
120. Electronic Medicines Compendium (emc). Bortezomib. Available from: https://wwwmedicinesorguk/emc/product/10201/smpc#gref. Accessed September 2021;
121. Joint British Diabetes Society (JBDS) for Inpatient Care Group. The Hospital Management of Hypoglycaemia in Adults with Diabetes Mellitus 3rd edition.

         Available from: https://abcdcare/joint-british-diabetes-societies-jbds-inpatient-care-group. 2018;

122. Joint British Diabetes Society for Inpatient Care. The Hospital Management of Hypoglycaemia in Adults with Diabetes Mellitus 4th Edition. Available at: https://abcdcare/sites/abcdcare/files/site_uploads/JBDS_HypoGuideline_4th_edition_FINALpdf. 2020;
123. Joharatnam-Hogan N, Chambers P, Dhatariya K, Board R. A guideline for the outpatient management of glycaemic control in people with cancer. Diabet Med. Jul 9 2021:e14636. doi:10.1111/dme.14636
124. The UK Chemotherapy Board (UKCB) and Joint British Diabetes Society (JBDS). Management of Glycaemic Control in Patients with Cancer. Available from: https://wwwukchemotherapyboardorg/publications. Accessed September 2021;
125. Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. Jun 6 2017;7(1):2824. doi:10.1038/s41598-017-02733-w

ABSTRACT

Numerous distinct pathophysiologic abnormalities have been associated with type 2 diabetes mellitus (T2DM).  It is well established that decreased peripheral glucose uptake (mainly muscle) combined with augmented endogenous glucose production are characteristic features of insulin resistance. Increased lipolysis, elevated free fatty acid levels, along with accumulation of intermediary lipid metabolites contributes to further increase glucose output, reduce peripheral glucose utilization, and impair beta-cell function.  Adipocyte insulin resistance and inflammation have been identified as important contributors to the development of T2DM. The presence of non-alcoholic fatty liver disease [NAFLD] is now considered an integral part of the insulin resistant state.  The traditional concepts of “glucotoxicity” and lipotoxicity, which covers the process of beta cell deterioration in response to chronic elevations of glucose and lipids, has been expanded to encompass all nutrients [‘nutri-toxicity”].  The delayed transport of insulin across the microvascular system is also partially responsible for the development of tissue insulin resistance.   Compensatory insulin secretion by the pancreatic beta cells may initially maintain normal plasma glucose levels, but beta cell function is already abnormal at this stage, and progressively worsens over time.  Concomitantly, there is inappropriate release of glucagon from the pancreatic alpha-cells, particularly in the post-prandial period. It has been postulated that both impaired insulin and excessive glucagon secretion in T2DM are secondary to an “incretin defect”, defined primarily as inadequate release or response to the gastrointestinal incretin hormones upon meal ingestion.  To a certain extent, the gut microbiome appears to play a role in the hormonal and metabolic disturbances seen in T2DM.  Moreover, hypothalamic insulin resistance (central nervous system) also impairs the ability of circulating insulin to suppress glucose production, and renal tubular glucose reabsorption capacity may be enhanced, despite hyperglycemia.   These pathophysiologic abnormalities should be considered for the treatment of hyperglycemia in patients with T2DM. 

NORMAL GLUCOSE HOMEOSTASIS

In the post-absorptive state (10-12 hour overnight fast), the majority of total body glucose disposal takes place in insulin independent tissues (1).  Under basal conditions, approximately 50% of all glucose utilization occurs in the brain, which is insulin independent and becomes saturated at a plasma glucose concentration of about 40 mg/dl (2). Another 25% of glucose uptake occurs in the splanchnic area (liver plus gastrointestinal tissues) and is also insulin independent (3). The remaining 25% of glucose metabolism in the post-absorptive state takes place in insulin-dependent tissues, primarily muscle (4,5). Basal glucose utilization averages ~2.0 mg/kg.min and is precisely matched by the rate of endogenous glucose production (1,3-7). Approximately 85% of endogenous glucose production is derived from the liver, and the remaining amount is produced by the kidney (1,8,9). Approximately one-half of basal hepatic glucose production is derived from glycogenolysis and one-half from gluconeogenesis (9,10).

Following glucose ingestion, the balance between endogenous glucose production and tissue glucose uptake is disrupted. The increase in plasma glucose concentration stimulates insulin release from the pancreatic beta cells, and the resultant hyperinsulinemia and hyperglycemia serve (i) to stimulate glucose uptake by splanchnic (liver and gut) and peripheral (primarily muscle) tissues and (ii) to suppress endogenous glucose production (1,3-7,11-14).

Hyperglycemia, in the absence of hyperinsulinemia, exerts its own independent effect to stimulate muscle glucose uptake and to suppress endogenous glucose production in a dose dependent fashion (14-16). The majority (~80-85%) of glucose that is taken up by peripheral tissues is disposed of in muscle (1,3-7,11-14), with only a small amount (~4-5%) being metabolized by adipocytes (17). Although fat tissue is responsible for only a fraction of total body glucose disposal, it plays a very important role in the maintenance of total body glucose homeostasis (see below). Insulin is a potent inhibitor of lipolysis and even small increments in the plasma insulin concentration exerts a potent anti-lipolytic effect, leading to a marked reduction in the plasma free fatty acid level (18). The decline in plasma FFA concentration results in increased glucose uptake in muscle (19) and contributes to the inhibition of endogenous glucose production (16,20). Thus, changes in the plasma FFA concentration in response to increased plasma levels of insulin and glucose play an important role in the maintenance of normal glucose homeostasis (21,22).

SITE OF INSULIN RESISTANCE IN TYPE 2 DIABETES (T2DM)

The maintenance of whole-body glucose homeostasis is dependent upon a normal insulin secretory response by the pancreatic beta cells and normal tissue sensitivity to the independent effects of hyperinsulinemia and hyperglycemia (i.e., the mass-action effect of glucose) to augment glucose uptake. In turn, the combined effects of insulin and hyperglycemia to promote glucose disposal are dependent on three tightly coupled mechanisms: (i) suppression of endogenous (primarily hepatic) glucose production; (ii) stimulation of glucose uptake by the splanchnic (hepatic plus gastrointestinal) tissues; and (iii) stimulation of glucose uptake by peripheral tissues, primarily muscle (1,4,14). Muscle glucose uptake is regulated by flux through two major metabolic pathways: glycolysis (of which ~90% represents glucose oxidation) and glycogen synthesis.

Hepatic Glucose Production

In the overnight fasted state, the liver of healthy subjects produces glucose at the rate of ~1.8-2.0 mg.kg^-1.min^-1 (1,3,4,6,18,54). This glucose flux is essential to meet the needs of the brain and other neural tissues, which utilize glucose at a constant rate of ~1-1.2 mg.kg^-1.min^-1 (2,169).  Brain glucose uptake accounts for ~50-60% of glucose disposal during the post-absorptive state and this uptake is insulin independent. Therefore, brain glucose uptake occurs at the same rate during absorptive and post-absorptive periods and is not altered in T2DM (214).  Following glucose ingestion, insulin is secreted into the portal vein and glucagon release is inhibited, and this new hormonal ratio is carried to the liver, where it suppresses hepatic glucose output. If the liver does not perceive this insulin signal and continues to produce glucose, there will be two superimposed inputs of glucose into the body, one from the liver and another from the gastrointestinal tract, and marked hyperglycemia will ensue.

In subjects with T2DM and mild to moderate fasting hyperglycemia (140-200 mg/dl, 7.8-11.1 mmol/L) basal endogenous glucose production [EGP] is increased by ~0.5 mg/kg.min. Consequently, during the overnight sleeping hours (i.e., 2200 h to 0800 h), the liver of an 80-kg individual with diabetes and modest fasting hyperglycemia adds an additional 35 g of glucose to the systemic circulation. The increase in basal EGP is closely correlated with the severity of fasting hyperglycemia (1,3,4,6,18,54,157-159,162). Thus, in T2DM with overt fasting hyperglycemia (>140 mg/dl, 7.8 mmol/l), an excessive rate of EGP and glucose output is the major abnormality responsible for the elevated fasting plasma glucose concentration. The close relationship between fasting plasma glucose concentration and EGP has been demonstrated in numerous studies (164-166,170-174).

In the post-absorptive state, the fasting plasma insulin concentration in subjects with T2DM is 2-4-fold greater than in subjects without diabetes. Because hyperinsulinemia is a potent inhibitor of EGP (1,3,4-6,16,18,164,165,175), hepatic resistance to the action of insulin must be present in the post-absorptive state to explain the excessive output of glucose. Hyperglycemia per se also exerts a powerful suppressive action on EGP (15,167,175-177). Therefore, the liver, primarily, also must be glucose resistant with respect to the inhibitory effect of hyperglycemia to suppress glucose output, and this has been well documented (15,167,178,179).

Using the euglycemic insulin clamp technique in combination with tritiated glucose, the dose response relationship between endogenous glucose production and the plasma glucose concentration has been defined by Groop, DeFronzo, et al (18). The following points should be emphasized: (i) first, the dose-response curve relating inhibition of EGP to the plasma insulin concentration is quite steep, with an effective dose for half-maximal insulin concentration (ED50) of ~30-40 µU/ml; (ii) in individuals with T2D the dose response curve is shifted to the right, indicating the presence of hepatic resistance to the inhibitory effect of insulin on hepatic glucose production. However, at plasma insulin concentrations within the high physiologic range (~100 µU/ml), the hepatic insulin resistance can be largely overcome and a near normal suppression of EGP can be achieved; (iii) the severity of the hepatic insulin resistance is related to the severity of the diabetic state. In T2DM with mild fasting hyperglycemia, an increment in plasma insulin concentration of 100 µU/ml causes a complete suppression of EGP. However, in diabetic subjects with more severe fasting hyperglycemia, the ability of the same plasma insulin concentration to suppress EGP is impaired (18). These results suggest that there is an acquired component of hepatic insulin resistance and that this defect becomes progressively worse as the diabetic state decompensates over time.

The glucose released by the liver in the post-absorptive state can be derived from either glycogenolysis or gluconeogenesis (6,16,176). Studies employing the hepatic vein catheter technique have shown that the uptake of gluconeogenic precursors, especially lactate, is increased in subjects with T2DM (180). Consistent with this observation, radioisotope turnover studies, using lactate, alanine, and glycerol have shown that ~90% of the increase in HGP above baseline can be accounted for by accelerated gluconeogenesis (181,182). More recent studies employing ¹³C-magnetic resonance imaging (183) and D2O (184,185) have confirmed the important contribution of accelerated gluconeogenesis to the increase in HGP. An increased rate of glutamine conversion to glucose also has been shown to contribute to the elevated rate of gluconeogenesis in subjects with T2DM (186), which may be, in part, derived from renal gluconeogenesis (8). The mechanisms responsible for the increase in hepatic gluconeogenesis include hyperglucagonemia (187), increased circulating levels of gluconeogenic precursors (lactate, alanine, glycerol) (181,188), increased FFA oxidation (18,162,189), enhanced sensitivity to glucagon (190) and decreased sensitivity to insulin (1,4.18,164,165). Although the majority of evidence indicates that increased gluconeogenesis is the major cause of the increase in EGP in subjects with T2DM (181- 186), it is likely that accelerated glycogenolysis also contributes to it (181,191). 

The presence of both direct and indirect effects of insulin in suppressing EGP and release into the circulation were recently demonstrated in animals using intra-portal and systemic insulin infusions (430). The results provided evidence that, in addition to a direct action of insulin on hepatic enzymes, the inhibition of adipose tissue lipolysis represents an important mechanism by which insulin regulates the rate of gluconeogenesis.  This is therefore, accomplished indirectly, by controlling the supply of free fatty acids, which are essential to the process of glucose synthesis de novo.  The rate-limiting step in achieving fast and complete inhibition of adipose tissue lipolysis is the transendothelial transport of insulin across tissue capillaries.  Additional data obtained during systemic infusions of free fatty acids and in experiments where adipocyte lipolytic factors were manipulated, together with observation in mice lacking hepatic Foxo1 & Akt1/2 signaling have confirmed this indirect action of insulin on gluconeogenesis (430-432).  These findings have generated the hypothesis that in patients with T2DM, insulin may be transported slowly across tissue capillaries, which delays the inhibition of lipolysis with subsequent impairment of the suppression of EGP.

On the other hand, animal studies (431), where insulin was infused directly into the portal vein, mimicking normal insulin secretory pattern, showed that there is complete and swift inhibition of EGP.  These observations were confirmed when plasma glucagon and fatty acid levels were clamped at basal values, and in conditions where brain insulin action was blocked.  Authors conclude that the direct hepatic effect of insulin in the regulation of EGP is more relevant and that, the indirect effect is redundant in physiological conditions.  Acute insulin suppression of endogenous gluconeogenesis is largely an indirect effect mediated by the inhibition of adipose tissue lipolysis, which reduces delivery of non-esterified fatty acids and glycerol to the liver.  The major direct effect of insulin on hepatic glucose metabolism is the regulation of glycogen metabolism.  Hyperglycemia and hyperinsulinemia are required to maximally stimulate net hepatic glycogenesis.  In T2DM, lipid-induced hepatic insulin resistance, high rates of adipose tissue lipolysis and hyperglucagonemia impair glucose metabolism in the liver (432).

Because of the inaccessibility of the liver in man, it has been difficult to assess the role of key enzymes involved in the regulation of gluconeogenesis (pyruvate carboxylase, phosphoenol- pyruvate carboxykinase), glycogenolysis (glycogen phosphorylase), and net hepatic glucose output (glucokinase, glucose-6-phosphatase). However, considerable evidence from animal models of T2DM and some evidence in humans have implicated increased activity of PEPCK and G-6-Pase in the accelerated rate of hepatic glucose production (192-194).

Recently, changes in hypothalamic insulin signaling have been shown to affect endogenous glucose production. The activation of the insulin receptor in the third cerebral ventricle is capable of suppressing glucose production, independent of plasma insulin or other counter-regulatory hormones.  Conversely, central antagonism to insulin signaling impairs the ability of circulating insulin to inhibit glucose production (6A).  These observations have raised the possibility that hypothalamic insulin resistance contributes to hyperglycemia in T2DM.

The Role of the Kidney

The kidney also has been shown to produce glucose and estimates of the renal contribution to total endogenous glucose production have varied from 5% to 20% (8,9,195). These varying estimates of the contribution of renal gluconeogenesis to total glucose production are largely related to the methodology employed to measure glucose production by the kidney (196). One unconfirmed study suggests that the rate of renal gluconeogenesis is increased in T2DM with fasting hyperglycemia (197). Arguing against this possibility are studies employing the hepatic vein catheter technique which have shown that all of the increase in total body EGP (measured with 3-³H-glucose) in T2DM can be accounted for by increased hepatic glucose output (measured by the hepatic vein catheter technique) (3). A more relevant aspect on the role of the kidney in the dysregulation of glucose homeostasis in diabetes is the maintenance of hyperglycemia, which results from a maladaptive enhancement of the tubular glucose transport threshold (9A, 9B). It has been hypothesized that in response to an elevated glucose load presented to the proximal tubular lumen, the sodium glucose co-transporter system increases its reabsorptive capacity by upregulating the SGLT-2 expression and kinetics (9C).  However, more recent studies conducted in humans who underwent unilateral nephrectomy were not able to confirm the over-expression of either SGLT-2 or SGLT-1 proteins in proximal renal tubules of patients with T2DM compared to non-diabetic controls (433, 434).  The augmented tubular glucose transport described in patients with type 1 and type 2 diabetes may result from a functional enhancement of the activity of these co-transporters.  The elevated renal threshold to plasma values between 220-250 mg/dl for the excretion of glucose into the urine in these patients, thus may be secondary to a sustained hyperglycemia. If this is confirmed, the maladaptive process of recycling a substantial amount of glucose back into the peripheral circulation may be attenuated with near-normoglycemia, possibly reversible. In any case, this contribution of the kidney to hyperglycemia in diabetic patients represents one additional pathogenic mechanism that has been underappreciated.

Peripheral (Muscle) Glucose Uptake

Muscle is the major site of glucose disposal in man (1,3-5,14). Under euglycemic hyperinsulinemic conditions, approximately 80% of total body glucose uptake occurs in skeletal muscle (1,3-5). Studies employing the euglycemic insulin clamp in combination with femoral artery/vein catheterization have examined the effect of insulin on leg glucose uptake in subjects with T2DM and control subjects (3). Since bone is metabolically inert with regards to carbohydrate metabolism and adipose tissue takes up less than 5% of an infused glucose load (17,198,199), muscle represents the major tissue responsible for leg glucose uptake.

In response to a physiologic increase in plasma insulin concentration (~80-100 μU/ml), leg (muscle) glucose uptake increases linearly, reaching a plateau value of 10 mg/kg leg wt per minute (3). In contrast, in lean subjects with T2DM, the onset of insulin action is delayed for ~40 min and the ability of the hormone to stimulate leg glucose uptake is markedly blunted, even though the study is carried out for an additional 60 min in the group with T2DMto allow insulin to more fully express its biological effects (3). During the last hour of the insulin clamp study, the rate of glucose uptake was reduced by 50% in the group with T2DM (3). These results provide conclusive evidence that the primary site of insulin resistance during euglycemic insulin clamp studies performed in subjects with T2DM resides in muscle tissue. Using the forearm and leg catheterization techniques (13,153,200,202), a number of investigators have demonstrated a decreased rate of insulin-mediated glucose uptake by peripheral tissues. The use of positron emission tomography (PET) scanning to quantitate leg glucose uptake in subjects with T2DM has provided additional support for the presence of severe muscle resistance to insulin in diabetic subjects (203).   

Vascular and Myocardial Insulin Resistance

The first and rate-limiting step in insulin-mediated glucose disposal is the transit of insulin from the plasma to the muscle.  Crossing of insulin from the circulation into the muscle interstitium is governed by vascular endothelium.  The transendothelial transport depends on the insulin receptor binding to the endothelial cell membrane and requires the activation of the nitric oxide synthase.  The transport of insulin across the endothelial cell layer appears to involve a complex vesicular trafficking process, which is saturable.  Insulin is known to promote capillary vasodilation particularly in the postprandial period to facilitate entry and distribution of fuel substrates, including glucose.  Several studies sampling lymph and interstitial glucose, using dialysis techniques, have suggested that a delay in insulin transfer from the plasma to the tissue may play an important role in the development of insulin resistance (427-429).  Thus, impairment of insulin action may be secondary to a decrease in capillary density [chronic situations] or to a defective increase in blood flow or micro-capillary recruitment [acute conditions] (429). These abnormalities have been described in obese insulin-resistant and in the skin flow response of patients with diabetes. 

Myocardial insulin resistance translates to abnormal intracellular signaling and reduced glucose oxidation rates in animal models of obesity (435).  It adversely affects myocardial mechanical function and tolerance to ischemia and reperfusion.  The heart is a dynamic organ that requires continuous energy in the form of ATP in order to meet contractile demands.  This is achieved via a constant supply of blood-borne oxidizable substrates.  The majority of ATP is derived from fatty acid oxidation [60-70%].  Glucose and lactate extracted from the circulation account for the remainder 30-40%.  However, when blood glucose and insulin levels are elevated, such as immediately after a meal, glucose becomes the major fuel for myocardial oxidation and, it may represent up to 70% of the total substrate oxidation by cardio-myocytes.  Long–chain fatty acids are taken up by the heart proportionately to circulating levels, via a passive facilitated transport.  Once inside the cytosol, they are degraded into acetyl-CoA moieties that enter the mitochondrial oxidative phosphorylation process.  The excess fatty acids are re-esterified to form diacyl- and triacyl-glycerides and, these lipid intermediates are stored in the form the myo-cellular lipid pool.  Glucose enters the myocardial cells both via GLUT-1 passive and insulin-stimulated GLUT-4 active transport.  These are dictated by myocardial contraction demands and circulating insulin levels.  Intracellular glucose is phosphorylated and, either stored as muscle glycogen or anaerobically oxidized to pyruvate. Under normal oxygen delivery, pyruvate is converted to acetyl-CoA, which enters mitochondrial oxidation.  In conditions of ischemia, low oxygen forces the conversion of pyruvate into lactate (435).

It is believed that myocardial insulin resistance with typical defects in glucose transport and oxidation develops, in part, because of an excess supply of fatty acids.  In addition to a direct competition with glucose utilization, there is evidence that the accumulation of intracellular lipid intermediates interferes with insulin signaling.  The molecular defects responsible for the insulin resistance in the cardio-myocytes are analogous to the skeletal muscle.  The local generation of reactive oxygen species and other elements also participate in obstructing insulin action. Although the cellular and metabolic manifestations may be similar, the consequences of insulin resistance in the heart muscle tends to express with lower tolerance for ischemia and poor mechanical function.  Consequently, patients with insulin resistance are susceptible to earlier and more severe cardiovascular complications.   

Splanchnic (Hepatic) Glucose Uptake

In humans, it is difficult to catheterize the portal vein, and glucose disposal by the liver has not been examined directly. Using the hepatic vein catheterization technique in combination with the euglycemic insulin clamp, the contribution of the splanchnic (liver plus gastrointestinal) tissues to overall glucose homeostasis has been examined in lean subjects with T2DM with mild to moderate fasting hyperglycemia (3). In the post-absorptive state, there is a net release of glucose from the splanchnic area (i.e., negative balance) in both control and subjects with T2DM, reflecting glucose production by the liver. In response to insulin, splanchnic glucose output is promptly suppressed (reflecting the inhibition of HGP) and, by 20 min, the net glucose balance across the splanchnic region declines to zero (i.e., there was no net uptake or release) (3). After 2 h of sustained hyperinsulinemia, there is a small net uptake of glucose (~0.5 mg.kg^{- 1}.min^-1) by the splanchnic area (i.e., positive balance). This uptake is virtually identical to the rate of splanchnic glucose uptake observed in the basal state, indicating that the splanchnic tissues, like the brain, are insensitive to insulin at least with respect to the stimulation of glucose uptake (3,5,6,175). There was no difference between diabetic and control subjects for glucose taken up by the splanchnic tissues at any time during the insulin clamp study (3).

The results of these studies illustrate another important point: namely, that under conditions of euglycemic hyperinsulinemia, very little of the infused glucose is taken up by the splanchnic (and therefore hepatic) tissues (3,5,6,175). During the insulin clamp, the rate of whole-body glucose uptake averaged 7 mg.kg^-1.min^-1, and of this, only 0.5 mg.kg^-1.min^-1 or 7%, was disposed of by the splanchnic region. Because the difference in insulin-mediated total body glucose uptake between the T2DM and control groups during the euglycemic insulin clamp study was 2.5 mg.kg^-1.min^-1, from a purely quantitative standpoint it is obvious that a defect in splanchnic (hepatic) glucose removal never could account for the magnitude of impairment in total body glucose uptake following intravenous glucose/insulin administration. However, after glucose ingestion, the oral route of administration and the resultant hyperglycemia conspire to enhance splanchnic (hepatic) glucose uptake (6,7,11,12,16,26,175) and, under these conditions, diminished hepatic glucose uptake has been shown to contribute to the impairment in glucose tolerance in T2DM (see discussion below) (6,204,205).

Summary: Whole Body Glucose Utilization

Insulin-mediated whole body glucose utilization during the euglycemic insulin clamp represents essentially skeletal muscle glucose utilization. There is a noticeable decrease for glucose taken up in the body in T2DM patients compared with non-diabetic subjects. On the other hand, net splanchnic glucose uptake, quantitated by the hepatic venous catheterization technique, is similar in both groups and averaged 0.5 mg.kg^-1.min^-1. Adipose tissue glucose uptake accounts for less than 5% of total glucose disposal (17,198,199). Brain glucose uptake, estimated to be 1.0-1.2 mg.kg^-1.min^-1 in the post-absorptive state (2,169,206), is unaffected by hyperinsulinemia (169). Muscle glucose uptake (extrapolated from leg catheterization data) in control subjects accounts for ~75-80% of the total glucose uptake (1,3,4). In subjects with T2DM, the largest part of the impairment in insulin-mediated glucose uptake is accounted for by a defect in muscle glucose disposal. Even if adipose tissue of subjects with T2DM took up absolutely no glucose, it could, at best, explain only a small fraction of the defect in whole body glucose metabolism.

Glucose Disposal during OGTT

In everyday life, the gastrointestinal tract represents the normal route of glucose entry into the body. However, the assessment of tissue glucose disposal following glucose ingestion presents a challenge because of the difficulties in quantitating the rate of glucose absorption, suppression of hepatic glucose production, and organ (liver and muscle) glucose uptake. Moreover, because the plasma glucose and insulin concentrations are changing simultaneously, it is difficult to draw conclusions about insulin secretion or insulin sensitivity.

To address these issues, Ferrannini, DeFronzo, and colleagues (7,11,12,205) administered oral glucose to healthy control subjects in combination with hepatic vein catheterization to examine splanchnic glucose metabolism. The oral glucose load and endogenous glucose pool were labeled with [1-¹⁴C] glucose and [3-³H] glucose, respectively, to quantitate total body glucose disposal (from tritiated glucose turnover) and endogenous HGP (difference between the total rate of glucose appearance, as measured with tritiated glucose, and the rate of oral glucose appearance, as measured with [1-¹⁴C] glucose).

During the 3.5 h after glucose (68 g) ingestion: (i) 19 g, or 28%, or the oral load was taken up by splanchnic tissues; (ii) 48 g, or 72%, was disposed of by peripheral (non-splanchnic) tissues; (iii) of the 48 g taken up by peripheral tissues, the brain (an insulin-independent tissue) accounted for ~15 g (~1 mg.kg^-1.min^-1), or 22%, of the total glucose load (12); (iv) basal HGP declined by 53%. Similar percentages for splanchnic glucose uptake (24%-29%) and suppression of HGP (50%-60%) in normal subjects have been reported by other investigators (13,204,207-209). The contribution of skeletal muscle to the disposal of an oral glucose load has been reported to vary from a low of 26% (207) to a high of 56% (208), with a mean of 45% (11,13,207-209). These results emphasize several important differences between oral and intravenous glucose administration. After glucose ingestion: (i) EGP is less completely suppressed, most likely due to activation of local sympathetic nerves that innervate the liver (210); (ii) peripheral tissue (primarily muscle) glucose uptake is quantitatively less important; (3) splanchnic glucose uptake is quantitatively much more important.

In individuals with T2DM (12,204,205,211,212) the disposition of an oral glucose load is significantly altered. The disturbance in glucose metabolism is accounted for by two factors: (i) decreased tissue glucose uptake and (ii) impaired EGP suppression. Splanchnic glucose uptake is similar in diabetic and control groups. Inappropriate suppression of EGP accounted for nearly one-third of the defect in total-body glucose homeostasis, while reduced peripheral (muscle) glucose uptake accounted for the remaining two-thirds. Since hyperglycemia per se enhances splanchnic (hepatic) glucose uptake in proportion to the increase in plasma glucose concentration (24,175), the splanchnic glucose clearance (SGU/plasma glucose concentration) is markedly reduced in all subjects with T2DM following glucose ingestion. Using a combined insulin clamp/OGTT technique, impairment in glucose uptake by the splanchnic tissues in subjects with T2DM has been demonstrated directly (213).

The gastrointestinal incretin hormones, which are produced in response to nutrient intake and potentiate the stimulus to insulin secretion in the postprandial period have been implicated as additional factors in the pathogenesis of T2DM (4A,28-30). The combined actions of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) can account for most of the incretin effect in normal subjects (4B). Recent demonstration that in T2DM the incretin effect is impaired, diminished or absent (4B) has rekindled interest in the potential role of these gastrointestinal peptides in the abnormal handling of glucose by splanchnic tissues and perhaps, in the decline in beta-cell insulin secretion.

When viewed in absolute terms, most studies have demonstrated that the total amount of glucose taken up by all tissues of body over the 4-hour period following the ingestion of an oral glucose load is normal (13) or slightly decreased (204,205,211). However, this occurs at the expense of postprandial hyperglycemia. Thus, the efficiency of glucose disposal, i.e., the glucose clearance (tissue glucose uptake/plasma glucose concentration), is severely reduced. It should be emphasized that it is not the absolute glucose disposal rate, but rather the increment in glucose disposal above baseline that determines the rise in plasma glucose concentration above the fasting value. Every published study (13,204,205,211) has demonstrated that the incremental response in whole-body glucose uptake is moderately to severely reduced in individuals with T2DM. Similar results have been reported for forearm muscle glucose uptake (13,201,202,208,209), pointing out the important contribution of diminished muscle glucose disposal to impaired oral glucose tolerance in T2DM.

In summary, results of the OGTT indicate that both impaired suppression of EGP and decreased tissue (muscle) glucose uptake contribute approximately equally to the glucose intolerance of T2DM. The efficiency of the splanchnic (hepatic) tissues to take up glucose (as reflected by the splanchnic glucose clearance) also is impaired in individuals with T2DM.

Summary of Insulin Resistance in T2DM

Insulin resistance involving both muscle and liver are characteristic features of the glucose intolerance in individuals with T2DM. In the basal state, the liver represents a major site of insulin resistance, and this is reflected by overproduction of glucose despite the presence of both fasting hyperinsulinemia and hyperglycemia. This accelerated rate of hepatic glucose output is the primary determinant of the elevated fasting plasma glucose concentration in T2DM. Although tissue (muscle) glucose uptake in the post-absorptive state is increased when viewed in absolute terms, the efficiency with which glucose is taken up (i.e., the glucose clearance) is diminished. After glucose infusion or ingestion (i.e., in the insulin stimulated state) both decreased muscle glucose uptake and impaired suppression of HGP contribute to the insulin resistance. Following glucose ingestion, the defects in insulin-mediated glucose uptake by muscle and the suppression of glucose production by insulin contribute approximately equally to the disturbance in whole-body glucose homeostasis in T2DM. However, under euglycemic hyperinsulinemic conditions, EPG is largely suppressed and impaired muscle glucose uptake is primarily responsible for the insulin resistance.

DYNAMIC INTERACTION BETWEEN INSULIN SENSITIVITY AND INSULIN SECRETION IN T2DM

Subjects with T2DM manifest abnormalities both in tissue (muscle, fat, and liver) sensitivity to insulin and in pancreatic insulin secretion. To understand how these two metabolic disturbances interact to produce the full-blown diabetic condition, it is necessary to quantitate insulin action and insulin secretion in the same individual over a wide range of insulin sensitivity. This dynamic interaction is demonstrated graphically by results obtained in healthy, lean, young normal glucose tolerant women who received a euglycemic insulin clamp (1 mU.kg^-1.min^-1) and were stratified into quartiles based upon the rate of insulin-mediated glucose disposal (49).

Insulin secretion was measured independently on a separate day with a +125 mg/dl hyperglycemic clamp. Insulin resistance and insulin secretion were strongly and positively correlated (r=0.79, p<0.001).  Women who were the most insulin resistant (quartile 1) had the highest fasting plasma insulin concentrations and highest early and late phase plasma insulin responses. Similar results relating the plasma insulin response and the severity of insulin resistance have been reported in normal glucose tolerant subjects with the minimal model technique (46,47) and the insulin suppression test/oral glucose tolerance test (214).

A number of groups have examined the dynamic interaction between insulin secretion and insulin sensitivity in subjects with T2DM (1,4,34,35,38,39,42,46-48,58-61,150,162).

DeFronzo (4) studied lean (ideal body weight < 120%) and obese (ideal body weight > 125%) subjects with varying degrees of glucose tolerance as follows: Group I-obese subjects (n=24) with normal glucose tolerance; Group II-obese subjects (n=23) with impaired glucose tolerance; Group III-obese subjects (n=35) with overt diabetes, subdivided into those with a hyperinsulinemic response and those with a hypoinsulinemic response during a 100-gram OGTT; Group IV-normal weight subjects with T2DM (n=26); Group V-normal weight subjects (n=25) with normal glucose tolerance. All subjects ingested 100 g of glucose to provide a measure of glucose tolerance and insulin secretion. Whole-body insulin sensitivity was quantitated with the euglycemic insulin (~100 µU/ml) clamp technique, which was performed with indirect calorimetry to quantitate rates of glucose oxidation and non-oxidative glucose disposal. The later primarily reflects glycogen synthesis (215).

In normal weight subjects with T2DM, insulin-mediated whole-body glucose uptake was reduced by 40-50% and the impairment in insulin action resulted from defects in both oxidative and non-oxidative glucose metabolism (4). Obese individuals without T2DM were as insulin resistant as the normal-weight subjects with T2DM (4). Defects in both glucose oxidation and glucose storage contributed to the insulin resistance in the obese nondiabetic group. From the metabolic standpoint, therefore, obesity and T2DM closely resemble each other.

Similar results concerning reduced whole-body insulin sensitivity in individuals with obesity and T2DM have been reported by other investigators (160,161,166,216-218). Despite nearly identical degrees of insulin resistance, normal-weight subjects with T2DM manifested fasting hyperglycemia and marked glucose intolerance, whereas the obese individuals without diabetes had normal or only minimally impaired oral glucose tolerance (4). This apparent paradox is explained by the plasma insulin response during the OGTT. Compared with control subjects, the obese group without diabetes secreted more than twice as much insulin, and this was sufficient to offset the insulin resistance. In contrast, in normal-weight subjects with T2DM, the pancreas, when faced with the same challenge, was unable to augment its secretion of insulin sufficiently to compensate for the insulin resistance. This imbalance between insulin supply by the beta-cells and the insulin requirement by tissues resulted in a frankly diabetic state, with fasting hyperglycemia and marked glucose intolerance.

The fact that plasma insulin response to the development of insulin resistance typically is increased during the natural history of T2DM does not mean that the beta cell is functioning normally. To the contrary, recent studies (4C) have demonstrated that the onset of beta-cell failure occurs much earlier and is more severe than previously appreciated.

Recognizing that simply measuring plasma insulin response to a glucose challenge does not provide a valid index of beta cell function, a series of studies were conducted in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and T2DM, using an oral glucose tolerance test to evaluate the increment in insulin secretion in response to an increment in plasma glucose. A euglycemic insulin clamp to measure insulin sensitivity was also performed to address the adjustment of the beta cell to the body’s sensitivity to insulin.

Thus, the results yielded a better measure of beta-cell function expressed per increment of plasma glucose and corrected for the degree of insulin resistance, the so-called disposition index [ΔI/ΔG ÷IR]. These data revealed a substantial decrease in beta-cell function, most evident in individuals with IGT who had lost anywhere from 60 to 85% of the total insulin secretory capacity.

When obesity and diabetes coexist in the same individual, the severity of insulin resistance is only slightly greater than that in either the normal-weight diabetic or nondiabetic obese groups (4), and the magnitude of the defects in glucose oxidation and non-oxidative glucose disposal are similar in all obese and diabetic groups. Although hyperinsulinemic and hypoinsulinemic obese diabetic subjects were equally insulin resistant, the severity of glucose intolerance is worse in the hypoinsulinemic group, and this was related entirely to the presence of severe insulin deficiency.

In the obese nondiabetic subjects, tissue sensitivity to insulin is markedly reduced, but glucose tolerance remains perfectly normal because the beta cells are able to augment their insulin secretory capacity appropriately to offset the defect in insulin action. As the obese individual develops impaired intolerance, there is a further reduction in insulin-mediated glucose disposal, which is due primarily to a decrease in glycogen synthesis. However, there is only a small additional impairment in glucose tolerance, because the beta cells are able to further augment their secretion of insulin to counteract the deterioration in insulin sensitivity. The progression of the obese, glucose intolerant person to overt diabetes is heralded by a decline in insulin secretion without any worsening of insulin resistance. The obese diabetic has tipped over the top of Starling's curve of the pancreas and is now on the descending portion. Even though the plasma insulin response is increased compared to nondiabetic control subjects, it is not elevated appropriately for the degree of insulin resistance and there is evidence that there is ~80% of beta-cell functional loss by the time of diagnosis in diabetic subjects. The beta cell insulin response during the OGTT is best represented by the change in plasma insulin over the change in plasma glucose concentration, taking into consideration the degree of insulin resistance for each individual, the so-called Insulin Secretion /Insulin Resistance Index or Disposition Index as shown in Figure 1 below.

Figure 1- Log normalization of the relationship between 2-hour plasma glucose and Insulin Secretion/ Insulin Resistance in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and patients with type 2 diabetes (T2DM). There is a linear decline in the insulin secretory capacity with the development of the disease, such that by the time clinical diabetes with hyperglycemia become evident, the loss of beta-cell secretion of insulin is below 5% of NGT controls.

The natural history of T2DM described above is consistent with results in humans and monkeys published by other investigators (33-39,42,43,59-61,98,150). In lean subjects with a wide range of glucose tolerance, Reaven et al (42) demonstrated that the progression from normal to impaired glucose tolerance was marked by the development of severe insulin resistance, which was counterbalanced by a compensatory increase in insulin secretion. The onset of T2DM was associated with no (or only slight) further deterioration in tissue sensitivity to insulin.  Rather, insulin secretion declined and the impairment in beta cell function was paralleled by a decrease in glucose tolerance.  A similar sequence of events has been documented prospectively in Pima Indians (34-39,58,60), in Caucasians (1,4,41,42,44,47,59, 162, 219), Pima Indians (34-39,58,60,219), and Pacific Islanders (33,62,220) and, is consistent with the development of T2DM in the rhesus monkeys (48).  As monkeys grow older, they become obese and develop a diabetic condition closely resembling human T2DM. The earliest detectable abnormality in this primate model is a decrease in tissue sensitivity to insulin. Because of a compensatory increase in insulin secretion, the fasting plasma glucose concentration and glucose tolerance remain normal.

The studies detailed above indicate that insulin resistance is an early and characteristic feature of the natural history of T2DM in high-risk populations. Overt diabetes develops only in those individuals whose beta cells are unable to appropriately augment their secretion of insulin to compensate for the defect in insulin action. It should be recognized, however, that there are well-described populations with T2DM in whom insulin sensitivity is normal at the onset of diabetes, whereas insulin secretion is severely impaired (81-83). How frequently this occurs in a typical patient with T2DM remains to be determined. This insulinopenic variety of diabetes appears to be more common in African-Americans, elderly subjects, and in lean Caucasians.  In this later group, it is important to exclude type 1 diabetes, since ~10% of Caucasians with older onset diabetes are islet cell antibody and/or GAD positive (220).

Primary Hypersecretion of insulin

An alternative view to explaining the “state of insulin resistance” is the notion that primary beta cell overstimulation results in insulin hypersecretion.  This leads to the development of obesity and insulin resistance, and then, to beta cell exhaustion (436).  In a model that presupposes beta cell hypersecretion as the initial manifestation of beta cell dysfunction, insulin sensitivity is modulated by insulin secretion.  When beta cell hypersecretion occurs, the responsiveness of insulin-sensitive tissues to insulin is downregulated and, these tissues become insulin resistant.  The latter becomes necessary to maintain normal glucose tolerance, without the adverse outcome of hypoglycemia.  However, considering that beta cell hypersecretion is primary and ‘fixed’, when insulin sensitivity is acutely improved, hypoglycemia would be expected to ensue.  In either case, the demonstration of the existence of a feedback loop that regulates glucose metabolism has made it clear that assessment of the adequacy of beta cell function requires knowledge of both the degree of insulin sensitivity and the magnitude of the insulin response. 

When considering the feedback loop governing glucose metabolism, in the face of increased insulin secretion, insulin resistance should develop as a protective measure to maintain normal glucose concentrations without hypoglycemia. This is supported by observations in patients with insulinomas, in whom the risk of hypoglycemia is reduced by the downregulation of insulin action with the development of insulin resistance (437).  Further support for this downregulation of insulin action comes from studies in healthy individuals with normal glucose tolerance in whom insulin resistance developed during 3–5 days of chronic physiologic hyperinsulinemia, achieved by insulin infusion balanced by glucose infusion to prevent hypoglycemia (438).  Higher basal insulin levels have been documented in individuals with obesity and impaired glucose tolerance before the development of T2DM and, identified as a risk factor for diabetes.  However, in these studies, OGTT glucose levels were already higher in those who progressed and could be a confounder. Thus, although studies provide some support for the concept of a potential independent pathogenic role of primary hyperinsulinemia in dysglycemia a stronger, more definitive proof is still missing. 

Therefore, while it is clear that T2DM is a heterogeneous condition characterized by beta cell failure, whether beta cell dysfunction or primary hyperinsulinemia is the early event in the pathogenesis of dysglycemia is now up for debate. Although there is sufficient evidence in humans (and animal models) to support the principal defect as being early beta cell dysfunction associated with reduced insulin secretion, it is incumbent on the proponents of the primary hyperinsulinemia hypothesis to undertake further studies to make their case more forcefully. Improved understanding of whichever mechanism underlies beta cell dysfunction should allow us to provide better preventative and therapeutic interventions for T2DM.

Delayed Insulin Clearance in Diabetes

The role of delayed (or decreased) insulin clearance as a contributor to insulin resistance and to the development of T2DM has been studied.  Insulin availability in the systemic circulation is determined by the rate of beta cell secretion and its rate of hepatic/peripheral/renal clearance.  Insulin levels modulate expression and activity of the insulin receptors in target tissues, which ultimately determines insulin action. The main site of insulin clearance is the liver that removes approximately 50% of endogenous insulin with the remainder being cleared by the kidneys and the skeletal muscle.  Receptor-mediated insulin endocytosis is the primary mechanism by which insulin is removed from the circulation and inactivated.  Upon binding to its receptor, the insulin-receptor complex is internalized through the formation of clathrin-coated vesicles, and is delivered to the endosomes; the acidification of the endosomes then allows the dissociation of the hormone from its receptor and their sorting in different directions. Most of the internalized insulin is next targeted to lysosomes where it is degraded, whereas a smaller fraction remains intact. Both degradation products and intact insulin are segregated in recycling vesicles and released from cell.  Defects in the intracellular processing of insulin have been reported in cells from insulin resistant individuals and reduced insulin clearance has been observed in individuals with IGT.  More recently, it has also been demonstrated that reduced insulin clearance predicts the development of T2DM independently of confounding factors.  There is evidence in animal model of fat-induced insulin resistance supporting the idea that decreased insulin clearance may serve as a compensatory mechanism to alleviate b-cell stress from excessive demand in these conditions of insulin resistance (439).  The extent to which delayed insulin clearance is responsible for the advancement of insulin resistance and its role in the pathogenesis of T2DM remains unknown.    

Nutrient-induced Stress on Insulin Secretion

There is growing support to the theory that an excess of calorigenic nutrients ingested over time presents the pancreatic islet beta-cells with an overwhelming burden, which might lead to toxic hormonal and metabolic adaptations.  It is well recognized that the short-term effects of glucose, lipids and amino acids perfusing the beta cells in the endocrine pancreas include the stimulation of insulin biosynthesis and secretion.  Excessive exposure to these nutrients is believed to over-stimulate the beta cells with a constant and uninterrupted demand for insulin release and, possibly induce changes in tissue insulin sensitivity.  Chronically, abundant nutritional intake will trigger augmented insulin secretion and insulin resistance, both of which have been shown to contribute to the pathogenesis of T2DM.  Eventually, there is altered glucose sensing and depletion of insulin stores.  The de-differentiation, with beta cell death that follows is likely to play a role in the progression of the disease.  Thus, the traditional concepts of “glucotoxicity” and lipotoxicity”, which defines the process of beta cell deterioration in response to chronic elevation of glucose and lipids in the pericellular milieu, has now been expanded to encompass all nutrients [‘nutri-toxicity”].

The biochemical mechanisms underlying beta cell adaptation and failure associated with “nutri-toxicity” are not entirely clear, but appear to be related to oxidative stress.  Various pathways in the cytosol, endoplasmic reticulum [ER] and mitochondria are involved, which tend to affect the insulin secretory capacity of the beta cell.  In conditions of mild-to-moderate “nutri-stress”, such as in overweight/obesity, there is exaggerated basal and nutrient stimulated insulin secretion.  Slightly elevated blood glucose concentration, hyperinsulinemia and insulin resistance become progressively more evident.  Obesity with beta cell failure and T2DM result when there is more advanced and prolonged nutri-stress”.  The metabolic machinery of the beta cell is overwhelmed and, there is mitochondrial and ER dysfunction, which result in severe oxidative stress.  As a consequence, insulin synthesis and secretion become impaired and there is intra- cellular accumulation of toxic metabolites with beta cell de-differentiation and death (440).

ROLE OF THE ADIPOCYTE IN THE PATHOGENESIS OF T2DM

The majority (>80%) of persons with T2DM in the US are overweight (221). Both lean and especially obese persons with T2DM are characterized by day-long elevations in the plasma free fatty acid concentration, which fail to suppress normally following ingestion of a mixed meal or oral glucose load (222). Free fatty acids (FFA) are stored as triglycerides in adipocytes and serve as an important energy source during conditions of fasting. Insulin is a potent inhibitor of lipolysis, and restrains the release of FFA from the adipocyte by inhibiting the enzyme hormone sensitive lipase. In patients with T2DM the ability of insulin to inhibit lipolysis (as reflected by impaired suppression of radioactive palmitate turnover) and reduce the plasma FFA concentration is markedly reduced (17). It is now recognized that chronically elevated plasma FFA concentrations can lead to insulin resistance in muscle and liver (1,4,19,21,22,51,162,223,224) and impair insulin secretion (22,225,226). Thus, elevated plasma FFA levels can cause/aggravate three major pathogenic disturbances that are responsible for impaired glucose homeostasis in individuals with T2DM and the "triumvirate" (muscle, liver, beta cell) was joined by the "fourth musketeer" (227) to form the "disharmonious quartet". In addition to FFA that circulate in plasma in increased amounts, individuals with T2DM and obese individuals without T2DM have increased stores of triglycerides in muscle (228,229) and liver (230,231) and the increased fat content correlates closely with the presence of insulin resistance in these tissues. Triglycerides in liver and muscle are in a state of constant turnover and the metabolites (i.e., fatty acyl CoAs) of intracellular FFAs have been shown to impair insulin action in both liver and muscle (1,4,92). This sequences of events has been referred to as "lipotoxicity" (1,4,22,93). Evidence also has accumulated to implicate "lipotoxicity" as an important cause of beta cell dysfunction (22,93) (see earlier discussion).

Adipocyte Inflammation and Insulin Resistance

Increased risk of developing T2DM is found in patients who have chronic, low-grade adipocyte inflammation and who are also insulin resistant (441).  The mechanisms of adipose tissue inflammation and the related insulin-resistant state are complex.  Visceral adiposity is known to be highly active in releasing numerous inflammatory cytokines [Adipokines] that are strongly implicated in the genesis of tissue insulin resistance and T2DM.  Adipokines provide an important link between obesity and insulin resistance IR.  Adiponectin is a unique adipokine that is inversely related to the metabolic syndrome, T2DM, and atherosclerosis.  Adiponectin increases fatty acid oxidation while reducing glucose production in liver, and ablation of the adiponectin gene in mice induces insulin resistance and T2DM.  Adiponectin is also anti-inflammatory; it suppresses tumor necrosis factor (TNF) actions in nonalcoholic fatty liver disease and inhibits nuclear factor kappa-beta [NFκB and monocyte adhesion to endothelial cells.  Human resistin is an adipokine secreted by infiltrating inflammatory cells in human adiposity and can stimulate synthesis and secretion of other cytokines in adipocytes and endothelial cells.  Leptin, a well-known adipokine, normally functions centrally to suppress appetite, but most obese patients are leptin resistant and have increased circulating leptin.  In obesity, hyperleptinemia contributes to inflammation through modulation of T-cell and monocyte functions.  A role for retinol-binding protein 4 [RBP-4], a more recently described adipokine has been proposed to be linked to inflammation.

Visfatin is a novel adipokine that is increased in obesity, is pro-inflammatory, and has an insulin-mimetic effect via binding to the insulin receptor.  A member of the lipocalin family, lipocalin-2, also known as neutrophil gelatinase–associated lipocalin, modulates inflammation and is another adipokine that is elevated in the adipose tissue of obese mouse models and in the plasma of obese and insulin-resistant humans.  In vitro studies suggest that lipocalin-2 induces insulin resistance in adipocytes and hepatocytes. The plasma level of another member of the lipocalin family, lipocalin-type prostaglandin D synthase, serves as a biomarker of coronary atherosclerosis.  Thus, multiple adipose-secreted factors that are capable of impairing the cellular action of insulin have been suggested to be involved in the development of insulin resistance and facilitate the development of T2DM.

It should be recognized that nutritional fatty acids can modulate the inflammatory response, particularly via NFκB activity, and promote insulin resistance.  Further-more, inflammatory modulation of adipocyte differentiation increases free fatty acid release. The mechanisms of free fatty acid-associated insulin resistance include protein kinase C (PKC) activation, endoplasmic reticulum stress, and increased oxidative burden.  Free fatty acids also inhibit insulin receptor substrates [IRSs] and induce insulin resistance in skeletal muscle and liver.  Increased fatty acid flux from adipose tissue to liver causes hepatic insulin resistance by increasing gluconeogenesis, glycogenolysis, and glucose-6-phosphatase expression and activity, and by enhancing lipogenesis and triglyceride synthesis attributable to activation of the transcription factor sterol-CoA regulatory element binding protein.  Finally, free fatty acids cause endothelial insulin resistance and damage by impairing insulin and nitric oxide–dependent signaling, thus contributing to the vascular injury observed in adiposity.

The initial insult in obese individuals that triggers inflammation and systemic insulin resistance may occur through recruitment of macrophages and innate immune antigen activation of inflammatory receptors in the membrane.  This can be perpetuated with secretion of chemokines, retention of macrophages in adipose, and secretion of adipokines.  The inflammatory milieu induces adipocyte inflammatory cascades, such as the NFκB pathway, via activation of various kinases, and this modulates adipocyte transcription factors, attenuates insulin signaling, and increases the release of pro-inflammatory adipokines and free fatty acids. Inflammatory attenuation of adipocyte differentiation further exacerbates adipose dysfunction. These paracrine and endocrine adipose inflammatory events induce a systemic inflammatory and insulin-resistant state, favoring the development of T2DM.

FFA and Muscle Glucose Metabolism

Four decades ago, Randle (232) proposed that increased FFA oxidation restrains glucose oxidation in muscle by altering the redox potential of the cell and by inhibiting key glycolytic enzymes. The excessive FFA oxidation: (i) leads to the intracellular accumulation of acetyl CoA, a potent inhibitor of pyruvate dehydrogenase (PDH), (ii) increases the NADH/NAD ratio, causing a slowing of the Krebs cycle, and (iii) results in the accumulation of citrate, a powerful inhibitor of phosphofructokinase (PFK). Inhibition of PFK leads to the accumulation of glucose-6-phosphate (G-6-P) which in turn inhibits hexokinase II. The block in glucose phosphorylation causes a buildup of intracellular free glucose which restrains glucose transport into the cell via the GLUT4 transporter. The resultant decrease in glucose transport was postulated to account for the impairment in glycogen synthesis, although a direct inhibitory effect of fatty acyl Co-As on glycogen synthase also has been demonstrated (233). This sequence of events via which accelerated plasma FFA oxidation inhibits muscle glucose transport, glucose oxidation, and glycogen synthesis is referred to as the "Randle Cycle" (232). It should be noted that the same scenario would ensue if the FFA were derived from triglycerides stored in muscle (228,229) or from plasma (222).

Felber and coworkers (59,159,162,234,235) were amongst the first to demonstrate that in obese non-diabetic and diabetic humans, basal plasma FFA levels and lipid oxidation (measured by indirect calorimetry) are increased and fail to suppress normally after glucose ingestion. The elevated basal rate of lipid oxidation was strongly correlated with a decreased basal rate of glucose oxidation, as well as with reduced rates of glucose oxidation and non-oxidative glucose disposal (glycogen synthesis) following ingestion of a glucose load. Further validation of the Randle Cycle in man has come from studies employing the euglycemic insulin clamp. In normal subjects, physiologic hyperinsulinemia (80-100 μU/ml) causes a 60-70% decline in plasma FFA concentration and a parallel decline in plasma FFA and total body lipid oxidation (18). When Intralipid is infused concomitantly with insulin to maintain or increase the plasma FFA concentration/oxidation, both glucose oxidation and non-oxidative glucose disposal are inhibited in a dose dependent fashion (223). Using magnetic resonance imaging, it has been shown that the FFA-induced inhibition of non-oxidative glucose disposal reflects impaired glycogen synthesis (236). The inhibitory effect of elevated plasma FFA levels can be observed at all plasma insulin concentrations, spawning the physiologic and pharmacologic range (223).

The inhibitory effect of an acute elevation in plasma FFA concentration on muscle glucose metabolism is time dependent. Thus, the earliest (within 2 hours) observed abnormality is a defect in glucose oxidation (237), as would be predicted by operation of the Randle cycle (232). This is followed (between 2-3 hours) by defects in glucose transport and phosphorylation and eventually (after 3-4 hours) by impaired glycogen synthesis.

Biochemical/Molecular Basis of FFA-Induced Insulin Resistance

The original description of the Randle cycle was formulated based upon experiments performed in rat diaphragm and heart muscle (232). More recent studies performed in human skeletal muscle suggest that mechanisms in addition to those originally proposed by Randle are involved in the FFA-induced insulin resistance. Thus, several groups (236,238,239) have failed to observe a rise in muscle G-6-P and citrate concentrations when insulin-stimulated glucose metabolism was inhibited by an increase in the plasma FFA concentration. Elevated plasma FFA levels also failed to inhibit muscle phosphofructokinase activity. Thus, while increased FFA/lipid oxidation and decreased glucose oxidation are closely coupled, as originally demonstrated by Randle, mechanisms other than product (i.e., elevated intracellular G-6-P and free glucose concentrations) inhibition of the early steps of glucose metabolism must be invoked to explain the defects in glucose transport, glucose phosphorylation and glycogen synthesis.

Studies in humans and animals have shown a strong inverse correlation between insulin- stimulated glucose metabolism and increased intramuscular lipid pools, including triglyceride (240-242), diacyl-glycerol (DAG) (243,244), and long chain fatty acyl CoAs (FA-CoA) (245). An acute elevation in plasma FFA concentration leads to an increase in muscle fatty acyl CoA and DAG concentrations. Both long chain fatty acyl CoAs and DAG activate PKC theta (243), which increases serine phosphorylation with subsequent inhibition of IRS-1 tyrosine phosphorylation (246,247). Consistent with this observation, two groups have shown that in human muscle elevated plasma FFA levels inhibit insulin-stimulated tyrosine phosphorylation of IRS-1, the association of the p85 subunit of PI-3 kinase with IRS-1, and activation of PI-3-kinase (248,249). Direct effects of long chain fatty acyl CoAs on glucose transport (250), glucose phosphorylation (251), and glycogen synthase (233) also have been demonstrated in muscle. Lastly, increased muscle ceramide levels (secondary to increased long chain fatty acyl CoAs) have been shown to interfere with glucose transport and to inhibit glycogen synthase in muscle via activation of PKB (252). In summary, elevated plasma FFA concentrations can induce insulin resistance in muscle via multiple mechanisms involving alterations in a variety of intracellular lipid signaling molecules which exert their inhibitory effects on multiple steps (insulin signal transduction system, glucose transport, glucose phosphorylation, glycogen synthase, pyruvate dehydrogenase, Krebs cycle) involved in glucose metabolism.

Fatty Liver Disease in T2DM

As the epidemics of obesity increases worldwide in conjunction with T2DM, there is a parallel and proportionate increase in the prevalence of nonalcoholic fatty liver disease (NAFLD).  A subtype of NAFLD, which can be characterized as nonalcoholic steato-hepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death.  NAFLD is also associated with extrahepatic manifestations such as chronic kidney disease, cardiovascular disease and sleep apnea.  Despite this important burden, we are only beginning to understand its pathogenesis and the contribution of environmental and genetic factors to the risk of developing the progressive course of fatty liver disease.  Of interest, however, despite the fact that the risk of liver-related mortality and the advancement to liver fibrosis are increased in patients with NAFLD, the leading cause of death is cardiovascular disease (442-443).

NAFLD and NASH are stages of fatty liver disease that are associated with obesity, insulin resistance, T2DM, hypertension, hyperlipidemia, and metabolic syndrome.  In these individuals, a net retention of lipids within hepatocytes, mostly in the form of triglycerides, is a prerequisite for the development of fatty liver disease.  The primary metabolic abnormality leading to lipid accumulation (steatosis), however, is not well understood, but it could potentially result from insulin resistance and alterations in the uptake, synthesis, degradation or secretory pathways of hepatic lipid metabolism. Insulin resistance represents the most reproducible factor in the development of fatty liver disease.  There is also some evidence that lipids synthesis de novo”, a process derived from excess non-utilized carbohydrates accumulated in hepatocytes contributes to the intracellular lipid pool.  Once an excessive amount of lipids accumulate inside the hepatocytes, a steatotic liver develops.  This makes the cellular architecture of the liver vulnerable to further injury, when challenged by additional insults. There is a presumption that progression from simple, uncomplicated steatosis to steato-hepatitis to advanced fibrosis results from two operating “hits” due to: i) insulin resistance with further accumulation of fat within hepatocytes, and ii) generation of reactive oxygen species due to lipid peroxidation with cytokine production and Fas ligand induction.  The oxidative stress and lipid peroxidation are key factors in the development and progression from steatosis to more advanced stages of liver damage.  In addition, this sequence of events reflects similar systemic processes, which worsen tissue insulin resistance with impairment of insulin secretion and accelerated atherogenesis, related primarily to the pro-inflammatory state (442).

FFA and Blood Flow

Insulin is a vaso-dilatory hormone and the stimulatory effect of insulin on muscle glucose metabolism has been shown to result from: (i) a direct action of insulin to augment muscle glucose metabolism, and (ii) increased blood flow to muscle (253,254). The vaso-dilatory effect of insulin is mediated via the release of nitric oxide from the vascular endothelium (255). In insulin resistant conditions, such as obesity and T2DM, some investigators have suggested that as much as half of the impairment in insulin-mediated whole body and leg muscle glucose uptake is related to a defect in insulin's vaso-dilatory action (253,254), although the link between insulin-mediated vasodilation and increased blood flow, as well as the underlying mechanisms have been challenged by others (256, 256A). More recent studies employed contrast-enhanced ultrasonography using 1-methyl-xantine to demonstrate that insulin infusion promotes capillary recruitment in healthy individuals. These data have suggested that there is a time-dependent effect of insulin on regional blood flow redistribution with capillary pre-sphincter relaxation preceding vasodilation and consequent increase in skeletal muscle glucose metabolism (256B). These observations also provided a partial explanation for the discrepant findings reported on the topic of insulin, fatty acids and vasodilatation.

Because T2DM and obesity are insulin resistant states characterized by day-long elevation in the plasma FFA concentration (222) and impaired endothelium dependent vasodilation (253), investigators have examined the effect of increased plasma FFA levels on limb blood flow and muscle glucose uptake (257,258). In healthy, non-diabetic subjects an acute physiologic increase in plasma FFA concentration inhibited metha-choline (endothelium dependent) but not nitroprusside (endothelium independent) stimulated blood flow in association with an impairment in insulin-stimulated muscle glucose disposal. In subsequent studies, the inhibitory effect of FFA on insulin-stimulated leg blood flow was shown to be associated with decreased nitric oxide availability (259). FFA elevation also inhibits nitric oxide production in endothelial cell cultures by decreasing nitric oxide synthase activity (259). Since the IRS-1/PI-3 kinase signal transduction pathway is involved in the regulation of nitric oxide synthase activity (260), one could hypothesize that FFA-induced inhibition of the insulin signal transduction pathway is responsible for the blunted vaso-dilatory response to the hormone.

FFA and Hepatic Glucose Metabolism

The liver plays a pivotal role in the regulation of glucose metabolism (1,4,6,11,16,205). Following carbohydrate ingestion, the liver suppresses its basal rate of glucose production and takes up approximately one-third of the glucose in the ingested meal (12,24,25,205).

Collectively, suppression of glucose production and augmentation of hepatic glucose uptake account for the maintenance of nearly one-half of the rise in plasma glucose concentration following ingestion of a carbohydrate meal.  Hepatic glucose production is regulated by a number of factors, of which insulin (inhibits) and glucagon and FFA (stimulate) are the most important. In vitro studies have demonstrated that plasma FFA are potent stimulators of endogenous glucose production and do so by increasing the activity of pyruvate carboxylase and phosphoenolpyruvate carboxy-kinase, the rate limiting enzymes for gluconeogenesis (261,262).  FFA also enhances the activity of glucose-6- phosphatase, the enzyme that ultimately controls the release of glucose by the liver (263).

In normal subjects, increase plasma FFA levels stimulate gluconeogenesis (264,265), while a decrease in plasma FFA concentration reduces gluconeogenesis (264). It has been shown that a significant portion of the suppressive effect of insulin on hepatic glucose production is mediated via inhibition of lipolysis and a reduction in circulating plasma FFA concentrations (16,266,267).  Moreover, FFA infusion in normal humans under conditions that simulate the diabetic state (268) and in obese insulin-resistant subjects (269) enhances hepatic glucose production, most likely secondarily to stimulation of gluconeogenesis.  In subjects with T2DM, the fasting plasma FFA concentration and lipid oxidation rate are increased and are strongly correlated with both the elevated fasting plasma glucose concentration and basal rate of hepatic glucose production (18,51,59,162,190,270). The relationship between elevated plasma FFA concentration, FFA oxidation, and hepatic glucose production in obesity and T2DM is explained as follows: (i) increased plasma FFA levels, by mass action, augment FFA uptake by hepatocytes, leading to accelerated lipid oxidation and accumulation of acetyl CoA. The increased concentration of acetyl CoA stimulates pyruvate carboxylase, the rate limiting enzyme in gluconeogenesis (261,262), as well as glucose-6-phosphatase, the rate-controlling enzyme for glucose release from the hepatocyte (263); (ii) the increased rate of FFA oxidation provides a continuing source of energy (in the  form of ATP) and reduced nucleotides (NADH) to drive gluconeogenesis; (iii) elevated plasma FFA induce hepatic insulin resistance by inhibiting the insulin signal transduction system (244- 248). In patients with T2DMthese deleterious effects of elevated plasma FFA concentrations occur in concert with increased plasma glucagon levels (181,190,271), increased hepatic sensitivity to glucagon, and increased hepatic uptake of circulating gluconeogenic precursors.

The Role of Gut Microbiome

Recently the potential role of the gut microbiome in metabolic disorders such as obesity and T2DM has been identified (444).  Obesity is associated with changes in the composition of the intestinal microbiota, and the obese microbiome seems to be more efficient in harvesting energy from the diet.  Lean male donor fecal microbiota transplantation (FMT) in males with the metabolic syndrome resulted in a significant improvement in insulin sensitivity in conjunction with an increased intestinal microbial diversity, including a distinct increase in butyrate-producing bacterial strains.  Such differences in gut microbiota composition might function as early diagnostic markers for the development of T2DM in high-risk patients.  Products of intestinal microbes such as butyrate may induce beneficial metabolic effects through enhancement of mitochondrial activity, prevention of metabolic endotoxemia, and activation of intestinal gluconeogenesis via different routes of gene expression and hormone regulation. There is currently an enormous effort in trying to better understand, amongst other things, whether bacterial products (like butyrate) have the same effects as the intestinal bacteria that produce it, in order to ultimately pave the way for more successful interventions for obesity and T2DM.   Rapid development of the currently available techniques, including the use of fecal transplantations, has already shown promising results, so there is hope for novel therapies based on the microbiota in the future.

Summary: FFA and the Pathogenesis of Obesity and T2DM

n obese individuals and in the majority (>80%) of subjects with T2DM, there is an expanded fat cell mass and the adipocytes are resistant to the anti-lipolytic effects of insulin (18). Most individuals with obesity or T2DM are characterized by visceral adiposity (272) and visceral fat cells have a high lipolytic rate, which is especially refractory to insulin (273). Not surprisingly, both T2DM and obesity are characterized by an elevation in the mean day-long plasma FFA concentration. Elevated plasma FFA levels, as well as increased triglyceride/fatty acyl CoA content in muscle, liver, and beta cell, lead to the development of muscle/hepatic insulin resistance and impaired insulin secretion.

THE OMNIOUS OCTET

Figure 2. Summary of the Eight Principal Mechanisms Contributing to Hyperglycemia in Patients with Type 2 Diabetes

The eight principle known causes leading to hyperglycemia through the pathogenesis of T2DM are summarized in Figure 2. It is already established that decreased peripheral glucose uptake combined with augmented endogenous (hepatic) glucose production are characteristic features of insulin resistance. Increased lipolysis with accumulation of intermediary lipid metabolites contributes to further enhance glucose output while reducing peripheral utilization. Compensatory insulin secretion by the pancreatic beta-cells eventually reaches a maximum and, then it progressively deteriorates. Concomitantly, there is inappropriate release of glucagon from the pancreatic alpha-cells, particularly in the post- prandial period. It has been postulated that both impaired insulin and excessive glucagon secretion in T2DM are facilitated by the “incretin defect”, defined primarily as inadequate response of the gastrointestinal “incretin” hormones to meal ingestion in addition to islet-cell resistance to the potentiating action on insulin-secretion by these gastrointestinal peptides. Moreover, considering that hypothalamic insulin resistance (central nervous system) with an elevated sympathetic drive, typically seen in patients with T2DM also impair the ability of circulating insulin to suppress glucose production. The fact that renal tubular glucose reabsorption capacity is enhanced in diabetic patients also contributes to the development and maintenance of chronic hyperglycemia.  Thus, the time has arrived to advance the concept from the “triumvirate” to the “omnious octet” (4A). Further, recent observations have recognized that a chronic low-grade inflammation with activation of the immune system are involved in the pathogenesis of obesity-related insulin resistance and T2DM (4D). Adipose tissue, liver, muscle and pancreas are themselves sites of inflammation in presence of obesity. Infiltration of macrophages and other immune cells as well as the presence of pro-inflammatory cytokines in these tissues has been associated with insulin resistance and beta-cell impairment. The possibility that endothelial dysfunction and changes in vascular capillary permeability affect peripheral insulin action has also been raised (4E). These pathogenic mechanisms must be taken into account when deciding for the treatment of hyperglycemia in patients with T2DM.

CELLULAR MECHANISMS OF INSULIN RESISTANCE

The stimulation of glucose metabolism by insulin requires that the hormone must first bind to specific receptors that are present on the cell surface of all insulin target tissues (1,274-277). After insulin has bound to and activated its receptor, "second messengers" are generated and these second messengers initiate a series of events involving a cascade of phosphorylation- de-phosphorylation reactions (1,274-280) that eventually result in the stimulation of intracellular glucose metabolism. The initial step in glucose metabolism involves activation of the glucose transport system, leading to influx of glucose into insulin target tissues, primarily muscle (1,281,282). The free glucose, which has entered the cell, subsequently is metabolized by a series of enzymatic steps that are under the control of insulin. Of these, the most important are glucose phosphorylation (catalyzed by hexokinase), glycogen synthase (which controls glycogen synthesis), and phosphofructokinase (PFK) and PDH (which regulate glycolysis and glucose oxidation, respectively).

Insulin Receptor/Insulin Receptor Tyrosine Kinase

The insulin receptor is a glycoprotein consisting of two alpha subunits and two beta subunits linked by disulfide bonds (1,274-277). The alpha subunit of the insulin receptor is entirely extracellular and contains the insulin-binding domain. The beta subunit has an extracellular domain, a transmembrane domain, and an intracellular domain that expresses insulin- stimulated kinase activity directed towards its own tyrosine residues (1,274-277). Insulin receptor phosphorylation of the beta subunit, with subsequent activation of insulin receptor tyrosine kinase, represents the first step in the action of insulin on glucose metabolism (274- 277). Mutagenesis experiments have shown that insulin receptors devoid of tyrosine kinase activity are completely ineffective in mediating insulin stimulation of cellular metabolism (283,284). Similarly, mutagenesis of any of the three major phosphorylation sites (at residues 1158, 1163, and 1162) impairs insulin receptor kinase activity, resulting in a decrease in the acute metabolic and growth promoting effects of insulin (283,285).

Insulin Receptor Signal Transduction

Following activation, insulin receptor tyrosine kinase phosphorylates specific intracellular proteins, of which at least nine have been identified (282). Four of these belong to the family of insulin-receptor substrate proteins: IRS-1, IRS-2, IRS-3, IRS-4 (the others include Shc, Cbl, Gab-1, p60dok, and APS). In muscle IRS-1 serves as the major docking protein that interacts with the insulin receptor tyrosine kinase and undergoes tyrosine phosphorylation in regions containing amino acid sequence motifs (YXXM or YMXM).  When phosphorylated, these serve as recognition sites for proteins containing src-homology 2 (SH2) domains (where y = tyrosine, M = methionine, and x - any amino acid) (274,275).  Mutation of these specific tyrosines severely impairs the ability of insulin to stimulate glycogen synthesis and DNA synthesis, establishing the important role of IRS-1 in insulin signal transduction (282). In liver, IRS-2 serves as the primary docking protein that undergoes tyrosine phosphorylation and mediates the effect of insulin on hepatic glucose production, gluconeogenesis and glycogen formation (287). In adipocytes, Cbl represents another substrate which is phosphorylated following its interaction with the insulin receptor tyrosine kinase, which is required for stimulation of GLUT 4 translocation.

Phosphorylation of Cbl occurs when the CAP/Cbl complex associates with flotillin in caveolae, or lipid rafts, containing insulin receptors (288,289).

In muscle, the phosphorylated tyrosine residues on IRS-1 mediate an association between the two SH2 domains of the 85-kDa regulatory subunit of phosphatidylinositol 3-kinase (PI3-kinase), leading to activation of the enzyme (274-284,290,291). PI3-kinase is a heterodimeric enzyme comprised of an 85-kDa regulatory subunit and a 110-kDa catalytic subunit. The latter catalyzes the 3-prime phosphorylation of phosphatidylinositol (PI), PI-4-phosphate, and PI-4,5- diphosphate, resulting in the stimulation of glucose transport (274-277). Activation of PI3-kinase by phosphorylated IRS-1 also leads to activation of glycogen synthase (274,275), via a process that involves activation of PKB/Akt and subsequent inhibition of kinases such as GSK-3 (292) and activation of protein phosphatase 1 (PP1) (293). Inhibitors of PI3-kinase impair glucose transport (274-277,294) by interfering with the translocation of GLUT 4 transporters from their intracellular location (281,282) and block the activation of glycogen synthase (295) and hexokinase (HK)-II expression (296). The action of insulin to increase protein synthesis and inhibit protein degradation also is mediated by PI-3 kinase and involves the activation of mTOR (297,298). mTOR controls translation machinery by phosphorylation and activation of p70 ribosomal S6 kinase (p70rsk) (297) and phosphorylation of initiation factors (299). Insulin also promotes hepatic triglyceride synthesis via increasing the transcription factor steroid regulatory element-binding protein (SREBP)-1c (300), and this lipogenic effect of insulin also appears to be mediated via the PI3-kinase pathway (274).

Other proteins with SH2 domains, including the adapter protein Grb2 and Shc, also interact with IRS-1 and become phosphorylated following exposure to insulin (274-276,301). Grb2 and Shc serve to link IRS-1/IRS-2 to the mitogen-activated protein (MAP) signaling pathway, which plays an important role in the generation of transcription factors (274,275). Following the interaction between IRS-1/IRS-2 and Grb2 and Shc, Ras is activated, leading to the stepwise activation of Raf, MEK, and ERK.  Activated ERK then translocates into the nucleus of the cell, where it catalyzes the phosphorylation of transcription factors.  These promote cell growth, proliferation, and differentiation (274-276,301-303).  Blockade of MAP kinase pathway prevents stimulation of cell growth by insulin but has no effect on the metabolic actions of the hormone (304-306).

Under anabolic conditions insulin stimulates glycogen synthesis by simultaneously activating glycogen synthase and inhibiting glycogen phosphorylase (307-309). The effect of insulin is mediated via the PI3 kinase pathway which inactivates kinases, such as glycogen synthase kinase-3 and activates phosphatases, particularly protein phosphatase 1 (PP1). It is believed that PP1 is the primary regulator of glycogen metabolism (307-310). In skeletal muscle, PP1 associates with a specific glycogen-binding regulatory subunit, causing the activation [de-phosphorylation] of glycogen synthase; PP1 also inactivates [phosphorylates] glycogen phosphorylase.  The precise steps that link insulin receptor tyrosine kinase/PI 3-kinase activation to the stimulation of PP1 have yet to be defined. Some evidence suggests that p90 ribosomal S6- kinase may be involved in the activation of glycogen synthase (274). Akt also has been shown to phosphorylate and thus inactivate GSK-3 (292). This decreases glycogen synthase phosphorylation, leading to the enzyme activation (292). A number of studies have convincingly demonstrated that inhibitors of PI3-kinase also inhibit glycogen synthase activity and abolish glycogen synthesis (274,293,310). From the physiological standpoint, it makes sense that activation of glucose transport and glycogen synthase should be linked to the same signaling mechanism to provide a coordinated stimulation of intracellular glucose metabolism.

Insulin Signal Transduction Defects in T2DM

Both receptor and post-receptor defects have been shown to contribute to insulin resistance in individuals with T2DM. Some, but not all studies have demonstrated a modest 20-30% reduction in insulin binding to monocytes and adipocytes from patients with T2DM (1,311- 316). This reduction is due to a decreased number of insulin receptors without change in insulin receptor affinity. In addition to the decreased number of cell-surface receptors, a variety of defects in insulin receptor internalization and processing have been described (314,315).

However, some caution should be employed in interpreting these studies. Muscle and liver, not adipocytes, represent the major tissues responsible for the regulation of glucose homeostasis in vivo and insulin binding to solubilized receptors obtained from skeletal muscle biopsies and liver has been shown to be normal in obese and lean diabetic individuals when expressed per milligram of protein (312,313,316-318). Moreover, a decrease in insulin receptor number cannot be demonstrated in over half of subjects with T2DM (319,320), and it has been difficult to demonstrate a correlation between reduced insulin binding and the severity of insulin resistance (321,322). The insulin receptor gene has been sequenced in a large number of patients with T2DM from diverse ethnic populations using denaturing-gradient gel electrophoresis or single- stranded conformational polymorphism analysis, and, with very rare exceptions (323), physiologically significant mutations in the insulin receptor gene have not been observed (324,325). This excludes a structural gene abnormality in the insulin receptor as a cause of common T2DM.

Insulin receptor tyrosine kinase activity has been examined in a variety of cell types (skeletal muscle, adipocytes, hepatocytes, and erythrocytes) from normal-weight and obese diabetic subjects. Most (278,301,312,313,320,326-328), but not all (317,329) investigators have found reduced tyrosine kinase activity that cannot be explained by alterations in insulin receptor number or insulin receptor binding. However, near-normalization of the fasting plasma glucose concentration, (by weight loss) has been reported to correct the defect in insulin receptor tyrosine kinase activity (330). This observation suggests that the defect in tyrosine kinase is acquired and results from some combination of hyperglycemia, defective intracellular glucose metabolism, hyperinsulinemia, and insulin resistance - all of which improved after weight loss. A glucose-induced reduction in insulin receptor tyrosine kinase activity has been demonstrated in rat fibroblast culture in vitro (331). Insulin receptor tyrosine kinase activity assays are performed in vitro, and the results of these assays could provide misleading information with regard to insulin receptor function in vivo. To circumvent this problem, investigators have employed the euglycemic hyperinsulinemic clamp in combination with muscle biopsies and anti- phospho-tyrosine immunoblot analysis (301). Such analysis yields a "snap shot" of the insulin- stimulated tyrosine phosphorylation state of the receptor in vivo. The results of these studies have demonstrated a substantial decrease in insulin receptor tyrosine phosphorylation in both obese nondiabetic and subjects with T2DM (301,328). When insulin-stimulated insulin receptor tyrosine phosphorylation was examined in normal-glucose-tolerant or impaired- glucose-tolerant individuals at high risk of developing T2DM, a normal increase in tyrosine phosphorylation of the insulin receptor has been observed (332). These observations are consistent with the concept that impaired insulin receptor tyrosine kinase activity in patients with T2DM is acquired secondarily to hyperglycemia or some other metabolic disturbance.

A physiologic increase in the plasma insulin concentration stimulates tyrosine phosphorylation of the insulin receptor and IRS-1 in lean healthy subjects to 150-200% of basal values (280,301,328,332,333). In obese subjects without T2DM, the ability of insulin to activate these two early insulin receptor signaling events in muscle is reduced, while in subjects with T2DM insulin has no significant stimulatory effect on either insulin receptor or IRS-1 tyrosine phosphorylation (301). The association of p85 protein and PI3-kinase activity with IRS-1 also is greatly reduced in obese non-diabetic and subjects with T2DM compared to lean healthy subjects (301,328- 334). Insulin also failed to increase the association of the p85 subunit of PI3-kinase with IRS-2 in muscle, indicating that T2DM is characterized by a combined defect in IRS-1 and IRS-2 function (301,328). The decrease in insulin stimulation of the association of the p85 regulatory subunit of PI3-kinase with IRS-1 is closely correlated with the impairment in muscle glycogen synthase activity and in vivo insulin-stimulated glucose disposal (301). Defective regulation of PI3-kinase gene expression by insulin also has been demonstrated in skeletal muscle and adipose tissue of subjects with T2DM (335). In animal models of diabetes, an 80% decrease in IRS-1 phosphorylation and a greater than 90% reduction in insulin-stimulated PI3-kinase activity have been reported (336).

In the insulin resistant, normal glucose tolerant offspring of two parents with T2DM, IRS-1 tyrosine phosphorylation and the association of p85 protein/PI3-kinase activity with IRS-1 are markedly decreased despite normal tyrosine phosphorylation of the insulin receptor; these insulin signaling defects are correlated closely with the severity of insulin resistance, measured with the euglycemic insulin clamp technique (332). In summary, a defect in the association of PI3-kinase with IRS-1 and its subsequent activation appears to be a characteristic abnormality in T2DM, is closely correlated with in vivo muscle insulin resistance, and is unrelated to a disturbance in insulin receptor tyrosine phosphorylation. Several groups (337,338) have reported that a common mutation in the IRS-1 gene (Gly 972 Arg) is associated with T2DM, insulin resistance, and obesity, but the physiologic significance of this mutation remains to be established (339).

The profound insulin resistance of the PI3-kinase signaling pathway contrasts markedly with the ability of insulin to stimulate MAP kinase pathway activity in insulin-resistant individuals with T2DM and in individuals with obesity without T2DM (301,328). Hyperinsulinemia increases MEK1 activity and ERK1/2 phosphorylation and activity to the same extent in lean healthy individuals as in patients with insulin resistance and obesity without T2DM and patients with T2DM (301,328). This finding of selective insulin resistance is similar to that recently observed in vasculature of Zucker fatty rats (340). Two possible reasons for this difference are alternate insulin signaling pathways and differential signal amplification. With regard to the former, the MAP kinase pathway can be activated either through Grb2/Sos interaction with IRS-1/IRS-2 or with Shc. Because IRS-1 tyrosine phosphorylation is dramatically reduced in the diabetics, it is possible that insulin activation of the MAP kinase pathway in vivo primarily occurs through Shc activation. There is evidence from in vitro studies to support this concept (341). Like ERK and MEK activity, insulin increased Shc phosphorylation to the same extent in lean and obese nondiabetic and subjects with T2DM (301). These results indicate that, in T2DM, insulin induces sufficient activation of the insulin receptor tyrosine kinase to increase Shc phosphorylation normally. It also is possible that differential signal amplification in the PI3-kinase and MAP kinase pathways can explain their differing susceptibilities to the effects of insulin resistance.

Maintenance of insulin stimulation of the MAP kinase pathway in the presence of insulin resistance in the PI3-kinase pathway may be important in the development of insulin resistance. ERKs can phosphorylate IRS-1 on serine residues (342), and serine phosphorylation of IRS-1 and the insulin receptor itself has been implicated in de-sensitization insulin receptor signaling (343). Continued ERK activity, when IRS-1 function already is impaired, could lead to a worsening of insulin resistance. Thus, subjects with T2DM or obesity have inappropriately high MAP kinase activity. One also could postulate that insulin resistance in the metabolic (PI3- kinase) pathway, with its compensatory increase in beta cell function and hyperinsulinemia, leads to excessive stimulation of the MAP kinase pathway in vascular tissue (301,302). This would result in the proliferation of vascular smooth muscle cells, increased collagen formation, and increased production of growth factors and inflammatory cytokines, possibly explaining the accelerated rate of atherosclerosis in individuals with T2DM (340A, 340B).

Glucose Transport

Activation of the insulin signal transduction system in insulin target tissues leads to the stimulation of glucose transport. The effect of insulin is brought about by the translocation of a large intracellular pool of glucose transporters (associated with low-density microsomes) to the plasma membrane (281,282,344). There are five major, different facilitative glucose transporters with distinctive tissue distributions (281,282,345,346) (Table 1). GLUT4, the transporter regulated by insulin is found in insulin-sensitive tissues (muscle and adipocytes), has a Km of ~5 mmol/l, which is close to that of the plasma glucose concentration, and is associated with HK-II (347- 349).  In adipocytes and muscle, its concentration in the plasma membrane increases markedly after exposure to insulin, and this increase is associated with a reciprocal decline in the intracellular GLUT4 pool.  GLUT1 represents the predominant glucose transporter in the insulin- independent tissues (brain and erythrocytes), but also is found in muscle and adipocytes. It is located primarily in the plasma membrane, where its concentration changes little after the addition of insulin. It has a low Km (~1 mmol/l) and is well suited for its function, which is to mediate basal glucose uptake. It is found in association with HKI (347-349).  GLUT2 predominates in the liver and pancreatic beta-cells, where it is found in association with a specific hexokinase, HKIV (347-350).  In the beta-cell, HKIV is referred to as gluco-kinase (350,351). GLUT2 has a high Km, (~15-20 mmol/l) and, as a consequence, the glucose concentration in cells expressing this transporter rises in direct proportion to the increase in plasma glucose concentration. This characteristic allows these cells to respond as glucose sensors.  In summary, each tissue has a specific glucose transporter and associated hexokinase, which allows it uniquely to carry out its specialized function to maintain whole-body glucose economy.

Glucose transport activity in patients with T2DM uniformly has been found to be decreased in adipocytes (281,282,320,351,352) and muscle (281,282,354-356). In adipocytes from humans with T2DM and rodent models of diabetes, there is a severe reduction in GLUT4 mRNA and protein, and the ability of insulin to elicit a normal translocation response and to activate the GLUT4 transporter after its insertion into the cell membrane is impaired (281,282,320,353,357). In contrast, muscle tissue obtained from lean and obese subjects with T2DM exhibits normal or increased levels of GLUT4 mRNA expression and normal levels of GLUT4 protein (358-361). Moreover, acute (2- 4-h) physiological hyperinsulinemia does not increase the number of GLUT4 transporters in muscle in either healthy subjects or subjects with T2DM (358-361). Several studies have demonstrated an increase in muscle GLUT4 mRNA levels in response to insulin in control subjects (333,360), but not in subjects with T2DM (360), suggesting insulin resistance at the level of gene transcription. However, the physiological significance of the blunted increase in muscle GLUT4 mRNA levels in subjects with T2DM is unclear, since both basal and insulin- stimulated GLUT4 protein levels are normal. Large populations of subjects with T2DM have been screened for mutations in the GLUT4 gene (362,363). Such mutations are very uncommon and, when detected, have been of questionable physiologic significance.

The results summarized above indicate that the gene (GLUT4) encoding the major insulin- responsive glucose transporter and its transcriptional/translational regulation are not impaired in T2DM. However, in contrast to the normal expression of GLUT4 protein and mRNA in muscle of subjects with T2DM, every study that has examined adipose tissue has reported reduced basal and insulin-stimulated GLUT4 mRNA levels, decreased GLUT4 transporter number in all subcellular fractions, diminished GLUT4 translocation, and impaired intrinsic activity of GLUT4 (281,282,353,361,364). These observations demonstrate that GLUT4 expression in humans is subject to tissue-specific regulation. Although insulin does not increase GLUT4 expression in muscle, it stimulates the translocation of GLUT4 transporters from their intracellular location to the cell membrane (354,365,366). In humans with T2DM, the ability of insulin to stimulate GLUT4 translocation in muscle is impaired (354,367). Using a novel triple- tracer technique, the in vivo dose-response curve for the action of insulin on glucose transport in forearm skeletal muscle has been examined in nondiabetic and subjects with T2DM (368-370). Insulin-stimulated inward muscle glucose transport is severely impaired in subjects with T2DM who are studied under euglycemic conditions. The defect in glucose transport cannot be overcome by repeating the insulin clamp at each subject's normal fasting glucose (hyperglycemia) level. Since the number of GLUT4 transporters in the muscle of subjects with T2DM is normal (358-361), impaired GLUT4 translocation (281,354,367) and decreased intrinsic activity of the glucose transporter (366,371) must be responsible for the defect in muscle glucose transport. Impaired in vivo muscle glucose transport in T2DM also has been demonstrated using MRI (372) and PET (373).

Glucose Phosphorylation

Glucose phosphorylation and glucose transport are tightly coupled phenomena (374). Isozymes of hexokinase (HKI-HKIV) catalyze the first committed intracellular step of glucose metabolism, the conversion of glucose to glucose-6-phosphate (G-6-P) (347-350,375) (Table 1). HKI, HKII, and HKIII are single-chain peptides that have a number of properties in common, including a very high affinity for glucose and product inhibition by G-6-P. HKIV, also called gluco-kinase, has a lower affinity for glucose and is not inhibited by G-6-P. Gluco-kinase (HKIVB) is believed to be the glucose sensor in the beta-cell, while HKIVL plays an important role in the regulation of hepatic glucose metabolism.

In both rat (375-377) and human (333,348,378-380) skeletal muscle, HKII transcription is regulated by insulin. HKI also is present in human skeletal muscle, but it is not regulated by insulin (378). In response to physiological euglycemic hyperinsulinemia, HKII cytosolic activity, protein content, and mRNA levels increase by 50-200% in healthy non-diabetic subjects (378,380) and this is associated with the translocation of hexokinase II from the cytosol to the mitochondria (381). In contrast, insulin has no effect on HK-I activity, protein content, or mRNA levels (378).

In forearm muscle, insulin-stimulated glucose transport (measured with the triple tracer technique) has been shown to be markedly impaired in lean subjects with T2DM (370). However, since the rate of intracellular glucose phosphorylation was impaired to an even greater extent, insulin caused an increase in the intracellular free glucose concentration. By performing the insulin clamp at each subject’s normal level of fasting hyperglycemia, normal rates of whole- body glucose disposal and a normal rate of glucose influx into muscle was elicited. However, the rate of intracellular glucose phosphorylation increased only modestly; consequently, there was a dramatic rise in the free glucose concentration within the intracellular space that is accessible to glucose. These observations indicate that in individuals with T2DM, while both glucose transport and glucose phosphorylation are severely resistant to the action of insulin, impaired glucose phosphorylation (HKII) appears to be the rate-limiting step for insulin action. A similar pattern of impaired muscle glucose phosphorylation and transport is present in the insulin-resistant, normal glucose-tolerant offspring of two diabetic parents (382). These results are consistent with dose-response studies using PET to evaluated glucose phosphorylation and transport in skeletal muscle of subjects with T2DM (373). They also are consistent with 31P-NMR studies (383) which demonstrate that, during hyperinsulinemia, muscle G-6-P concentrations decline in subjects with T2DM versus control subjects. However, subsequent studies using ³¹P-NMR in combination with 1-¹⁴C-glucose suggest that the defect in insulin-stimulated muscle glucose transport exceeds the defect in glucose phosphorylation and is responsible for the decline in muscle glucose-6-P concentration (372). Because of methodologic differences, the results of the triple tracer (370) and MRI (372) studies cannot be reconciled at present. Nonetheless, observations from these studies are consistent in demonstrating that the defects in glucose phosphorylation and glucose transport in muscle are established early in the natural history of T2DM and cannot be explained by glucose toxicity (91). Clear evidence that HKII activity is crucial for glucose uptake derives from studies in transgenic mice who overexpress HKII. In this model, HKII over-expression increased both insulin- and exercise-stimulated muscle glucose uptake (384).

In healthy nondiabetic subjects, physiologic hyperinsulinemia for as little as 2-4 hours increases muscle HKII activity, gene transcription, and translation (333,378). In lean subjects with T2DM insulin-stimulated HKII activity and mRNA levels are markedly reduced compared to controls (383,385). Decreased basal muscle HKII activity and mRNA levels (385) and impaired insulin-stimulated HKII activity (379,380,386,387) in subjects with T2DM have been reported by other investigators. A decrease in insulin-stimulated muscle HKII activity also has been described in individuals with IGT (388). Because of its central role in insulin-mediated muscle glucose metabolism, several groups have looked for point mutations in the HKII gene in individuals with T2DM (388-390). Although several nucleotide substitutions have been found, none have been located close to the glucose and ATP binding sites and none have been associated with insulin resistance. Thus, an abnormality in the HKII gene is unlikely to explain the inherited insulin resistance in common variety T2DM.

Glycogen Synthesis

After glucose is phosphorylated by hexo-kinase II, it either can be converted to glycogen or enter the glycolytic pathway. Of the glucose that enters the glycolytic pathway, ~90% is oxidized. At low physiologic plasma insulin concentrations, glycogen synthesis and glucose oxidation are of approximately equal quantitative importance. With increasing plasma insulin concentrations, glycogen synthesis predominates (18,391). If the rate of glucose oxidation (determined by indirect calorimetry) is subtracted from the rate of whole-body insulin-mediated glucose disposal (determined from the insulin clamp), the difference represents non-oxidative glucose disposal (or glucose storage) (17,360), which primarily reflects glycogen synthesis (1,4,162,216,392).  Glucose conversion to lipid accounts for <5% of total body glucose disposal (18,198,199) and, less than 5-10% of the glucose taken up by muscle is released as lactate (5,393,394).  

Reduced insulin-stimulated glycogen synthesis is a characteristic finding in all insulin-resistant states, including obesity, diabetes, and the combination of obesity plus diabetes (1,4,18,43,59,159,162,218,219,377,393-395). Impaired glycogen synthesis also represents the major cause of insulin resistance in obese subjects with normal or only slightly impaired glucose tolerance (1,4,162,218,393,395,396).  Thus, the inability of insulin to promote glycogen synthesis is a characteristic and early defect in the development of insulin resistance in both obesity and T2DM. The emergence of overt diabetes with fasting hyperglycemia is associated with a major reduction in insulin-mediated non-oxidative glucose disposal (glycogen synthesis) in all ethnic groups (1,4,18,162,377,396).  Impaired glycogen synthesis also has been demonstrated in the normal-glucose-tolerant offspring of two diabetic parents (43,397), in the first-degree relatives of people with T2DM (41,398,399), and in a normoglycemic twin of a monozygotic twin pair in which the other has T2DM (101).

Using NMR imaging spectroscopy, a decrease in insulin-stimulated incorporation of [1H, ¹³C]- glucose into muscle glycogen of subjects with T2DM has been demonstrated directly (215). In T2DM, there was a marked lag in the onset of insulin-stimulated glycogen synthesis that was similar to the delay in insulin-mediated leg muscle glucose uptake. The rate of glycogen synthesis in subjects with T2DM was decreased by ~50%, paralleling the decrease in total glucose uptake by leg muscle (3).  Also, impaired muscle glycogen synthesis accounted for essentially all of the defect in whole body glucose disposal.

In summary, an abundance of convincing evidence demonstrates that impaired glycogen synthesis is the major metabolic defect in normal glucose tolerant subjects with obesity, in individuals with IGT, and in patients with overt diabetes. Moreover, numerous studies have documented that the earliest detectable metabolic abnormality responsible for the insulin resistance in normal glucose tolerant individuals who are destined to develop T2DM is impaired glycogen synthesis (4,41,43,101,382,392,399,400).

Glycogen synthase is the key insulin-regulated enzyme which controls the rate of muscle glycogen synthesis (307,308,310,379,401,402). Insulin enhances glycogen synthase activity by stimulating a cascade of phosphorylation/de-phosphorylation reactions (307,308,361-363,403) (see above discussion of insulin receptor signal transduction), which ultimately lead to activate PP1 (also called glycogen synthase phosphatase) (307,308,310,402). The regulatory subunit (G) of PP1 has two serine phosphorylation sites, called site 1 and site 2.  Phosphorylation of site 2 by cAMP-dependent kinase (PKA) inactivates PP1, while phosphorylation of site 1 by insulin activates PP1, leading to the stimulation of glycogen synthase (307,308,402,404). Phosphorylation of site 1 of PP1 by insulin in muscle is catalyzed by insulin-stimulated protein kinase 1 (ISPK-1) (309,405), which is part of a family of serine/threonine protein kinases termed ribosomal S6-kinases.  Because of their central role in muscle glycogen formation, considerable attention has focused on the three enzymes glycogen synthase, PP1, and ISPK-1 in the pathogenesis of insulin resistance in T2DM.

Glycogen synthase exists in an active (dephosphorylated) and an inactive (phosphorylated) form (307-310). Under fasting conditions, total glycogen synthase activity in subjects with T2DM is reduced and the ability of insulin to activate glycogen synthase is severely impaired (301,384,406-410). An impaired ability of insulin to activate glycogen synthase also has been demonstrated in the normal glucose tolerant relatives of individuals with T2DM (400).

Insulin-mediated activation of glycogen synthase and insulin-stimulated glycogen synthase gene expression has been shown to be impaired in cultured myocytes and fibroblasts from subjects with T2DM (411,412). Studies in insulin-resistant nondiabetic and diabetic Pima Indians have documented that the ability of insulin to activate muscle PP1 (glycogen synthase phosphatase) is severely reduced (413). PP1 dephosphorylates glycogen synthase, leading to its activation. Therefore, a defect in PP1 appears to play an important role in muscle insulin resistance (309).

The effect of insulin on glycogen synthase gene transcription and translation in vivo has been studied extensively. Most studies (378,414,415) have shown that insulin does not increase glycogen synthase mRNA or protein expression in human muscle studied in vivo. However, glycogen synthase mRNA expression is decreased in muscle of patients with T2DM (415,416), explaining in part the decreased glycogen synthase activity in this disease. However, the major abnormality in glycogen synthase regulation in T2DM and other insulin resistant conditions is its lack of de-phosphorylation and activation by insulin as a result of insulin receptor signaling abnormalities (see previous discussion). The glycogen synthase gene (417) has been the subject of intensive investigation. An association between glycogen synthase gene markers and T2DM has been demonstrated in Japanese, French, Finnish, and Pima Indian populations. However, DNA sequencing has revealed either no mutations (418) or rare nucleotide substitutions (419,420) that cannot explain the defect in insulin-stimulated glycogen synthase. Nonetheless, the association between the glycogen synthase gene and T2DM (418) suggests that another gene close to the glycogen synthase gene may be involved in the development of T2DM. The genes encoding the catalytic subunits of PP1 (421) and ISPK-1 (422) have been examined in insulin-resistant Pima Indians and Danes with T2DM. Several silent nucleotide substitutions were found in the PP1 and ISPK-1 genes in the Danish population; the mRNA levels of both genes were normal in skeletal muscle (422). No structural gene abnormalities in the catalytic subunit of PP1 were detected in Pima Indians (422). Thus, neither abnormalities in the PP1 and ISPK-1 genes nor abnormalities in their translation can explain the impaired enzymatic activities of glycogen synthase and PP1 that have been observed in vivo. Similarly, there is no evidence that an alteration in glycogen phosphorylase plays any role in the abnormality in glycogen formation in T2DM (423). In summary, glycogen synthase activity is severely impaired in patients with T2DM and in insulin-resistant normal glucose tolerant individuals who are predisposed to develop T2DM. However, the defect cannot be explained by an abnormality in the genes encoding glycogen synthase or is promoter or by other key genes - PP1 or ISPK-1 - involved in the regulation of glycogen synthase activity.

Glycolysis/Glucose Oxidation

Glucose oxidation accounts for ~90% of total glycolytic flux, while anaerobic glycolysis accounts for the other 10% (393,394). Two enzymes, phosphofructokinase (PFK) and pyruvate dehydrogenase (PDH) play pivotal roles in the regulation of glycolysis and glucose oxidation, respectively. In individuals with T2DM the glycolytic/glucose oxidative pathway has been shown to be impaired in many individuals with T2DM (393,394). Although one study suggested that the activity of PFK is modestly reduced in muscle biopsies from subjects with T2DM (424), the majority of evidence indicates that the activity of PFK is normal (407,412,417). Insulin has no effect on muscle PFK activity, mRNA levels, or protein content in either nondiabetic or diabetic individuals (417). PDH is a key insulin-regulated enzyme whose activity in muscle is acutely stimulated by a physiological increment in the plasma insulin concentration (415). Three previous studies have examined PDH activity in patients with T2DM. Insulin-stimulated PDH activity is decreased in isolated subcutaneous human adipocytes from patients with T2DM (425) and in skeletal muscle from subjects with T2DM undergoing euglycemic hyperinsulinemic clamps (426). However, when patients with T2DM had muscle biopsies during hyperglycemic hyperinsulinemic clamps, activation of PDH by insulin was normal (409), in concert with normalized rates of muscle glucose uptake. These results suggest that insulin stimulation of PDH activity is influenced by glycolytic flux.

Both obesity and T2DM are associated with accelerated FFA turnover and oxidation (1,4,18,162), which would be expected, according to the Randle cycle (232), to inhibit PDH activity and consequently glucose oxidation (see prior discussion). Thus, any observed defect in glucose oxidation or PDH activity could be acquired secondarily to increased FFA oxidation and feedback inhibition of PDH by elevated intracellular levels of acetyl-CoA and reduced availability of NAD. Consistent with this observation, the rates of basal and insulin- stimulated glucose oxidation have been shown to be normal in the normal glucose tolerant offspring of two parents with T2DM (43) and in the first-degree relatives of subjects with T2DM (41,423), while it is decreased in subjects with overt T2DM (1,4,393,394,427). Studies examining PHD activity in muscle tissue from lean diabetic subjects with mild fasting hyperglycemia are needed before the role of this enzyme in the development of insulin resistance in T2DM can be established or excluded.

In summary, post-binding defects in insulin action primarily are responsible for the insulin resistance in T2DM. Diminished insulin binding, when present, is small, occurs in individuals with IGT or very mild diabetes, and results secondarily from downregulation of the insulin receptor by chronic sustained hyperinsulinemia. In patients with T2DM and overt fasting hyperglycemia, post-binding defects are responsible for the insulin resistance. A number of post-binding defects have been documented, including diminished insulin receptor tyrosine kinase activity, insulin signal transduction abnormalities, decreased glucose transport, reduced glucose phosphorylation, and impaired glycogen synthase activity. The glycolytic/glucose oxidative pathway appears to be largely intact and, when defects are observed, they appear to be acquired secondarily to enhanced FFA/lipid oxidation. From the quantitative standpoint, impaired glycogen synthesis represents the major pathway responsible for the insulin resistance in T2DM, and family studies suggests that a defect in the glycogen synthetic pathway represents the earliest detectable abnormality in T2DM. Recent studies link the impairment in glycogen synthase activation to a defect in the ability of insulin to phosphorylate IRS-1, causing a reduced association of the p85 subunit of PI 3-kinase with IRS-1 and decreased activation of the enzyme (PI 3-kinase).

Mitochondrial Dysfunction

In obesity and T2DM, impaired oxidation, reduced mitochondrial contents, lowered rates of oxidative phosphorylation and the production and release of excessive reactive oxygen species (ROS) have been reported. Mitochondrial biogenesis is regulated by various transcription factors such as peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), peroxisome proliferator-activated receptors (PPARs), estrogen-related receptors (ERRs), and nuclear respiratory factors (NRFs).  Mitochondrial fusion is promoted by mitofusin 1 (MFN1), mitofusin 2 (MFN2) and optic atrophy 1 (OPA1), while fission is governed by the recruitment of dynamin-related protein 1 (DRP1) by adaptor proteins, such as mitochondrial fission factor (MFF), mitochondrial dynamics proteins of 49 and 51 kDa (MiD49 and MiD51), and fission 1 (FIS1).  Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) and PARKIN promote DRP1-dependent mitochondrial fission, and the outer mitochondrial adaptor MiD51 is required in DRP1 recruitment and PARKIN-dependent mitophagy.  Several molecular abnormalities affecting these critical aspects of mitochondrial dynamics have been identified in obese individuals and in patients with T2DM (446). 

The generation of new mitochondria, mitochondrial biogenesis, is presumed to be defective in patients with T2DM because the expressions of PGC-1α and its targeted genes are reduced.  They are associated with an impaired ability to produce mitochondrial ATP and increased ROS production from the electron transport chain.  There is some preliminary evidence that stimulation of mitochondrial biogenesis by pharmacological activation targeting these molecules is beneficial in the treatment of T2DM and obesity.  The accumulation of damaged or depolarized mitochondria in pancreatic β cells is associated with oxidative stress and favors subsequent development of diabetes.  Mitochondria in pancreatic β cells are continuously recruited in the fusion and fission processes.  In a cultured pancreatic β cell line (INS-1), high levels of glucose- and palmitate-induced mitochondrial fusion arrested and reduced respiratory function.  In INS1 cells, mitochondria with fission demonstrated reduced Δψ and decreased levels of the fusion protein OPA1. The inhibition of fission machinery proteins using DRP1 and FIS1 RNAi resulted in decreased mitochondrial autophagy, the accumulation of oxidized mitochondrial proteins, reduced respiration, and impaired insulin secretion.  All of these suggest that selective fission of damaged mitochondria is followed by their removal by autophagy.  In another study, INS-1 cells were treated with palmitate and high glucose, and the fragmentation of mitochondria with reduced fusion activities was observed. The application of FIS1 RNAi that shifts the dynamic balance to favor fusion is able to prevent mitochondrial fragmentation, maintain mitochondrial dynamics, and prevent apoptosis.  Thus, although not entirely elucidated, abnormal mitochondrial fusion and fission dynamics in the pancreatic β cells may play an important role in beta cell dysfunction and the progression of T2DM.

Obesity and T2DM are associated with impaired skeletal muscle oxidation, reduced mitochondrial contents, and lowered rates of TCA cycle enzymes and OXPHOS.  Patients with T2DM and obesity also demonstrated reduced expression of MFN2, which may be related to the reduced function of mitochondria in skeletal muscle.  In 17 subjects with obesity, 12 weeks of exercise improved insulin sensitivity and fat oxidation.  Skeletal muscle biopsy in these patients revealed that decreased phosphorylation and reduction of DRP1 at serine 616 were negatively correlated with increases in fat oxidation and insulin sensitivity (447).  In this same study, there was a trend towards an increase in the expression of both MFN1 and MFN2.  Studies in hepatocytes have recently demonstrated that the role of MAMs in calcium, lipid, and metabolite exchange is altered in obesity and T2DM.  Although the ER and mitochondria play distinct cellular roles in the process of intermediary metabolism, obesity is known to lead to a marked reorganization of MAMs, which results in mitochondrial calcium overload, reduced respiratory function, and augmented oxidative stress (448).  In contrast, disrupting the integrity of MAMs by knocking out cyclophilin D leads to hepatic insulin resistance through the disruption of inter-organelle Ca^2＋ transfer, ER stress, mitochondrial dysfunction, lipid accumulation, the activation of c-Jun N-terminal kinase and PKCε.  In addition to the beta-cell and skeletal muscle defects described earlier, these altered molecular pathways in the liver represent potential targets for new pharmaceutical intervention to be explored in future studies including individuals with obesity and patients with T2DM.

REFERENCES

1. DeFronzo Pathogenesis of type 2 diabetes mellitus: metabolic and molecular implications for identifying diabetes genes. Diabetes 5:117-269, 1997.
2. Grill V. A comparison of brain glucose metabolism in diabetes as measured by positron emission tomography or by arteriovenous techniques. Ann Med 22:171-175,
3. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin dependent diabetes mellitus. J. Clin Invest 76: 149-155,
4. DeFronzo Lilly Lecture. The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667-687, 1988.

4A. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-795, 2009

4B. Nauck M, Stockmann F, Ebert R, Creutzfeld W. Reduced incretin effect in type 2 (non- insulin-dependent) diabetes. Diabetologia 29:46-52, 1986

4C. Gastaldelli A. Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio Metabolism (SAM) study. Diabetologia 47:31-39, 2004

4D.   Wellen KE and Hotamisligil GS. Inflammation, stress, and diabetes. J of Clin Invest 115 (5):1111–1119, 2005. doi:10.1172/JCI25102.

4E.   Clark MG, Walls MG, Barrett EJ, Vincent MA, Richards SM, Clerk LH, Rattigan, S. Blood flow and muscle metabolism: a focus on insulin action. Am J Physiol: Endocrinol and Metabol 284 (2): E241-E258, 2003 /https://doi.org/10.1152/ajpendo.00408.2002

5. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose: results from indirect calorimetry. Diabetes 30:1000- 1007,
6. DeFronzo RA, Ferrannini E. Regulation of hepatic glucose metabolism in humans. Diabetes Metab Rev 3:415-459, 1987.

6A.   Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nature Medicine 8(12): 1376-1382, 2002

7. Mari A, Wahren J, DeFronzo RA, Ferrannini E. Glucose absorption and production following oral glucose: comparison of compartmental and arteriovenous-difference methods. Metabolism 43:1419-1425,
8. Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal glucose metabolism in humans. Am J Physiol 276(39): E788-E84,
9. Ekberg K, Landau BR, Wajngot A, Chandramouli V, Efendic S, Brunengraber H, Wahren J. Contributions by kidney and liver to glucose production in the post-absorptive state and after 60 h of fasting. Diabetes 48:292-298,

9A.    Farber SJ, Berger EY and Earle DP. Effect of diabetes and insulin on the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30:125-29, 1951

9B.   Morgensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 28:101-09, 1971

9C.   Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427-34. 2005.

9D.   Cersosimo E. Renal glucose handling and the kidney as target for anti-diabetic medication. Current Trends in Endocrinology, vol. 7, 2014

10. Magnusson I. Katz LD. Shulman RG. Shulman GI. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science. 254:573-6, 1991
11. Katz LD, Glickman MG, Rapoport S, Ferrannini E, DeFronzo Splanchnic and peripheral disposal of oral glucose in man. Diabetes 32:675-679, 1983.
12. Ferrannini E, Bjorkman O, Reichard GA Jr, Pilo A, Olsson M, Wahren J, DeFronzo RA. The disposal of an oral glucose load in healthy subjects. Diabetes 34:580-588,
13. Mitrakou A, Kelley D, Veneman T, Jensen T, Pangburn T, Reilly J, Gerich Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39:1381-90, 1990.
14. Mandarino L, Bonadonna R, McGuinness O, Wasserman D. Regulation of Muscle Glucose Uptake In Vivo. In: Handbook of Physiology, Section 7, The Endocrine System, Vol. II, The Endocrine Pancreas and Regulation of Metabolism, pp 803-848, L.S. Jefferson and A.D. Cherrington, eds., Oxford University Press,
15. Del Prato S. Riccio A. Vigili de Kreutzenberg S. Dorella M. Tiengo A. DeFronzo RA. Basal plasma insulin levels exert a qualitative but not quantitative effect on glucose-mediated glucose uptake. Am J Physiol 268: E1089-95,
16. Cherrington AD. Control of glucose uptake and release by the liver in Diabetes 48:1198-1214, 1999.
17. Jansson P-A, Larsson A, Smith U, Lonroth P. Lactate release from the subcutaneous tissue in lean and obese men. J Clin Invest 93:240-246,
18. Groop LC, Bonadonna RC, Del Prato S Ratheiser K, Zych K, Ferrannini E, DeFronzo RA. Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84:205-215, 1989
19. Santomauro A, Boden G, Silva M, Rocha DM, Santos RF, Ursich MJM, Strassman PG, Wajchenberg BL. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and non-diabetic subjects. Diabetes 48:1836-1841,
20. Bergman RN. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia. 43:946-52,
21. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10,
22. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 51:7-18,
23. Baron AD. Schaeffer L. Shragg P. Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 36:274-83,
24. DeFronzo RA, Ferrannini E, Hendler R, Wahren J, and Felig P. Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. Proc Natl Acad Sci 75:5173-5177,
25. Ferrannini E, Wahren J, Felig P, DeFronzo Role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. Metabolism 29:28-35, 1980.
26. Hsieh P-S, Moore MC, Neal DW, Cherrington AD. Hepatic glucose uptake rapidly decreases after removal of the portal signal in conscious dogs. Am J Physiol 275: E987-E992,

27. Adkins-Marshall B, Pagliassotti MJ, Asher JR, Connolly CC, Neal DW, Williams PE, Myers SR, Hendrick GK, Adkins RB Jr, Cherrington AD. Role of hepatic nerves in response of liver to intraportal delivery in dogs. Am J Physiol 262: E679-E686,
28. Creutzfeldt W. The incretin concept today. Diabetologia 16:75-85, 1979.
29. Drucker Glucagon-like peptides. Diabetes 47:159-169, 1998.
30. Holst JJ, Gromada J, Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40:984-986,
31. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334:777-783,
32. Cerasi E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia 38:992-997,
33. Sicree RA, Zimmet P, King HO, Coventry JO. Plasma insulin response among Nauruans. Prediction of deterioration in glucose tolerance over 6 years. Diabetes 36:179-186,
34. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet i:1356-1359,
35. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. New Engl J Med 319:1500-1505,
36. Haffner SM, Miettinen H, Gaskill SP, Stern Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican- Americans. Diabetes 44:1386-1391, 1995.
37. Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance. Evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 49:2094-2101,
38. Weyer C, Bogardus C, Pratley Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 48:2197-2203, 1999.
39. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24:89-94,
40. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, Dailey G, Gerich Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first degree NIDDM relative. JAMA 273:1855-1861, 1995.
41. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. New Engl J Med 321:337-343, 1989.
42. Reaven GM, Hollenbeck CB, Chen YDI. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 32:52-55,
43. Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo RA. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 41:1575-1586,

44. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn RC. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25- year follow-up study. Lancet 340:925-929,
45. Lillioja S, Mott DM, Zawadzki JK, Young AA, Abbott WG, Knowler WC, Bennett PH, Moll P, Bogardus C. In vivo insulin action is familial characteristic in nondiabetic Pima Indians. Diabetes 36:1329-1335,
46. Kahn SE. Clinical Review 135. The importance of ß-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047-4058,
47. Bergman RN, Finegood DT, Kahn SE. The evolution of ß-cell dysfunction and insulin resistance in type 2 diabetes. European J Clin Invest 32:35-45,
48. Hansen BC, Bodkin NH. Heterogeneity of insulin responses: phases leading to type 2 (noninsulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia 29:713-719, 1986.
49. Diamond MP, Thornton K, Connolly-Diamond M, Sherwin RS, DeFronzo Reciprocal variations in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. J Soc Gynecol Invest 2:708-715, 1995.
50. Hollenbeck CB, Reaven GM. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 64:1169-1173,
51. Reaven GM. Banting Lecture. Role of insulin resistance in human disease. Diabetes 37:595- 607,
52. Faber OK, Damsgaard EM. Insulin secretion in type II diabetes. Acta Endocrinol 262 (suppl.):47-50,
53. Faber OK, Hagen C, Binder C, Markussen J, Naithani VK, Blix PM, Kuzuya H, Horwitz DL, Rubenstein AH, Rossing N. Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest 62: 197-203,
54. DeFronzo RA, Ferrannini E, Simonson DC. J Fasting hyperglycemia in non-insulin- dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38: 387-95,
55. Hales CN. The pathogenesis of NIDDM. Diabetologia 37: S162-S168,
56. Reaven GM, Hollenbeck C, Jeng C-Y, Wu MS, Chen Y-DI. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 hours in patients with NIDDM. Diabetes 37: 1020-4,
57. Garvey WT, Olefsky JM, Rubenstein AH, Kolterman OG. Day-long integrated urinary C- peptide excretion. Diabetes 37: 590-9,
58. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. New Engl J Med 318: 1217-25,
59. Jallut D, Golay A, Munger R, Frascarolo P, Schutz Y, Jequier E, Felber JP. Impaired glucose tolerance and diabetes in obesity: a 6 year follow-up study of glucose metabolism. Metabolism 39:1068-1075,
60. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non- insulin-dependent diabetes mellitus. N Engl J Med 329:1988-1992,

61. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, the American Diabetes Association GENNID Study Group. ß-cell function is a major contributor to oral glucose tolerance in high-risk relatives of our ethnic groups in the U.S. Diabetes 51:2170-2178,
62. Dowse GK, Zimmet PZ, Collins VR. Insulin levels and the natural history of glucose intolerance in Nauruans. Diabetes 45:1367-1372,
63. Haffner SM, Stern MP, Hazuda HP, Pugh JA, Patterson JK. Hyperinsulinemia in a population at high risk for non-insulin-dependent diabetes mellitus. New Engl J Med 315: 220-4,
64. Ho LT, Chang ZY, Wang JT, Li SH, Liu YF, Chen Y-DI, Reaven GM. Insulin insensitivity in offspring of parents with type 2 diabetes mellitus. Diabet Med 7: 31-34,
65. Clement K, Pueyo ME, Vaxillaire M, Rakotoambinina B, Thuillier F, Passa PH, Froguel PH, Robert JJ, Velho G. Assessment of insulin sensitivity in glucokinase-deficient subjects. Diabetologia 39:82-90,
66. Polonsky KS. Lilly Lecture 1994. The beta cell in diabetes: from molecular genetics to clinical research. Diabetes 44:705-717,
67. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in ß-cell function. Nature 414:788-791,
68. McCarthy MI, Froguel P. Genetic approaches to the molecular understanding of type 2 diabetes. Am J Physiol 283: E217-E225,
69. Bell GI, Zian K, Newman M, Wu S, Wright L, Fajans S., Spielman RS, Cox NJ. Gene for non-insulin-dependent diabetes mellitus (maturity-onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome 20q. Proc. Natl. Acad. Sci. 88:1484- 1488,
70. Froguel PH, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F, Lesage S, Stoffel M, Takeda J, Passap P. Familial hyperglycaemia due to mutations in glucokinase: definition of a subtype of diabetes mellitus. N Engl J Med 328:697-702,
71. Menzel S, Yamagata K, Trabb JB, Nerup J, Permutt MA, Fajans SS, Menzel R, Iwasaki N, Omori Y, Cox N, Bell GI. Localization of MODY3 to a 5-cM Region of Human Chromosome 12. Diabetes 44:1408-1413,
72. Zhang Y, Warren-Perry M, Saker PJ, Hattersley AT, Mackie ADR, Baird JD, Greenwood RH, Stoffel M, Bell GI, Turner RC. Candidate gene studies in pedigrees with maturity-onset diabetes of the young not lined with glucokinase. Diabetologia 38:1055-1066,
73. Weng J, Macfarlane WM, Lehto M, Gu HF, Shepherd LM, Ivarsson SA, Wibell L, Smith T, Groop LC. Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations. Diabetologia 44:249-258,
74. Sturis J, Kurland IJ, Byrne MM, Mosekilde E, Froguel P, Pilkis SJ, Bell GI, Polonsky Compensation in pancreatic ß-cell function in subjects with glucokinase mutations. Diabetes 43:718-723, 1994.
75. Beck-Nielsen H, Nielsen OH, Pedersen O, Bak J, Faber O, Schmitz O. Insulin action and insulin secretion in identical twins with MODY: evidence for defects in both insulin action and insulin secretion. Diabetes 37:730-735, 1988.
76. Mohan V, Sharp PS, Aber VR, Mather HM, Kohner EM. Insulin resistance in maturity-onset diabetes of the young. Diabetes Metab 13:193-197,

77. Elbein SC, Hoffman M, Qin H, Chiu K, Tanizawa Y, Permutt MA. Molecular screening of the glucokinase gene in familial type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia37:182-187,
78. Efendic S, Grill V, Luft R, Wajngot A. Low insulin response: a marker of pre-diabetes. Adv Exp Med Biol 246:167-174,
79. Davies MJ, Metcalfe J, Gray IP, Day JL, Hales CN. Insulin deficiency rather than hyperinsulinaemia in newly diagnosed type 2 diabetes mellitus. Diabetic Med 10:305-312, 1993.
80. Chen K-W, Boyko EJ, Bergstrom RW, Leonetti DL, Newell-Morris L, Wahl PW, Fujimoto WY. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 18:747-753,
81. Arner P, Pollare T, Lithell H. Different etiologies of Type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 34:483-487,
82. Ferrannini E. Natali A. Bell P. Cavallo-Perin P. Lalic N. Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). [Journal Article] Journal of Clinical Investigation. 100(5):1166-73, 1997
83. Banjeri MA, Lebovitz HE. Insulin action in black Americans with NIDDM. Diates Care 15:1295-1302,
84. Mbanya J-CN, Pani LN, Mbanya DNS, Sobngwi E, Ngogang Reduced insulin secretion in offspring of African type 2 diabetic patients. Diabetes Care 23:1761-1765, 2000.
85. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 6: E214-23,
86. Curry DL, Bennett LL, Grodsky GM. Dynamics of insulin secretion by the perfused rat pancreas. Endocrinology 83: 572-584,
87. Temple R, Clark PMS, Hales CN. Measurement of insulin secretion in type 2 diabetes: problems and pitfalls. Diab Med 9:503-512,
88. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte D. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol 46: 222-229,
89. Vague P, Moulin J-P. The defective glucose sensitivity of the B cell in insulin dependent diabetes. Improvement after twenty hours of normoglycaemia. Metabolism 31: 139-142, 1982.
90. Kosaka K, Kuzuya T, Akanuma Y, Hagura R. Increase in insulin response after treatment of overt maturity onset diabetes mellitus is independent of the mode of treatment. Diabetologia 18: 23-28,
91. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 13:610-630,
92. Prentki M, Corkey BE. Are the beta cell signaling molecules malonyl-CoA and cytosolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 45:273-283,
93. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44:863-870,
94. Shimabukuro M, Zhou Y-T, Levi M, Unger RH. Fatty acid induced ß cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci 95:2498-2502,

95. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin dependent diabetes. Diabetes 37: 736-744, 1988.
96. Luzi L. Effect of the loss of first phase insulin secretion on glucose production and disposal in man. Am J Physiol 257: E241-E246,
97. Bonner-Weir S. ß-cell turnover. Its assessment and implications. Diabetes 50: S20-S24, 2001.
98. Haffner SM, Miettinen H, Stern MP. Insulin secretion and resistance in nondiabetic Mexican Americans and non-Hispanic whites with a parental history of diabetes. J Clin Endocrinol Metab 81:1846-1851,
99. Gautier J-F, Wilson C, Weyer C, Mott D, Knowler WC, Cavaghan M, Polonsky KS, Bogardus C, Pratley RE. Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes. Diabetes 50:1828-1833,
100. Vauhkonen N, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M. Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands. J Clin Invest 100:86-96,
101. Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin- dependent diabetes mellitus. J Clin Invest 95:690-698,
102. Barnett AH, Spilipoulos AJ, Pyke DA, Stubbs WA, Burrin J, Alberti KGMM. Metabolic studies in unaffected co-twins of non-insulin-dependent diabetics. Brit Med J 282:1656- 1658,
103. Watanabe RM. Valle T. Hauser ER. Ghosh S. Eriksson J. Kohtamaki K. Ehnholm C. Tuomilehto J. Collins FS. Bergman RN. Boehnke M. Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators. Human Heredity. 49(3):159-68,
104. Mahtani MM. Widen E. Lehto Thomas J. McCarthy M. Brayer J. Bryant B. Chan G. Daly M. Forsblom C. Kanninen T. Kirby A. Kruglyak L. Munnelly K. Parkkonen M. Reeve-Daly MP. Weaver A. Brettin T. Duyk G. Lander ES. Groop LC. Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families. Nature Genetics. 14:90-4, 1996.
105. Rossetti L, Shulman Gi, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80:1037-1044,
106. Leahy JL, Bonner-Weir S, Weir GC. Abnormal glucose regulation of insulin secretion in models of reduced beta-cell mass. Diabetes 33: 667-73,
107. Leahy JL, Bonner-Weir S, Weir GC. Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest 81: 1407-14, 1988.
108. Leahy JL, Cooper HE, Weir GC. Impaired insulin secretion associated with near normoglycemia. Diabetes 36: 459-464,
109. Robertson RP, Olson IK, Zhang H-J. Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes 43:1085-1089,

110. Newgard CB, McGarry JD. Metabolic coupling factors in pancreatic beta cell signal transduction. Annu Rev Biochem 64:689-719,
111. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607-614,
112. Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93:870-876,1994.
113. Shimabukuro M. Higa M. Zhou YT. Wang Newgard CB. Unger RH. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem. 273:32487-90, 1998.
114. Fehmann HC. Goke R. Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocrine Reviews. 16:390-410,
115. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology. 142:521-527, 2001
116. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7- 36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917, 1993
117. D'Alessio DA. Vogel R. Prigeon Laschansky E. Koerker D. Eng J. Ensinck JW. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:133-138, 1996.
118. Schirra Sturm K. Leicht P. Arnold R. Goke B. Katschinski M. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 101:1421-30, 1998
119. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 Amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 91:301-307,
120. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613,
121. Ahren B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478,
122. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin- dependent) diabetic patients. Diabetologia 36:741-744,
123. Xu G. Stoffers DA. Habener JF. Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 48:2270-2276,
124. Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid. A long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253,
125. Johnson KH, O'Brien TD, Betysholtz C, Westermark P. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. New Engl J Med 321: 513-518,

126. Ohsawa H, Kanatsuka A, Yamaguchi T, Makino H, Yoshida S. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Comm 160: 961-967,
127. Howard Longitudinal studies on the development of diabetes in individual macaca nigra. Diabetologia 29: 301-306, 1986.
128. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, Prager R. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in Diabetologia 34:52-54, 1991.
129. Eriksson J, Nakazato M, Miyazato M, Shiomi K, Matsukura S, Groop L. Islet amyloid polypeptide: plasma-concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:292-293,
130. Westermark GT, Christmanson L, Terenghi G, Permerth J, Betsoltz C, Larsson J, Polak JM, Westermark P. Islet amyloid polypeptide: demonstration of mRNA in human pancreatic islets by in situ hybridization in islets with and without amyloid deposits. Diabetologia 36:323-328,1993.
131. Ghatei MA, Datta HK, Zaidi M, BrethertonWatt D, Wimalawansa SJ, Maclntyre 1, Bloom SR. Amylin and amylin-amide lack an acute effect on blood glucose and insulin. Endocrinol 124: R9-R11, 1990.
132. Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J, Bloom SR. Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in Diabetologia 33: 115-117, 1990.
133. Hoppener JWM, Verbeek JS, de Koning EJP, Oosterwijk C, van Hulst KL, Visser-Vernooy HJ, Hofhuis FMA, van Gaalen S, Berends MJH, Hackeng WHL, Jansz HS, Morris JF, Clark A, Capel PJA, Lipis CJM. Chronic overproduction of islet amyloid polypeptide-amylin in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycaemia or hyperinsulinaemia. Diabetologia 36:1258-1265,
134. Gebre-Medhin S, Olofsson C, Mulder Islet amyloid polypeptide in the islets of Langerhans: friend or foe? Diabetologia 43:687-695, 2000.
135. Westermark P, Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15: 417-421,
136. Gepts W, Lecompte PM. The pancreatic islets in diabetes. Am J Med 70: 105-114,
137. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type I and type 2 diabetes mellitus revisited. Surv Synth Path Res 4: 110- 25,
138. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, Turner RC. Islet amyloid, increased alpha-cells, reduced beta-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9: 151-159,

139   Butler AE, Janson J, Bonner-Weir S, Ritzel RA, Butler PC. Decreased beta-cell mass inpatients with type-2 diabetes mellitus. Diabetes 51(suppl 2): A367, 2002.

140. Stefan Y, Orci L, Malaisse-Lagae F, Perrelet A, Patel Y, Unger R. Quantitation of endocrine cell content in the pancreas of non-diabetic and diabetic humans. Diabetes 31: 694-700,

141. Rahier J, Sempoux C, Moulin P, Guiot Y. No decrease of the B cell mass in type 2 diabetic patients. Diabetologia 43(Suppl 1): A65,
142. Janson J, Butler AE, Bonner-Weir S, Ritzel RA, Sultana C, Butler PC. Failure of compensatory increase in new islet formation in humans with type-2 diabetes mellitus. Diabetes 51(suppl 2): A377,
143. Hales CN, Barker DJP, Clark PM, Cox J, Fall C, Osmond C, Winter PD. Fetal and infant growth and impaired glucose tolerance at age 64 years. BMJ 303:1019-1022,
144. Eriksson UJ. Lifelong consequences of metabolic adaptations in utero? Diabetologia 39:1123-1125,
145. Hales CN, Barker DJP. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 35:595-601,
146. Phillips DIW. Insulin resistance as a programmed response to fetal under nutrition. Diabetologia 39:1119-1122,
147. Strauss W, Hales Plasma insulin in minor abnormalities of glucose tolerance: a 5 year follow-up. Diabetologia 10:237-243, 1974.
148. Hara H, Egusa G Yamakido M, Kawate R. The high prevalence of diabetes mellitus and hyperinsulinemia among the Japanese-Americans living in Hawaii and Los Angeles. Diabetes Res Clin Pract 24:(Suppl. 1): S37-S42,
149. Berrish TS, Hetherington CS, Alberti KGMM, Walker M. Peripheral and hepatic insulin sensitivity in subjects with impaired glucose tolerance. Diabetologia 38:699-704,
150. Lillioja S, Nyomba BL, Saad MF, Ferraro R, Castillo C, Bennett PH, Bogardus C. Exaggerated early insulin release and insulin resistance in a diabetes-prone population: a metabolic comparison of Pima Indians and Caucasians. J Clin Endocrinol Metab 73:866- 876,
151. Himsworth HP, Kerr RB. Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 4: 120-152,
152. Ginsberg H, Kimmerling G, Olefsky JM, Reaven GM. Demonstration of insulin resistance in untreated adult-onset diabetic subjects with fasting hyperglycemia. J Clin Invest 55: 454- 461,
153. Butterfield WJH, Whichelow MJ. Peripheral glucose metabolism in control subjects and diabetic patients during glucose, glucose-insulin, and insulin sensitivity tests. Diabetologia 1:43-53,
154. Katz H, Homan M, Jensen M, Caumo A, Cobelli C, Rizza Assessment of insulin action in NIDDM in the presence of dynamic changes in insulin and glucose concentration. Diabetes 43:289-296, 1994.
155. Wangot A, Roovete A, Vranic M. Luft R, Efendic S. Insulin resistance and decreased insulin response to glucose in lean type II diabetes. Proc Natl Acad Sci USA 79:4432-4437, 1982.
156. Bergman RN. Lilly Lecture. Toward physiological understanding of glucose tolerance- minimal-model approach. Diabetes 38:1512-26,
157. DeFronzo RA, Deibert D, Hendler R, Felig P. Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes. J Clin Invest 63: 939-946,

158. DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature in non-insulin-dependent and insulin-dependent diabetes. Diabetologia 23: 313-319,
159. Golay A, DeFronzo RA, Ferrannini E, Simonson DC, Thorin D, Acheson K, Thiebaud D, Curchod B, Jequier E, Felber JP. Oxidative and non-oxidative glucose metabolism in non- obese Type 2 (non-insulin dependent) diabetic patients. Diabetologia 31:585-591,
160. Dall'Aglio E, Chang H, Hollenbeck CB, Mondon CE, Sims C, Reaven GM. In vivo and in vitro resistance to maximal insulin-stimulated glucose disposal in insulin deficiency. Am J Physiol 249: E312-E316,
161. Vuorinen-Markkola H, Koivisto VA, Yki-Järvinen H: Mechanisms of hyperglycemia- induced insulin resistance in whole body and skeletal muscle of type 1 diabetic patients. Diabetes 41:571-580,
162. Golay A, Felber JP, Jequier E, DeFronzo RA, Ferrannini E. Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. Diabetes Metab Rev 4:727-747,
163. DeFronzo RA, Sherwin RS, Hendler R, and Felig P. Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. J Clin Invest 62:204-213,
164. Firth R, Bell P, Rizza R. Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity. Metabolism 36:1091 -1095, 1987.
165. Campbell PJ, Mandarino LJ, Gerich JE. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin dependent diabetes mellitus. Metabolism 37: 15-21,
166. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in non-diabetic and noninsulin-dependent subjects. J Clin Invest 74:1238-46,
167. Del Prato S, Simonson DC, Sheehan P, Cardi F, DeFronzo RA. Studies on the mass effect of glucose in Evidence for glucose resistance. Diabetologia 40:687-697, 1997.
168. Nielsen MF, Basu R, Wise S, Caumo A, Cobelli C, Rizza RA. Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes. Evidence for a concentration-dependent defect in uptake. Diabetes 47:1735- 1747,
169. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Non-invasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 238: E69- E82,
170. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin dependent diabetes mellitus. Diabetes 35: 990-998,
171. Best JD, Judzewitsch RG, Pfeiffer MA, Beard JC, Halter JB, Porte D. The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes mellitus. Diabetes 31:333-338,
172. Tayek JA, Katz Glucose production, recycling, and gluconeogenesis in normals and diabetics: a mass isotopomer [U-13C] glucose study. Am J Physiol 270: E709-E717, 1996.
173. Fery F. Role of hepatic glucose production and glucose uptake in the pathogenesis of fasting hyperglycemia in Type 2 diabetes: normalization of glucose kinetics by short-term fasting. J Clin Endocrinol Metab 78:536-542,

174. Jeng C-Y, Sheu WHH, Fuh MM-T, Chen I, Reaven GM. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes 43:1440-1444,
175. DeFronzo RA, Ferrannini E, Hendler R, Felig P, Wahren J, Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia. Diabetes 32: 35-45,
176. Cherrington AD, Stevenson RW, Steiner KE, Davis MA, Myers SR, Adkins BA, Abumrad NN, Williams PE. Insulin, glucagon, and glucose as regulators of hepatic glucose uptake and production in vivo. Diabetes Metab Rev 3:307-332,
177. Bergman RN, Bucolo RJ. Interaction of insulin and glucose in the control of hepatic glucose balance. Am J Physiol 227:1314-1322,
178. Mevorach M, Giacca A, Aharon Y, Hawkins M, Shamoon H, Rossetti L. Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J Clin Invest 102:744-753,
179. Basu R, Basu A, Nielsen M, Shah P, Rizza RA. Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus. J Cin Endocrinol Metab 84:2314-2319,
180. Waldhausl W, Bratusch-Marrain P, Gasic S, Korn A, Nowotny P. Insulin production rate, hepatic insulin retention, and splanchnic carbohydrate metabolism after oral glucose ingestion in hyperinsulinemic type II (non-insulin dependent) diabetes mellitus. Diabetologia 23: 6-15,
181. Consoli A, Nurjahn N, Capani F, Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38: 550-556,
182. Nurjhan N, Consoli A, Gerich J. Increased lipolysis and its consequences on gluconeogenesis in noninsulin-dependent diabetes mellitus. J Clin Invest 89:169-175,
183. Magnusson I, Rothman D, Katz L, Shulman R, Shulman G. Increased rate of gluconeogenesis in type II diabetes: a 13C nuclear magnetic resonance study. J Clin Invest 90:1323-1327,
184. Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, Landau BR, Ferrannini E. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49:1367-1373,
185. Gastaldelli A, Toschi E, Pettiti M, Frascerra S, Qinones-Galvan A, Sironi AM, Natali A, Ferrannini E. Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 50:1807-1812,
186. Stumvoll M, Perriello G, Nurjhan N, Bucci A, Welle S, Jansson P-A, Dailey G, Bier D, Jenssen T, Gerich J. Glutamine and alanine metabolism in NIDDM. Diabetes 45:863-868, 1996.
187. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36:274-283,
188. Felig P, Wahren J, Hendler R. Influence of maturity-onset diabetes on splanchnic balance after oral glucose ingestion. Diabetes 27: 121-126,
189. Foley JE. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 15:773-784,

190. Matsuda M, DeFronzo RA, Glass L, Consoli A, Giordano M, Bressler P, DelPrato S. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 51:1111-1119,
191. Cusi K, Consoli A, DeFronzo Metabolic effects of metformin on glucose and lactate metabolism in NIDDM. J Clin Endocrinol Metab 81:4059-4067, 1996.
192. Clore JN, Stillman J, Sugerman H. Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes. Diabetes 49:969-974,
193. O'Brien RM, Granner DK. PEPCK gene as model of inhibitory effects of insulin on gene transcription. Diabetes Care 13:327-339,
194. Sutherland C, O'Brien RM, Granner DK. New connections in the regulation of PEPCK gene expression by insulin. Phil Trans R Soc Long B 351:191-199,
195. Cersosimo E, Garlick P, Ferretti J. Regulation of splanchnic and renal substrate supply by insulin in Metabolism 49:676-683, 2000.
196. Moller N. Rizza RA. Ford GC. Nair KS. Assessment of postabsorptive renal glucose metabolism in humans with multiple glucose tracers. Diabetes. 50:747-751, 2001
197. Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 102:619-624,
198. Bjorntorp P, Berchtold P, Holm The glucose uptake of human adipose tissue in obesity. Eur J Clin Invest 1:480-485, 1971.
199. Frayn KN, Coppack SW, Humphreys SM, Whyte PL. Metabolic characteristics of human adipose tissue in Clin Sci 76:509-516, 1989.
200. Campbell P, Mandarino L, Gerich J. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose intake in non-insulin- dependent diabetes mellitus. Metabolism 37:1 5-22,
201. Capaldo B, Napoli R, Dimarino L, Picardi A, Riccardi G, Sacca L. Quantitation of forearm glucose and free fatty acid (FFA) disposal in normal subjects and type 2 diabetic patients: evidence against an essential role for FFA in the pathogenesis of insulin resistance. J Clin Endocrinol Metab 67:893-898,
202. Jackson RA, Perry G, Rogers J, Advoni U, Pilkington TRE. Relationship between the basal glucose concentration, glucose tolerance, and forearm glucose uptake in maturity onset diabetes. Diabetes 22:751-761,
203. Utriainen T. Takala T. Luotolahti M. Ronnemaa Laine H. Ruotsalainen U. Haaparanta M. Nuutila P. Yki-Jarvinen H. Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia. 41:555-559, 1998.
204. Firth RG, Bell PM, Marsh HM, Hansen I, Rizza RA. Postprandial hyperglycemia in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 77:1525-1532,
205. Ferrannini E, Simonson DC, Katz LD, Reichard G Jr, Bevilacqua S, Barrett EJ, Olsson M, DeFronzo The disposal of an oral glucose load in patients with non-insulin dependent diabetes. Metabolism 37:79-85, 1988.
206. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Non-invasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 238: E69- E82,

207. Kelley D, Mitrakou A, Marsh H, Schwenk F, Benn J, Sonnenberg G, Arcangeli M, Aoki T, Sorensen J, Berger M, Sonksen P, Gerich J. Skeletal muscle glycolysis oxidation, and storage of an oral glucose load. J Clin Invest 81:1563-1571,1988.
208. Jackson RA, Roshania RD, Hawa MI, Sim BM, DiSilvio L. Impact of glucose ingestion on hepatic and peripheral glucose metabolism in man: an analysis based on simultaneous use of the forearm and double isotope techniques. J Clin Endocrinol Metab 63:541-549,
209. Jackson RA, Perry G, Rogers J, Advoni U, Pilkington TRE. Relationship between the basal glucose concentration, glucose tolerance, and forearm glucose uptake in maturity onset diabetes. Diabetes 22:751-761,
210. Shimazu T. Neuronal regulation of hepatic glucose metabolism in mammals. Diabetes Metab Rev 3:185-206, 1987.
211. McMahon V, Marsh HM, Rizza Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM. Diabetes 38:291-303, 1989.
212. Basu A, Basu R, Shah P, Vella A, Johnson M, Nair KS, Jensen MD, Schwenk WF, Rizza RA. Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism. Evidence for a defect in hepatic glucokinase activity. Diabetes 49:272-283,
213. Ludvik B, Nolan JJ, Roberts A, Baloga J, Joyce M, Bell Jo M, Olefsky JM. Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin- dependent diabetes mellitus. J Clin Invest 100:2354-2361,
214. Reaven GM, Brand RJ, Ida Chen Y-D, Mathur AK, Goldfine I. Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes 42:1324-1332,
215. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. New Engl J Med 322:223-228, 1990.
216. Bonadonna RC, Bonora E. Glucose and free fatty acid metabolism in human obesity: relationships to insulin resistance. Diabetes Rev 5:21-51, 1997.
217. Reaven GM, Chen Y-DI, Donner CC, Fraze E, Hollenbeck CB. How insulin resistant are patients with non-insulin-dependent diabetes mellitus? J Clin Endocrinol Metab 61:32-36, 1985.
218. Lillioja A, Mott DM, Zawadzki JK, Young AA, Abbott WG, Bogardus C. Glucose storage is a major determinant of in vivo 'insulin resistance' in subjects with normal glucose tolerance. J Clin Endocrinol Metab 62: 922-927,
219. Tripathy D, Carlsson M, Almgren P, Osomaa B, Raskinen M-R, Tuomi T, Groop LC. Insulin secretion and insulin sensitivity in relation to glucose tolerance. Lessons from the Botnia Study. Diabetes 49:975-980,
220. Zimmet PZ. The pathogenesis and prevention of diabetes in adults. Diabetes Care 18:1050-1064,
221. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS: Diabetes trends in the United States, 1990-1998. Diabetes Care 23:1278-1283,

222. Reaven GM, Hollenbeck C, Jeng C-Y, Wu MS, Chen Y-DI: Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 hours in patients with NIDDM. Diabetes 37:1020-1024,
223. Thiebaud D, DeFronzo RA, Jacot E, Golay A, Acheson K, Maeder E, Jequier E, Felber Effect of long-chain triglyceride infusion on glucose metabolism in man. Metabolism 31:1128-1136, 1982.
224. Kelley De, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance. A reexamination. Diabetes 49:677-683,
225. Kashyap S, Belfort R, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K: Chronic elevation in plasma free fatty acids impairs insulin secretion in non-diabetic offspring with a strong family history of T2DM. Diabetes 51(Suppl 2): A12, 2002.
226. Carpentier A. Mittelman SD. Bergman RN. Giacca A. Lewis GF. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes. 49:399-408,
227. Reaven GM. The fourth Musketeer - from Alexandre Dumas to Calude Diabetologia 38:3-13, 1995.
228. Goodpaster BH, Thaete FL, Kelley BE. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 71:885-892, 2000.
229. Greco AV, Mingrone G, Giancaterini A, Manco M, Morroni M, Cinti S, Granzotto M, Vettor R, Camastra S, Ferrannini E. Insulin resistance in morbid obesity. Reversal with intramyocellular fat depletion. Diabetes 51:144-151,
230. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H: Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749-758,
231. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791, 2002.
232. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1785-789, 1963.
233. Wititsuwannakul D, Kim K. Mechanism of palmityl coenzyme A inhibition or liver glycogen synthase. J Biol Chem 252:7812-7817,
234. Golay A, Felber JP, Meyer HU, Curchod B, Maeder E, Jequier E. Study on lipid metabolism in obesity diabetes. Metabolism 33:111-116,
235. Felber JP, Meyer HU, Curchod B, Iselin HU, Rousselle J, Maeder E, Pahud P, Jequier E.. Glucose storage and oxidation in different degrees of human obesity measured by continuous indirect calorimetry. Diabetologia 20: 39-44,
236. Roden M, Krssak M, Stingl H, Gruber S, Hofer A, Furnsinn C, Moser E, Waldhausl W. Rapid impairment of skeletal muscle glucose transport/phosphorylation by free fatty acids in humans. Diabetes 48:358-364,

237. Bonadonna RC, Groop LC, Zych K, Shank M, and DeFronzo RA. Dose dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans. Am J Physiol 22:736- 750,
238. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians 111:241-248,
239. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 93:2438-2446,
240. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Roden M, Shulman GI. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1HNMR spectroscopy study. Diabetologia 42:113-116,
241. Jacobs S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E, Matthaei S, Schick F, Claussen CD, Hearing H-U. Association of increased intramyocellular lipid content with insulin resistance in lean non-diabetic offspring of type 2 diabetic subjects. Diabetes 48:1113-1119,
242. Kelley DE, Goodpaster BH. Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance. Diabetes Care 24:933-941,
243. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance. Diabetes 49:677-683,
244. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkB-a. Diabetes 51:2005-2011,
245. Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, Kraegen EW, Cooney GJ. Long- chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol 279: E554-E560,
246. De Fea K, Roth RA. Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612. Biochemistry 36:12939-12947,
247. Ravichandran LV, Esposito DL, Chen J, Quon MJ. PKC-zeta phosphorylates IRS-1 and impairs its ability to activate P-3-kinase in response to insulin. J Biol Chem 276:3543-3549, 2001.
248. Kruszynska YT, Worrall DS, Ofrecio J, Frias JP, Macaraeg G, Olefsky JM. Fatty acid- induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation. J Clin Endocrinol Metab 87:226-234,
249. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline SW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI. Effects of free fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259,
250. Thompson AL, Cooney GJ. Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance. Diabetes 49:1761- 1764,
251. Tippett PS, Neet KE. An allosteric model for the inhibition of glucokinase by long chain acyl coenzyme A. J Biol Chem 257:14846-14852,
252. Schmitz-Peiffer C, Craig DL, Biden TJ. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 274:24202-24210,

253. Baron AD. Hemodynamic actions of insulin. Am J Physiol 267: E187-E202,
254. Mather K, Laakso M, Edelman S, Hook G, Baron A. Evidence for physiological coupling of insulin-mediated glucose metabolism and limb blood flow. Am J Physiol Endocrinol Metab 279: E1264-E1270,
255. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94:1172-1179,
256. Utriainen T, Nuutila P, Takala T, Vicini P, Ruotsalainen U, Ronnemaa T, Tolvanen T, Raitakari M, Haaparanta M, Kirvela O, Cobelli C, Yki-Jarvinen H. Intact stimulation of skeletal muscle blood flow, its heterogeneity and redistribution, but not of glucose uptake in non-insulin-dependent diabetes mellitus. J Clin Invest 100:777-785,

256A. Cersosimo E, DeFronzo RA. Insulin Reistance and Endothelial Dysfunction: the road map for cardiovscular disease. Diabetes Metab Res Rev 22:423-436, 2006.

256B. Coggins M, Lidner J, Rattigan S et al. Physiologic hyperinsulinemia enhance human skeletal muscle muscle perfuioson by capillary rectuiment Diabetes 50:2682-2690, 2001.

257. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 49:1231-1238,
258. Kreutzenberg SV, Crepaldi C, Marchetto S, Calo L, Tiengo A, Del Prato S, Avogaro A. Plasma free fatty acids and endothelium-dependent vasodilation: effect of chain-length and cyclooxygenase inhibition. J Clin Endocrinol Metab 85:793-798,
259. Davda RK, Chandler LJ, Guzman Protein kinase C modulates receptor-independent activation of endothelial nitric oxide synthase. Eur J Pharmacol 266:237-244, 1994.
260. Zeng G, Quon MJ. Insulin stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. J Clin Invest 98:894-898,
261. Exton JH, Corbin JG, Park CR. Control of gluconeogenesis in IV. Differential effects of fatty acids and glucagon on ketogenesis and gluconeogenesis in the perfused rat liver. J Biol Chem 244:4095-4102, 1969.
262. Bahl JJ, Matsuda M, DeFronzo RA, Bressler R. In vitro and in vivo suppression of gluconeogenesis by inhibition of pyruvate carboxylase. Biochem Pharmacol 53:67-74, 1997.
263. Massillon D, Barzailai N, Hawkins M, Prus-Wetheimer D, Rossetti L. Induction of hepatic glucose-6-phosphatase gene expression by lipid infusion. Diabetes 46:153-157,
264. Chen X, Iqbal N, Boden G. The effect of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 103:365-372,
265. Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR, Nowotny P, Waldhausl W, Shulman GI. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 49:701-707, 2000.
266. Lewis GF. Vranic Harley P. Giacca A. Fatty acids mediate the acute extrahepatic effects of insulin on hepatic glucose production in humans. Diabetes. 46:1111-11119, 1997.
267. Rebrin K. Steil GM. Getty L. Bergman RN. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes. 44:1038-45,

268. Ferrannini E, Barrett EJ, Bevilacqua S, and DeFronzo Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72:1737-1747, 1983.
269. Bevilacqua S, Bonadonna R, Buzzigoli G, Boni C, Ciociaro D, Maccari F, Giorico MA, Ferrannini E: Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism 36:502-506, 1987.
270. Golay A, Swislocki ALM, Chen Y-DI, Reaven GM: Relationships between plasma free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. Metabolism 36:692-696,
271. Baron AD, Schaeffer L, Shragg P, Kolterman OG: Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36:274-283,
272. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 14:1132-1143, 1991.
273. Arner P. Regional adipocity in man. J Endocrinol 155:191-192,
274. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414:799-806,
275. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103:931-943,
276. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106:165-169,
277. Whitehead JP, Clark SF, Urso B, James DE. Signalling through the insulin receptor. Current Opinion in Cell Biology 12:222-228,
278. Wilden PA, Kahn CR. The level of insulin receptor tyrosine kinase activity modulates the activities of phosphatidylinositol 3-kinase, microtubule-associated protein, and S6 kinases. Mol Endo 8:558-567,
279. Haring HU, Mehnert H. Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle. Diabetologia 36:176-182,
280. Wajtaszewski JFP, Hansen BF, Kiens B, Richter EA. Insulin signaling in human skeletal muscle. Time course and effect of exercise. Diabetes 46:1775-1781,
281. Shepherd PR, Kahn BB. Glucose transporters and insulin action. Implications for insulin resistance and diabetes mellitus. N Engl J Med 341:248-257,
282. Garvey WT. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med 105:331-345,
283. Chou DK, Dull TJ, Russell DS, Gherzi R, Lebwohl D, Ullrich A, Rosen OM. Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. J Biol Chem 262:1842-1847,
284. Ebina Y, Araki E, Tiara F, Shimada F, Mari M, Craik CS, Siddle K, Pierce SB, Roth RA, Rutter Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin and antibody-stimulated glucose uptake and receptor kinase activity. Proc Natl Acad Sci USA 84:704-708, 1987.
285. Ellis LE, Clauser E, Morgan ME, Roth RA, Rutter WJ. Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-dexoyglucose. Cell 45:721-732,
286. White MF, Livingston JN, Backer JM, Lauria V, Duli TJ, Ullrich A, Kahn DR. Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity. Cell 54:641-649,
287. Kerouz, N.J., Horsch, D., Pons, S., Kahn, R. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest 100:3164-3172, 1997
288. Baumann CA. Ribon V. Kanzaki M. Thurmond DC. Mora S. Shigematsu S. Bickel PE. Pessin JE. Saltiel AR. CAP defines a second signalling pathway required for insulin- stimulated glucose transport. Nature. 407:202-207,
289. Chiang SH. Baumann Kanzaki M. Thurmond DC. Watson RT. Neudauer CL. Macara IG. Pessin JE. Saltiel AR. Insulin-stimulated GLUT4 translocation requires the CAP- dependent activation of TC10. Nature. 410:944-948, 2001.
290. Backer JM, Myers Jr MG, Shoelson SE, Chin DJ, Sun XJ, Miralpeix M., Hu P, Margolis B., Skoinik EY, Schlessinger J, White, MF. The phosphatidylinositol 3' kinase is activated by association with IRS-1 during insulin stimulation. EMBO J 11:3469-3479,
291. Sun XJ, Miralpeix M, Myers Jr MG, Glasheen EM, Backer JM, Kahn CR, White MF. The expression and function of IRS-1 in insulin signal transmission. J Biol Chem 267-22662- 22672,
292. Cross DA. Alessi DR. Cohen P. Andjelkovich M. Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378:785-789,
293. Brady MJ. Nairn AC. Saltiel AR. The regulation of glycogen synthase by protein phosphatase 1 in 3T3-L1 adipocytes. Evidence for a potential role for DARPP-32 in insulin action. J Biol Chem. 272:29698-703,
294. Okada T, Sakuma L, Fukui Y, Hazeki O, Ui M. Essential role of phosphatidylinositol 3- kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. J Biol Chem 269:3568-3573,
295. Cross D, Alessi D, Vandenheed J, McDowell H, Hundal H, and Cohen P. The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin but not rapamycin. Biochem J 303:21-26, 1994.
296. Osawa H, Sutherland C, Robey R, Printz R, Granner D. Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin. J Biol Chem 271:16690-16694,
297. Thomas G. Hall MN. TOR signalling and control of cell growth. Current Opinion in Cell Biology. 9:782-7,
298. Nave BT. Ouwens Withers DJ. Alessi DR. Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 344(Pt 2):427-31, 1999

299. Miron M. Verdu J. Lachance PE. Birnbaum Lasko PF. Sonenberg N. The translational inhibitor 4E-BP is an effector of PI (3)K/Akt signalling and cell growth in Drosophila. Nature Cell Biology. 3:596-601, 2001
300. Shimomura I. Bashmakov Y. Ikemoto S. Horton JD. Brown Goldstein JL. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Nat Acad Sci USA. 96:13656-61, 1999
301. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle. J Clin Invest 105:311-320,
302. Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol 84:21J-24J, 1999
303. Xi X-P, Graf K, Goetze S, HsuehWA, Law RE. Inhibition of MAP kinase blocks insulin- mediated DNA synthesis and transcriptional activation of c-fos by Elk-1 in vascular smooth muscle cells. FEBS Lett 417:283-286,
304. Boulton TG. Nye SH. Robbins DJ. Ip NY. Radziejewska E. Morgenbesser SD. DePinho RA. Panayotatos Cobb MH. Yancopoulos GD. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 65:663-75, 1991.
305. Lazar DF. Wiese RJ. Brady MJ. Mastick CC. Waters SB. Yamauchi K. Pessin JE. Cuatrecasas P. Saltiel AR. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem. 270:20801-7,
306. Dorrestijn J, Ouwens DM, Van den Berghe N, Box JL, Maassen JA. Expression of dominant-negative Ras mutant does not affect stimulation of glucose uptake and glycogen synthesis by insulin. Diabetologia 39:558-563,
307. Dent P, Lavoinne A, Nakielny S, Caudwell FB, Watt P, Cohen The molecular mechanisms by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature 348:302-307, 1990.
308. Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem 58:453-508,
309. Newgard CB, Brady MJ, O'Doherty RB, Saltiel AR. Organizing glucose disposal. Emerging roles of the glycogen targeting subunits of protein phosphatase-1. Diabetes 49:1967-1977, 2000.
310. Sheperd PR, Nave BT, Siddle K. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3L1 adipocytes: evidence for the involvement of phosphoinositide 3 kinase and p70 ribosomal protein S6 kinase. Biochem J 305:25-28,
311. Freidenberg GR, Henry RR, Klein HH, Reichart DR, Olefsky JM. Decreased kinase activity of insulin receptors from adipocytes of non-insulin-dependent diabetic studies. J Clin Invest 79:240-250,
312. Caro JF, Sinha MK, Raju SM, Ittoop O, Pories WJ, Flickinger EG, Meelheim D, Dohm GL. Insulin receptor kinase in human skeletal muscle from obese subjects with and without non- insulin dependent diabetes. J Clin Invest 79:1330-7.1987
313. Caro JF, Ittoop O, Pories WJ, Meelheim D, Flickinger EG, Thomas F, Jenquin M, Silverman JF, Khazanie PG, Sinha MK. Studies on the mechanism of insulin resistance in the liver from humans with non-insulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity. J Clin Invest 78: 249- 58, 1986.
314. Molina JM, Ciaraldi TP, Brady D, Olefsky JM. Decreased activation rate of insulin-mediated glucose transport in adipocytes from obese and NIDDM Diabetes 38:991-995, 1989.
315. Trichitta V, Brunetti A, Chiavetta A, Benzi L, Papa V, Vigneri R. Defects in insulin-receptor internalization and processing in monocytes of obese subjects and obese NIDDM patients. Diabetes 38:1579-1584,
316. Comi RJ, Grunberger G, Gorden P. Relationship of insulin binding and insulin-stimulated tyrosine kinase activity is altered in type II diabetes. J Clin Invest 79: 453-462,
317. Klein HH, Vestergaard H, Kotzke G, Pedersen O. Elevation of serum insulin concentration during euglycemic hyperinsulinemic clamp studies leads to similar activation of insulin receptor kinase in skeletal muscle of subjects with and without NIDDM. Diabetes 344:1310- 1317,
318. Obermaier-Kusser B, White MF, Pongratz DE, Su Z, Ermel B, Muhlbacher C, Haring HU. A defective intramolecular autoactivation cascade may cause the reduced kinase activity of the skeletal muscle insulin receptor from patients with non-insulin-dependent diabetes mellitus. J Biol Chem 264:9497-9503,
319. Arner P, Einarsson K, Ewerth S, Livingston J, Studies on the human liver insulin receptor in non-insulin-dependent diabetes mellitus. J Clin Invest 77: 1716-1718,
320. Kashiwagi A, Verso MA, Andrews J, Vasquez B, Reaven G, Foley JE. In vitro insulin resistance of human adipocytes isolated from subjects with non-insulin-dependent diabetes mellitus. J Clin Invest 72: 1246-1254,
321. Lonnroth P, Digirolamo M, Krotkiewski M, Smith U. Insulin binding and responsiveness in fat cells from patients with reduced glucose tolerance and type II diabetes. Diabetes 32:748-754,
322. Olefsky JM, Reaven GM. Insulin binding in Relationships with plasma insulin levels and insulin sensitivity. Diabetes 26:680-688, 1977.
323. Cocozza S, Procellini A, Riccardi G, Monticelli A, Condorelli G, Ferrara A, Pianese L, Miele C, Capaldo B, Beguinot F, Varrone S. NIDDM associated with mutation in tyrosine kinase domain of insulin receptor gene. Diabetes 41:521-526, 1992.
324. Moller DE, Yakota A, Flier JS. Normal insulin receptor cDNA sequence in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetes 38:1496-1500,
325. Kusari J, Verma US, Buse JB, Henry RR, Olefsky JM. Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT4) in patients with common-type non-insulin-dependent diabetes mellitus. J Clin Invest 88:1323-1330,
326. Nyomba BL, Ossowski VM, Bogardus C, Mott DM. Insulin-sensitive tyrosine kinase relationship with in vivo insulin action in Am J Physiol 258: E964-E974, 1990.
327. Nolan JJ, Friedenberg G, Henry R, Reichart D, Olefsky JM. Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes and obesity. J Clin Endocrinol Metab 78:471-477,
328. Krook A, Bjornholm M, Galuska D, Jiang XJ, Fahlman R, Myers MG, Wallberg-Henriksson H, Zierath JR. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49:284-292,

329. Bak JF, Moller N, Schmitz O, Saaek A, Pedersen O. In vivo insulin action and muscle glycogen synthase activity in type 2 (non insulin dependent) diabetes mellitus: effects of diet treatment. Diabetologia 35:777-794,
330. Freidenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin dependent diabetes mellitus. Effect of weight loss. J Clin Invest 82:1398-1406,
331. Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn L, Mosthaf L, Haring H. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 43:447-453,
332. Pratipanawatr W, Pratipanawatr T, Cusi K, Berria R, Adams JM, Jenkinson CP, Maezono K, DeFronzo RA, Mandarino LJ. Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin- stimulated insulin receptor substrate-1 tyrosine phosphorylation. Diabetes 50:2572-2578, 2001.
333. Laville M, Auboeuf D, Khalfallah Y, Vega N, Riou JP, Vidal Acute regulation by insulin of phosphatidylinositol-3-kinase, Rad, Glut 4, and lipoprotein lipase in mRNA levels in human muscle. J Clin Invest 98:43-49, 1996.
334. Kim Y-B, Nikoulina S, Ciaraldi TP, Henry RR, Kahn BB. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 104:733-741,
335. Andreelli F, Laville M, Ducluzeau P-H, Vega N, Vallier P, Khalfallah Y, Riou J-P, Vidal Defective regulation of phosphatidylinositol-3-kinase gene expression in skeletal muscle and adipose tissue of non-insulin-dependent diabetes mellitus patients. Diabetologia 42:358-364, 1999.
336. Folli F, Saad JA, Backer JM, Kahn CR. Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus. J Clin Invest 92:1787-1794,
337. Imai Y, Philippe N, Accili D, Taylor SI. Expression of variant forms of insulin receptor substrate-1 identified in patients with noninsulin dependent diabetes mellitus. J Clin Endocrinol Metab 82:4201-4207,
338. Hitman GA, Hawrammi K, McCarthy MI, Viswanathan M, Snehalatha C, Ramachandran A, Tuomilehto J, Tumilehto-Wolf E, Nissenen A, Pedersen O. Insulin receptor substrate-1 gene mutations in NIDDM: implication for the study of polygenic disease. Diabetologia 38:481-486,
339. Pratley RE. Thompson DB. Prochazka M. Baier L. Mott D. Ravussin E. Sakul Ehm MG. Burns DK. Foroud T. Garvey WT. Hanson RL. Knowler WC. Bennett PH. Bogardus C. An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians. J Clin Invest. 101:1757-64, 1998.
340. Jiang ZY. Lin YW. Clemont A. Feener EP. Hein KD. Igarashi M. Yamauchi T. White MF. King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 104:447-57,

340A. Cersosimo E, XiaoJing X, Musi N. Role of insulin signaling in vascular smooth muscle cell migration, proliferation and inflammation. Am J Physiol: Cell Physiol. C652-C657, Feb 15th, 2012

340B. Cersosimo E, XiaoJing X, Upala S, Triplitt C, Musi N.  Acute Insulin Resistance Stimulates and Insulin Sensitization Attenuates Vascular Smooth Muscle Cell Migration and Proliferation.  Physiological Reports Vol. 2, Iss. 8; e12123, August, 2014

341. Sasaoka T. Draznin B. Leitner JW. Langlois WJ. Olefsky JM. Shc is the predominant signaling molecule coupling insulin receptors to activation of guanine nucleotide releasing factor and p21ras-GTP formation. J Biol Chem 269:10734-8,
342. De Fea K. Roth RA. Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J Biol Chem 272:31400-6,
343. Dunaif A. Xia J. Book CB. Schenker E. Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 96:801-10,
344. Kono T, Robinson FW, Blevins TL, Ezaki O. Evidence that translocation of the glucose transport activity is the major mechanism of insulin action on glucose transport fat cells. J Biol Chem 257: 10942-10947,
345. Bell Gl, Kayano T, Buse JB, Burant CF, Takeda J, Lin D, Fikomoto H, Seino S. Molecular biology of mammalian glucose transporters. Diabetes Care 13:198-200,
346. Joost H-G, Bell GI, Best JD, Birnbaum MJ, Charron MJ, Chen YT, Doege H, James DE, Lodish HF, Moley KH, Moley JF, Mueckler M, Rogers S, Schurmann A, Seino S, Thorens B. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 282: E974-E976, 2002.
347. Colowick SP. The hexokinases. In Boyer PD (ed.) The Enzymes, vol. 9. New York: Academic Press, pp 1-48,
348. Printz RL, Koch S, Potter LR, O'Doherty RM, Tiesinga JJ, Moritz S, Granner DK. Hexokinase II mRNA and gene structure, regulation by insulin, and evolution. J Biol Chem 268:5209-5219,
349. Rogers PA, Fisher RA, Harris H. An electrophoretic study of the distribution and properties of human hexokinases. Biochem Genet 13:857-866,
350. Magnuson MA, Andreone IL, Printz RL, Koch S, Granner DK. The glucokinase gene: structure and regulation by insulin. Proc Natl Acad Sci USA 86: 4838-4842,
351. Matchinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45:223-241,
352. Mandarino LJ, Campbell PJ, Gottesman IS, Gerich JE. Abnormal coupling of insulin receptor binding in non-insulin-dependent diabetes. Am J Physiol 247: E688-E692,
353. Garvey WT, Huecksteadt TP, Mattaei S, Olefsky JM. Role of glucose transporters in the cellular insulin resistance of type II non-insulin dependent diabetes mellitus. J Clin Invest 81:1528-1536,
354. Zierath JR, He L, Guma A, Odegoard Wahlstrom E, Klip A, Wallenberg-Henriksson H. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 39:1180-1189,
355. Krook A, Bjornholm M, Galuska D, Jiang XJ, Fahlman R, Myers MG, Wallenberg- Henriksson H, Zierath JR. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49:284-282,

356. Andreasson K, Galuska D, Thorne T, Sonnenfeld T, Wallberg-Henriksson Decreased insulin-stimulated 3-O-methylglucose transport in in vitro incubated muscle strips from type II diabetic subjects. Acta Physiol Scan 142:255-260, 1991.
357. Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 87:561- 570,
358. Pedersen O, Bak J, Andersen P, Lund S, Moller DE, Flier JS, Kahn BB. Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM. Diabetes 39:865-870,
359. Eriksson J, Koranyi L, Bourey R, Schalin-Jantti C, Widen E, Mueckler M, Permutt AM, Groop LC. Insulin resistance in type 2 (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (GLUT-4) gene in human skeletal muscle. Diabetologia 35:143-147,
360. Schalin-Jantti C, Yki-Jarvinen H, Koranyi L, Bourey R, Lindstrom J, Nikula-Ijas P, Franssila-Kallunki A, Groop LC. Effect of insulin on GLUT-4 mRNA and protein concentrations in skeletal muscle of patients with NIDDM and their first-degree relatives. Diabetologia 37:401-407,
361. Garvey WT, Maianu L, Hancock JA, Golichowski AM, Baron A. Gene expression of glut4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes 41:465-475,
362. Kusari J, Verma US, Buse JB, Henry RR, Olefsky JM. Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT 4) in patients with common type non insulin dependent diabetes mellitus. J Clin Invest 88:1323-1330,
363. Choi WH, O'Rahilly S, Rees A, Morgan R, Flier JS, Moller Molecular scanning of the insulin-responsive glucose transporter (GLUT 4) gene in patients with non-insulin dependent diabetes mellitus. Diabetes 40:1712-1718, 1991.
364. Sinha M, Raineri-Maldonado C, Buchanan C, Pories W, Carter-Su C, Pilch P, Caro J. Adipose tissue glucose transporters in NIDDM: decreased levels of muscle/fat isoform. Diabetes 40:474-477,
365. Guma A, Zierath JR, Wallberg-Henriksson H, Klip A. Insulin induces translocation of GLUT-4 glucose transporters in human skeletal muscle. Am J Physiol 268:E613-E622, 1995.
366. Goodyear LJ, Hirschman MF, Napoli R, Calles J, Markuns JF, Ljungqvist O, Horton Glucose ingestion causes GLUT4 translocation in human skeletal muscle. Diabetes 45:1051-1056, 1996.
367. Kelley DE, Mintun MA, Watkins SC, Simoneau J-A, Jadali F, Fredrickson A. The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 97:2705-2713,
368. Bonadonna RC, Saccomani MP, Seely L, Zych KS, Ferrannini E, Cobelli C, DeFronzo RA. Glucose transport in human skeletal muscle. The in vivo response to insulin. Diabetes 42:191-198

369. Bonadonna RC, Del Prato S, Saccomani MP, Bonora E, Gulli G, Ferrannini E, Bier D, Cobelli C, DeFronzo RA. Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes. J Clin Invest 92:486-494,
370. Bonadonna RC, Del Prato S, Bonora E, Saccomani MP, Gulli G, Natali A, Frascerra S, Pecro N, Ferrannini E, Bier D, Cobelli C, DeFronzo RA. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. Diabetes 45:915-925, 1996.
371. Napoli R, Hirschman MF, Horton FS. Mechanisms of increased skeletal muscle glucose transport activity after an oral glucose load in Diabetes 44:1362-1368, 1995.
372. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, Inzucchi S, Dresner A, Rothman DL, Shulman GI. Impaired glucose transport as a cause of decreased insulin stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341:240-246,
373. Williams KV, Price JC, Kelley Interactions of impaired glucose transport and phosphorylation in skeletal muscle insulin resistance. A dose-response assessment using positron emission tomography. Diabetes 50:2069-2079, 2001.
374. Perriott LM, Kono T, Whitesell RR, Knobel SM, Piston DW, Granner DK, Powers AC, May JM. Glucose uptake and metabolism by cultured human skeletal muscle cells: rate-limiting steps. Am J Physiol Endocrinol Metab 281: E72-E80,
375. Printz RL, Ardehali H, Koch S, Granner DK. Human hexokinase II mRNA and gene structure. Diabetes 44:290-294,
376. Postic CA, Leturque A, Rencurel F, Printz R, Forest C, Granner D, Girard The effects of hyperinsulinemia and hyperglycemia on GLUT4 and hexokinase II mRNA and protein in rat skeletal muscle and adipose tissue. Diabetes 42:922-929, 1993.
377. Jones JP, Dohn GL. Regulation of glucose transporter GLUT-4 and hexokinase II gene transcription by insulin and epinephrine. Am J Physiol (Endocrinol Metab 36): E682-E687, 1997.
378. Mandarino LJ, Printz RL, Cusi KA, Kinchington P, O'Doherty RM, Osawa H, Sewell C, Consoli A, Granner DK, DeFronzo RA. Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle. Am J Physiol 269: E701-E708,
379. Kruszynska YT, Mulford MI, Baloga J, Yu JG, Olefsky JM. Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 47:1107-1113,
380. Vogt C, Ardehali H, Iozzo P, Yki-Jarvinen H, Koval J, Maezono K, Pendergrass M, Printz R, Granner D, DeFronzo R, Mandarino L. Regulation of hexokinase II expression in human skeletal muscle in vivo. Metabolism 49:814-818,
381. Vogt C, Yki-Jarvinen H, Iozzo P, Pipek R, Pendergrass M, Koval J, Ardehali H, Printz R, Granner D, DeFronzo RA, Mandarino L. Effects of insulin on subcellular localization of hexokinase II in human skeletal muscle in vivo. J Clin Endocrinol Metab 83:230-234,
382. Pendergrass M, Fazioni E, Saccomani MP, Collins D, Bonadonna R, Gulli G. In vivo glucose transport and phosphorylation in skeletal muscle is impaired in insulin resistant, normal glucose tolerant offspring of two NIDDM parents. Diabetes 44 (suppl 1):197A,
383. Rothman DL, Shulman RG, Shulman GI. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. J Clin Invest 89:1069-1075,

384. Halseth AE, Bracy DP, Wasserman DH. Overexpression of hexokinse II increases insulin- and exercise-stimulated muscle glucose uptake in Am J Physiol 276: E70-E77, 1999.
385. Pendergrass M, Koval J, Vogt C, Yki-Jarvinen H, Iozzo P, Pipek R, Ardehali H, Printz R, Granner D, DeFronzo RA, Mandarino L. Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes 47:387-394,
386. Vestergaard H, Bjorbaek C, Hansen T, Larsen FS, Granner DK, Pedersen O. Impaired activity and gene expression of hexokinase II in muscle from non-insulin-dependent diabetes mellitus patients. J Clin Invest 96:2639-2645,
387. Ducluzeau P-H, Perretti N, Laville M, Andreelli F, Vega N, Riou J-P, Vidal H. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes 50:1134-1142,
388. Lehto M, Huang X, Davis EM, Le Beau MM, Laurila E, Eriksson KF, Bell GI, Groop L. Human hexokinase II gene: exon-intron organization, mutation screening in NIDDM, and its relationship to muscle hexokinase activity. Diabetologia 38:1466-1474,
389. Laakso M, Malkki M, Kekalainen P, Kuusito J, Deeb SS. Polymorphisms of the human hexokinase II gene: lack of association with NIDDM and insulin resistance. Diabetologia 38:617-622,
390. Echwald SM, Bjorbaek C, Hansen T, Clausen JO, Vestergaard H, Zierath JR, Printz RL, Granner DK, Pedersen O. Identification of four amino acid substitutions in hexokinase II and studies of relationships to NIDDM, glucose effectiveness, and insulin sensitivity. Diabetes 44:347-353,
391. Thiebaud D, Jacot E, DeFronzo RA, Maeder E, Jequier E, Felber JP. The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes 31: 957-963,
392. Young A, Bogardus C, Wolfe-Lopez D, Mott D. Muscle glycogen synthesis and disposition of infused glucose in humans with reduced rates of insulin-mediated carbohydrate storage. Diabetes 37:303-307,
393. Avogaro A, Toffolo G, Miola M, Valerio A, Tiengo A, Cobelli C, Del Prato S. Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin- dependent diabetic individuals. J Clin Invest 98:108-115,
394. Del Prato S, Bonadonna RC, Bonora E, Gulli G, Solini A, Shank M, DeFronzo RA. Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. J Clin Invest 91:484-494,
395. Bonadonna RC, Groop L, Kraemer N. Ferrannini E, Del Prato S, DeFronzo RA. Obesity and insulin resistance in man. A dose response study. Metabolism 39: 452-459,
396. Mandarino LJ, Consoli A, Kelley DE, Reilly JP, Nurjhan N. Fasting hyperglycemia normalizes oxidative and nonoxidative pathways of insulin-stimulated glucose metabolism in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 71:1544-1551,
397. Kelley DE, Mandarino LJ. Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in noninsulin-dependent diabetes mellitus. J Clin Invest 86:1999-2007,
398. Bogardus C, Lillioja A, Stone K, Mott D. Correlation of muscle glycogen synthase activity and in vivo insulin action in man. J. Clin Invest 1984; 73: 1185-90.

399. Rothman DL, Magnusson I, Cline G, Gerard D, Kahn CR, Shulman RG, Shulman GI. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 92:983-987,
400. Vaag A, Henriksen JE, Beck-Nielsen. Decreased insulin activation of glycogen synthase in skeletal muscles in young non-obese Caucasian first-degree relatives of patients with non- insulin-dependent diabetes mellitus. J Clin Invest 89:782-788,
401. Yki-Jarvinen H, Mott D, Young AA, Stone K, Bogardus C. Regulation of glycogen synthase and phosphorylase activity by glucose and insulin in human skeletal muscle. J Clin Invest 80: 95-100,
402. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its Biochem J 359(Pt 1):1-16, 2001.
403. Cohen P. The Croonian Lecture 1999. Identification of a protein kinase cascade of major importance in insulin signal transduction. Phil Trans Royal Soc London Series B: Biological Sciences 354:485-495,
404. Stralfors P, Hiraga A, Cohen P. The protein phosphatases involved in cellular regulation: purification and characterization of the glycogen-bound form of protein phosphatase-1 from rabbit skeletal muscle. Eur J Biochem 149:295-303,
405. Sutherland C, Campbell DG, Cohen P. Identification of insulin-stimulated protein kinase-1 as the rabbit equivalent of rsk-mo-2. Eur J Biochem 212:581-588,
406. Damsbo P, Vaag A, Hother-Nielsen O, Beck-Nielsen Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin- dependent) diabetes mellitus. Diabetologia 34:239-245, 1991.
407. Mandarino LJ, Wright KS, Verity LS, Nichols J, Bell JM, Kolterman OG, Beck-Nielsen H. Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. Evidence for their role in oxidative glucose metabolism. J Clin Invest 80: 655-63,
408. Thorburn AW. Gumbiner B. Bulacan F, Wallace P, Henry RR. Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake. J Clin Invest 85: 522-9,
409. Mandarino LJ, Consoli A, Jain A, Kelley Interaction of carbohdyrate and fat fuels in human skeletal muscle: impact of obesity and NIDDM. Am J Physiol 270: E463-E470, 1996.
410. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 49:263-271,
411. Henry RR, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Park KS, Nikoulina SE. Glycogen synthase activity is redued in cultured skeletal muscle cells of non-insulin-dependent diabetes mellitus subjects. J Clin Invest 98:1231-1236,
412. Wells AM, Sutcliffe IC, Johnson AB, Taylor Abnormal activation of glycogen synthesis in fibroblasts from NIDDM subjects. Evidence for an abnormality specific to glucose metabolism. Diabetes 42:583-589, 1993.
413. Nyomba BL, Freymond D, Raz I, Stone K, Mott DM, Bogardus C. Skeletal muscle glycogen synthase activity in subjects with non-insulin-dependent diabetes mellitus after glyburide therapy. Metabolism 39:1204-1210,

414. Pratipanawatr T, Cusi K, Ngo P, Pratipanawatr W, Mandarino LJ, DeFronzo RA. Normalization of plasma glucose concentration by insulin therapy improves insulin- stimulated glycogen synthesis in type 2 diabetes. Diabetes 51:462-468,
415. Vestergaard H, Lund S, Larsen FS, Bjerrum OJ, Pedersen O. Glycogen synthase and phosphofructokinase protein and mRNA levels in skeletal muscle from insulin-resistant patients with non-insulin-dependent diabetes mellitus. J Clin Invest 91:2342-2350,
416. Vestergaard H, Bjocbaek C, Andersen PH, Bak JF, Pedersen O. Impaired expression of glycogen synthase mRNA in skeletal muscle of NIDDM patients. Diabetes 40:1740-1745, 1991.
417. Browner MF, Nakano K, Bang AG, Fleffenzk RJ. Human muscle glycogen synthase with DNA sequence: anegatively charged protein with asymmetric charge distribution. Proc Natl Acad Sci USA 86:1443-1447,
418. Majer M, Mott DM, Mochizuki H, Rowles JC, Pederson O, Knowler WC, Bogardus C, Prochazka M. Association of the glycogen synthase locus on 19q13 with NIDDM in Pima Indians. Diabetologia 39:314-321,
419. Orho M, Nikua-Ijas P, Schalin-Jantti C, Permutt M, Groop L. Isolation & characterization of human the muscle glycogen synthase gene. Diabetes 44:1099-1105, 1995.
420. Bjorbaek C, Echward SM, Hubricht P, Vestergaard H, Hansen T, Zierath J, Pedersen O. Genetic variants in promoters and coding regions of the muscle glycogen synthase and the insulin-responsive GLUT4 genes in Diabetes 43:976-983, 1994.
421. Bjorbaek C, Fik TA, Echward SM, Yang P-Y, Vestergaard H, Wang JP, Webb GC, Richmond K, Hansen T, Erikson RL, Miklos GLG, Cohen PTW, Pedersen O. Cloning of human insulin-stimulated protein kinase (ISPK-1) gene and analysis of coding regions and mRNA levels of the ISPK-1 and the protein phosphatase-1 genes in muscle from NIDDM patients. Diabetes 44:90-97,
422. Procharzka M, Michizuki H, Baier LJ, Cohen PTW, Bogardus C. Molecular and linkage analysis of type-1 protein phosphatase catalytic beta-subunit gene: lack of evidence for its mjaor role in insulin resistance in Pima Indians. Diabetologia 38:461-466,
423. Schalin-Jantti C, Harkonen M, Groop LC. Impaired activation of glycogen synthase in people at increased risk for developing NIDDM. Diabetes 41:598-604,
424. Falholt K, Jensen I, Lindkaer Jensen S, MortensenHB, Volund A, Heding LG, Norskov Petersen P, Falholt W. Carbohydrate and lipid metabolism of skeletal muscle in type 2 diabetic patients. Diab Med 5:27-31,
425. Mandarino LJ, Madar Z, Kolterman OG, Bell JM, Olefsky JM. Adipocyte glycogen synthase and pyruvate dehydrogenase in obese and type II diabetic patients. Am J Physiol 251: E489-E496,
426. Kelley D, Mokan M, Mandarino L. Intracellular defects in glucose metabolism in obese patients with noninsulin-dependent diabetes mellitus. Diabetes 41:698-706,
427. Barrett EJ, Eringa EC. The Vascular Contribution to Insulin Resistance: promise, proof, and pitfalls.  Diabetes 61: 3063-65. 2012.
428. Love KM et al. Insulin-mediated muscle microvascular perfusion and its phenotypic predictors in humans. Scientific Reports 11:11433, 2021

[doi.org/10.1038/s41598-021 90935-8].

429. Clark M et al. The Microvasculature in Insulin Resistance and Type 2 Diabetes.  Semin Vasc Med 2(1):21-32, 2002 [doi:10.1055/s-2002-23506]
430. Bergman RN, Iyer MS. Indirect Regulation of Endogenous Glucose Production by Insulin: The Single Gateway Hypothesis Revisited.  Diabetes 66:1742-47, 2017 [doi.org/10.2337/db16-1320].
431. Edgerton DS, Kraft G, Smith M et al. Insulin direct hepatic effect explains the inhibition of glucose production caused by insulin secretion.  JCI Insight 2(6):e91863, 2017 [doi.org/10.1172/jci.insight.91863].
432. Petersen, MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease.  Nature Reviews Endocrinology 13,572-87, 2017
433. Solini A, Chiara R, Chiara MM, Proietti A, Koepsell H, Ferrannini E.  Sodium glucose co-transporter SGLT-2 and SGLT-1 renal expression in patients with type 2 diabetes.  Diabetes, Obesity and Metabolism 19(9):1289-1294, 2017.  [doi.org/10.1111/dom12970].
434. Luke N, Shannon C, Fourcaudot M et al. Sodium-glucose cotransporter and glucose transporter [GLUT] expression in the kidney of type 2 diabetic -subjects. Diabetes, Obesity and Metabolism 19(9):1322-1326, 2017. [doi.org/10.1111/dom13003].
435. du Toit EF and Donner DG.  (December 12th 2012).  Myocardial Insulin Resistance: An Overview of Its Causes, Effects, and Potential Therapy, Insulin Resistance, Sarika Arora, Intech Open. [DOI: 10.5772/50619] [www.intechopen.com/chapters/41432]
436. Nathalie Esser, Kristina M. Utzschneider, Steven E. Kahn.  Early beta-cell dysfunction vs. insulin hypersecretion as the primary event in the pathogenesis of dysglycemia.   Diabetologia 63, 2007–2021, 2020. [https://doi.org/10.1007/s00125-020-05245-x]
437. Pontiroli AE, Alberetto M, Capra F, Pozza G. The glucose clamp technique for the study of patients with hypoglycemia: insulin resistance as a feature of insulinoma. J Endocrinol Investig 13(3):241–245, 1990. [https://doi.org/10.1007/bf03349549]
438. Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 37(10):1025–1035, 1994. [https://doi.org/10.1007/bf00400466].
439. Marini MA, Frontoni S, Succurro E, Arturi F, Fiorentino TV, Sciacqua A, Hribal ML, Perticone F, Sesti G. Decreased Insulin Clearance in Individuals with Elevated 1-h Post-Load Plasma Glucose Levels. PLOS ONE: Volume 8, Issue 10, October 2013 [e77440].
440. Prentki, M, Peyot ML, Pellegrino M, Madiraju SRM.  Nutrient-induced metabolic stress, adaptation, detoxification, and toxicity in the pancreatic beta cell.  Diabetes 2020; 68:279-290 [doi.org/10.2337/dbi19-001].
441. Arti Shah, Nehal Mehta, Muredach P. Reilly.  Adipose Inflammation, Insulin Resistance, and Cardiovascular Disease.  JPEN J Parenter Enteral Nutr. 32(6): 638–644. 2008. [doi:10.1177/0148607108325251].
442. Angulo P, Lindor KD.  Non-alcoholic fatty liver disease.  Journal of Gastroenterology and Hepatology 17 (Suppl.) S186–S190, 2002.
443. Younossi ZM.  Non-alcoholic fatty liver disease. Journal of Hepatology 70:531-544, 2019.
444. Hartstra AV, Bouter KEC, Backhed F, Nieuwdorp M^. Insights Into the Role of the Microbiome in Obesity and Type 2 Diabetes.  Diabetes Care 38:159–165, 2015 [DOI: 10.2337/dc14-0769].
445. Wada J, Nakatsuka A.  Mitochondrial Dynamics and Mitochondrial Dysfunction in Diabetes.  Acta Med. Okayama 70 (3): 151-158, 2015 [http://escholarship.lib.okayama-u.ac.jp/amo/].
446. Fealy CE, Mulya A, Lai N and Kirwan JP.  Exercise training decreases activation of the mitochondrial fission protein dynamin-related protein-₁ in insulin-resistant human skeletal muscle. J Appl Physiol 1985 (117): 239-245, 2014.
447. Sivitz WI, Yorek MA. Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities. ANTIOXIDANTS & REDOX SIGNALING Volume 12, Number 4, 2010 (by Mary Ann Liebert, Inc.) [DOI: 10.1089=ars.2009.2531].

ABSTRACT

Pancreas transplantation is the most effective therapeutic option that can restore insulin independence in beta-cell penic recipients with diabetes. Because of life-long immunosuppression and the initial surgical risk, pancreas transplantation is a therapeutic option only in selected patients with diabetes. Based on renal function, candidates for pancreas transplantation can be classified into three categories: uremic patients, post-uremic patients (following a successful kidney transplantation), and non-uremic patients. Uremic patients are best treated by a simultaneous kidney-pancreas transplantation. Post-uremic patients can receive a pancreas after kidney transplantation. Non-uremic patients can receive a pancreas transplant alone, if diabetes is poorly controlled resulting in hypoglycemia unawareness, and in the presence of evolving chronic complications of diabetes. Results of pancreas transplantation have improved over time and are currently non-inferior to those of renal transplantation alone in recipients without diabetes. A functioning pancreatic graft can prolong patient survival, dramatically improves quality of life of recipients, and may ameliorate the course of chronic complications of diabetes. Unfortunately, because of ageing of the donor population and lack of timely referral of potential recipients, the annual volume of pancreas transplants is declining. Considering that the results of pancreas transplantation depend on center volume, and that adequate center volume is required also for training of newer generations of transplant surgeons, centralization of pancreas transplantation activity should be considered. The recent world consensus conference on pancreas transplantation provides an independent appraisal of the impact of pancreas transplantation on modern management of diabetes as well as expert guidelines for the practice of pancreas transplantation.

INTRODUCTION

Transplantation of an immediately vascularized pancreas allograft (PTx) is currently the most effective therapy to consistently restore insulin-independence in beta-cell depleted recipients with diabetes (1-3). Islet cell transplantation may achieve the same result, especially in patients who require fewer insulin units (4-5). As compared with PTx, islet cell transplantation is associated with lower procedure-related morbidity but requires the same immunosuppression, may necessitate multiple donors, and insulin-independence, when achieved, is not often maintained long-term (1-5). However, results reported very recently from centers of excellence show, that in properly selected patients, islet cell transplantation may achieve insulin-independence rates similar to those of PTx (6).

PTx includes several approaches. In the most common scenario a pancreas allograft is transplanted simultaneously with a kidney in patients with insulin-dependent diabetes and end stage diabetic nephropathy (simultaneous pancreas-kidney transplantation; SPK). Grafts are typically obtained from a single deceased donor. Alternatively, a cadaver pancreas can be transplanted simultaneously with a living donor kidney (SCPLK) (28), or a segmental pancreas graft and a kidney graft can be donated from the same live donor (SLPK) (29). The pancreas can also be transplanted alone (PTA), in pre-uremic recipients, or after a successful kidney transplant (PAK), in post-uremic recipients. When the pancreas is transplanted without a kidney from the same donor, the graft is considered to be solitary because renal function cannot be used to anticipate rejection in the pancreas (so called “sentinel kidney” function) (30). In rare circumstances the pancreas is transplanted in the setting of multivisceral organ transplantation (31). This type of PTx is not considered in this review, since it is not performed in the typical recipient with diabetes to primarily reverse diabetes, but rather for technical reasons in the context of a multiorgan graft required to address specific, and rare, conditions requiring this extreme type of transplantation.

THE BURDEN OF DIABETES

Thanks to the availability of exogenous insulin therapy, Type 1 diabetes has changed from an immediately fatal disease to a chronic disease. Sub-optimal metabolic control, coupled with genetic predisposition (32-34), can lead to the development of severe secondary complications many years after the diagnosis of diabetes. These complications are associated with significant morbidity and reduce life expectancy of affected individuals. Patients with diabetes who have poor metabolic control despite intensive insulin therapy and/or who develop progressive secondary complications can benefit from PTx as near-physiologic metabolism is re-established. These complications include: retinopathy, nephropathy, neuropathy, and cardiovascular disease. Diabetic nephropathy is the leading indication to PTx, as either SPK or PAK.

Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both (35). Diabetes mellitus can be classified into four types: type 1 (resulting from autoimmune destruction of beta-cells, and accounting for 5-10% of all cases), type 2 (caused by relative insulin deficiency in the setting of insulin resistance, typically associated with obesity, and representing some 90% of the cases), gestational diabetes (first diagnosed during pregnancy), and a heterogeneous group identified as “other specific types” (35).

In nearly all countries diabetes has a high, and continuously growing, prevalence (36,37). In Western countries, these figures are mainly due to changes in life style, including diet high in saturated fats and decreased physical activity, eventually leading to obesity. Regarding type 1 diabetes, which accounts for most potential recipients of PTx, the prevalence of the disease in the United States is estimated to be 1,250,000 persons, with an annual incidence of 35,000 new cases (38).

Diabetes causes significant morbidity and increases mortality in affected individuals (35,39). The risk of heart disease and stroke is increased 3 to 5-fold, and 50-70% of patients with diabetes die of these events. Fifteen years after the onset of diabetes, diabetic retinopathy is present in the majority of patients. Eventually, 20-30% of patients with diabetes will develop severe visual impairment over the years. Reduction in the incidence of diabetic nephropathy among patients with type 1 diabetes, by approximately 10%, was overcompensated by a 20% increase in the incidence of this complication in patients with type 2 diabetes, leading to a net increase of the prevalence of diabetic nephropathy among dialyzed patients and confirming diabetic nephropathy as the leading cause of end-stage renal failure (39). Incidence of end-stage renal disease in patients with diabetes is higher compared to the patients without diabetes, with a relative risk of 6.2 in the white population and 62.0 among Native Americans. Diabetic neuropathy, in its several forms, affects up to 50% of people with diabetes. In combination with reduced blood flow, neuropathy in the feet increases up to 25-fold the chance of foot ulcers and of several fold eventual limb amputation (40).

TREATMENT GOALS IN DIABETES

There is a large amount of evidence recommending that glycated hemoglobin (HbA1c) should be maintained below 7.0% to reduce the incidence of microvascular disease (35,41). However, the effects of intensive diabetes management on the occurrence of macrovascular complications remains somewhat elusive, tending to be more evident in type 1 diabetes (42), as compared with type 2 diabetes (43,44). More stringent metabolic control (e.g., HbA1c 6.0–6.5%), when achieved without significant hypoglycemia or other adverse effects of treatment, can be preferred in patients with short disease duration, long life expectancy, and without significant cerebrovascular disease (41). On the other hand, less tight metabolic control (e.g., HbA1c 7.5–8.0%) can be accepted in patients at risk of severe hypoglycemia and/or with limited life expectancy, advanced vascular complications, or extensive comorbid conditions (41).

INDICATIONS FOR PANCREAS TRANSPLANTATION AND CANDIDATE SELECTION

PTx is performed to restore an endogenous source of servoregulated insulin production in beta-cell penic patients with diabetes. In technically successful PTx, restoration of beta-cell mass is consistently and reproducibly expected to induce insulin-independence, although at the price of significant surgical morbidity and life-long immunosuppression (2,45). In most patients with diabetes there is a clear advantage in receiving a pancreas graft, when also a kidney graft is needed to reverse end-stage renal failure. Moreover, PTx is indicated in selected patients with complicated and/or labile diabetes, when the risk of surgery and immunosuppression is surpassed by the ongoing risk of ineffective insulin therapy (2,45,46).

Based on these principles, the prototype recipient for PTx is a patient with type 1 diabetes without detectable c-peptide, poor metabolic control and/or progressive secondary complications of diabetes. However, selected patients with type 2 diabetes with high insulin needs, low to mild insulin resistance, and non- or mildly obese, may achieve insulin-independence after PTx and enjoy results similar to those of patients with type 1 diabetes (2,45,46).

Since failure of conventional, insulin-based, therapy is required to become eligible for PTx, most recipients have a 20- to 25-year history of diabetes. By this time, most recipients have developed end-stage nephropathy and also require a kidney transplant. Ideally, these patients should receive an SPK transplant because diabetic nephropathy is associated with high mortality rate, and 75% of insulin-dependent patients with diabetes do not survive longer than 5 years with dialysis (47-49). SPK improves patient survival versus either dialysis or deceased donor kidney transplantation (9,10,50).

In fragile recipients deemed not suitable for SPK, renal transplantation from a live donor is an attractive possibility either as definitive treatment or as a bridge to PAK. Actually, live donor renal transplantation may be worthily pursed also in patients otherwise eligible for SPK because of organ shortage (2,45,46). SCPLK provides an additional transplant opportunity, since it still exploits the benefits of live donation for the kidney but does not require the sequential PAK to correct the diabetes. The main disadvantages of SCPLK are the fact that the pancreas is a solitary graft, and that live renal donation cannot be programmed as it has to be performed when the deceased donor pancreas graft becomes available. To do so, three surgical teams have to work simultaneously (one for the deceased donor, one for the live donor, and one for the transplant) making organization and coordination quite complex (28). Considering that correction of uremia is key in these patients (10), but that ideal donors suitable for SPK are becoming extremely rare (51), when a deceased donor is available a kidney alone transplantation (KTA) should be considered as a valid alternative to leaving the patient with end-stage renal disease while waiting for a SPK donor, who may never become actually available. After KTA, PAK could allow correction of diabetes, thus preventing recurrence of diabetic nephropathy in the renal graft in the long-term period. Paradoxically, surgical complications associated with PAK could jeopardize renal function in the short-term period making the indication for PAK a matter of debate especially in terms of baseline renal function. Although there is no agreed cut-off of renal function to safely proceed with PAK, a stable renal function with a creatinine clearance of at least 60 ml/min/1.73 m2, and a negative urine analysis are all considered important criteria (2,46,52).

According to the American Diabetes Association, PTA may be an option in selected patients with diabetes who have recurrent hypoglycemia unawareness, and/or have medical or psychological problems with insulin therapy (52). Normal or near-normal renal function is also required because the anticipated long-term beneficial effects of sustained insulin-independence on diabetic nephropathy may be surpassed by accelerated deterioration of renal function caused mostly by the nephrotoxic effects of immunosuppressants (22,50,53). Additional evidence shows that also patients with progressive complications (i.e., reversible nephropathy, progressive retinopathy, and severe neuropathy) may improve significantly with PTA (13,20). Although the impact of PTA on patient survival is still debated (54,55), in suitable recipients, PTA improves the course of diabetic retinopathy (18), diabetic neuropathy (13), and diabetic nephropathy (22,50,53), and reduces the level of cardiovascular risk (13,15).

Each patient eligible for PTx is, by definition, at high risk for cardiovascular disease, making cardiac and vascular work up key in this transplant population. In recipients of solitary pancreas grafts (PAK and PTA) accurate estimate of renal function is also mandatory, as the risk of renal dysfunction/failure is reduced when the GFR is ≥ 60-70 mL/min (56). The decision to pursue a solitary PTx should hence be well balanced against the inherent risks of PTx. On the contrary, insulin-dependent patients with diabetes have in SPK their ideal treatment modality. The evaluation process in these patients should explore all possible venues to permit transplantation because continued dialysis is associated with short survival. Unfortunately, many patients are already too sick when they are first referred for transplantation and cannot be offered the chance of SPK.

Although type-2 diabetes is often characterized by obesity and peripheral insulin resistance, recent studies have demonstrated that the old paradigm is no longer generally applicable. Several studies showed improved glycemic control after pancreas transplantation in subsets of patients with type 2 diabetes, especially if body mass index is less than 35 kg/m2 (57).

CURRENT PANCREAS TRANSPLANTATION ACTIVITY

According to the International Pancreas Transplant Registry (IPTR) and the US Organ Procurement and Transplantation Network (OPTN) approximately 51,000 PTx have been performed worldwide (> 31,000 from the United States and >20,000 from other countries) (51,56). Considering that reporting to these registries is mandatory only for US Centers, the real number of PTx performed worldwide exceeds reported registry figures.

According to IPTR data, the total number of PTx steadily increased in the United States until 2004 (peaking at a total of 1484) but has since declined substantially with fewer than 1000 procedures performed in 2014 and in 2015. The overall amount of pancreas transplants decreased slightly, from 1027 in 2018 to 1015 in 2019(56). This remains considerably higher than the nadir of 947 reported in 2015, with a slight decrease attributed to declining in PTAs (124 to 99) and PAKs (68 to 44) from 2018 to 2019. In fact, SPKs continued to increase, from 835 to 872, the highest annual number of SPKs performed in the last decade.

The reasons for the decline in PTx activity are not immediately understood. In the history of solid organ transplantation good results, such as those currently achieved by PTx, typically portend higher volumes. Decline in PTx volumes coincided with a reduction in the number of active PTx centers with only 11 Institutions performing ≥ 20 PTxs per year and most centers performing < 5 PTxs annually (51). The outcome of PTx is known to be influenced by center volume (58). Additionally, lower PTx volumes per center are expected to reduce the opportunities for training of younger generations of transplant physicians and surgeons, thus potentially worsening future outcomes of PTx and further reducing the volumes of PTx, in a vicious circle.

The reason for the current decline in PTx activity is multifactorial. Some factors are historical, such as limited referral of potential recipients (51), and incomplete procurement of pancreas grafts from otherwise suitable donors (59). Other factors, however, are newer and less correctable with educational or training programs for healthcare professionals (60). These factors include the progressive ageing of donor population (61), the increasing number of obese donors (62), and the growing proportion of cerebrovascular accidents as a cause of brain death (61). The combination of these epidemiologic factors makes the “ideal” pancreas donor (age ≤ 40 years, low BMI, death due to trauma, short stay in the intensive care unit, and hemodynamic stability without, or with low dose, vasoactive amines) extremely rare (63). These factors, along with the duration of cold graft storage, are summarized in the Pancreas Donor Risk Index (63). This index, conceived to optimize the use of all grafts suitable for PTx, has instead promoted additional donor selection and further reduced the number of PTx (64). Although it is known that PTx can be pursued using marginal donors with good results (65,66), most centers are not willing to accept this type of donor, as their use may be associated with higher rates of early graft failure.

IMPACT OF COVID-19 PANDEMIC ON PANCREAS TRANSPLANTATION

The global coronavirus disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 virus reduced the worldwide transplant activity due to the overload of the health system and concern for patient safety. Since the first few months of the pandemic, the transplant community worked on characterizing infection, morbidity, and mortality from COVID-19 in the transplanted or waitlisted patient comparing outcomes to the general population. According to a worldwide survey, pancreas transplant activity declined shortly after the beginning of the COVID-19 pandemic because of both a reduction in patient referrals and utilization of deceased donors (67). There are limited clinical data on COVID-19 in PTx recipients, including a few case reports (68,69) and small series (70-73). As detailed in a recent review, COVID-19 in PTX recipients was mostly managed by reduction of immunosuppression with withdrawal of antimetabolites. Despite lower immunosuppression, the risk of rejection and graft loss does not appear to be clearly increased (74).

PANCREAS TRANSPLANTATION FROM DONORS AFTER CARDIAC DEATH

Shortage of suitable brain-dead donors (DBD), has forced the transplant community to explore the venue of donation after cardiac death (DCD). Based on Maastricht criteria (64) there are four categories of DCD donors. PTx is pursued in type 3 DCD donors, also known as controlled DCD donors. In this category of donors, cardiac arrest is awaited following withdrawal of ventilatory support in patients with fatal brain injuries who are not expected to progress to brain death (64). The use of this type of donors is associated with high organizational needs and may be influenced by national attitudes and regulations (65), but the results of PTx are quite encouraging making this source of grafts worth of further exploration (75-78).

In a recent systematic review and meta-analysis, Shahrestani and Co-workers identified 18 studies on PTx from DCD donors. No difference was noted in allograft survival (hazard ratio, 0.98; 95% confidence interval [95% CI], 0.74-1.31; p= 0.92), and recipient survival up to 10 years after PTx between DBD and DCD donors (hazard ratio, 1.31; 95% CI, 0.62-2.78; p= 0.47). The odds ratio for vascular thrombosis was 1.67 times higher in PTx from DCD organs (95% CI, 1.04-2.67; p= 0.006), but this difference was not evident in PTx from a subgroup of DCD who were treated with heparin (78).

GRAFT PROCUREMENT, PRESERVATION, AND TRANSPLANTATION TECHNIQUES

The history of pancreas transplantation has been shaped by developments in surgical techniques (7) and advancements in immunosuppressive regimens (79). It is now accepted that pancreas grafts are composed by the entire gland with an attached duodenal segment and that the organs are procured with minimal dissection in the donor during the heart beating period. A single arterial conduit is prepared at the back-table, usually by anastomosing the peripheral branches of a Y-shaped donor iliac graft to the cut ends of the superior mesenteric and splenic arteries (80). In rare circumstances, a segmental pancreas graft made of the body and tail of the gland, can be transplanted. This type of graft is used when there are concerns on perfusion of the pancreatic head/duodenum to allow PTx in otherwise “difficult to transplant” recipients, such as patients with high immunization titers. A segmental pancreas graft is also used from live donors (29). Pancreas grafts are highly sensitive to ischemia-reperfusion injury (63). Despite the incidence of surgical complications not significantly increasing until 20 hours of preservation (81), most centers now prefer to maintain the period of cold storage to ≤ 12 hours (82).

At the moment, the gold standard for pancreas graft preservation is static cold storage using the University of Wisconsin solution (83). When the period of cold storage is not exceedingly long also Celsior (84) and histidine-tryptophan-ketoglutarate (85) can be accepted. The use of histidine-tryptophan-ketoglutarate has been associated with higher rates of graft pancreatitis (86). Reduction of perfusion volumes are thought to prevent these complications. IGL-1 in a newer preservation solution, but data on PTx are yet scarce (87). As with other organs, machine perfusion is being explored also for pancreas allografts. The potential of this innovative preservation strategy in PTx remains to be established (88).

Regarding transplantation techniques, it is quite surprising that none was clearly shown to be superior over the other procedures (89). Despite this, some surgical techniques have become very popular and are currently considered standard procedures for PTx. The main variations in PTx technique regard the site for venous drainage (either systemic or portal) and the site for exocrine drainage (either urinary or enteric). In enterically drained grafts other major variations are the use of a Roux-en-Y isolated loop or the creation of a direct anastomosis between the donor duodenum and the recipient small bowel (90), duodenum (91-94), or stomach (95).

The combination of systemic venous effluent and enteric exocrine drainage is currently prevalent (7) as the alleged metabolic and immunologic advantages of portal venous drainage have not been unambiguously proven (96). Bladder drainage along with the inclusion in the graft of a duodenal segment (97 PTx is not employed very frequently at the present time because of frequent urologic and metabolic complications.

The greatest innovation in surgical technique is the description of laparoscopic, robotic-assisted, PTx. The initial experience by Boggi et al (98,99) was recently duplicated at the University of Illinois at Chicago (100). This makes PTx a minimally invasive procedure and is associated with obvious advantages but has high organizational needs, and requires surgeon and team training in advanced robotic procedures.

IMMUNOSUPPRESSIVE PROTOCOLS

Current state-of-the art immunosuppression in PTx was recently reported in a review article (101) and practice recommendations were provided by the proceedings of the first world consensus conference on pancreas transplantation (WCCPTx) (102-103).

Although the immunologic outcome of PTx has improved over the years, rejection still occurs quite frequently (from 20-30% in SPK to around 40% in PTA) (104). Accordingly, the use of T-cell depleting antibody induction is still preferred in some 90% of recipients, while an anti-interleukin-2 receptor antibody alone is used in the remaining 10%. In last two decades, maintenance immunosuppression regimens have employed tacrolimus and mycophenolate in over 80% of the patients (105-106). The use of cyclosporine and/or mammalian target of rapamycin has been mostly considered in the setting of switching in case of documented side effects related to the standard regimen (107) Steroids may be withdrawn or minimized to avoid their side effects, including the risk of glucose intolerance (108-109). The recent evidence that development of donor specific antibodies occurs in PTx and is associated with worse immunologic outcome, further compounds the field and could require the adoption of newer protocols for the treatment of antibody-mediated rejection such as a combination of anti CD20, intravenous immunoglobulins, and protease inhibitors (110). Early experiences suggest that switch from calcineurin inhibitors to belatacept, a T-cell co-stimulation blocker used to prevent acute rejection in adult renal transplant recipients, may reduce nephrotoxicity without evidence of increased risk of kidney or pancreas rejection (111,112). Belatacept may represent an important strategy for preservation of renal and pancreatic function after SPK transplantation, either as first-line or rescue therapy. A trial in primary SPK transplantation (NCT01790594), using belatacept for induction and for maintenance, in combination with mycophenolate mofetil and low dose calcineurin inhibitors, with early steroid withdrawal, was recently completed.

According to a recent review no major improvement in immunosuppressive regimens used for PTx was achieved during the last 20 years. Most PTx patients receive induction with depleting antibodies and maintenance with a combination of a calcineurin inhibitor (with tacrolimus being more prevalent than cyclosporine) plus mycophenolate and steroid maintenance. Newer drug combinations and well-designed prospective studies are needed to further improve the outcome of PTx (101).

POST-TRANSPLANT COMPLICATIONS

PTx carries the highest risk of post-transplant complications among all solid organ transplants, as a consequence of the medical complexity of recipients with diabetes and the susceptibility of pancreas allografts to develop vascular thrombosis and pancreatitis. Occurrence of post-operative complications reduces the rate of graft survival, with allograft pancreatectomy being required in some 5% of PTx recipients, but does not affect patient survival (113). Life-threatening complications still occur in approximately 3% of recipients, mostly because of development of an arterial pseudoaneurysm or an arteroenteric fistula (114).

In the long–term, malignancies as well as bacterial, viral, and fungal infections remain a significant cause of mortality and morbidity (114). Among a cohort of 360 SPK transplants, overall 5-year patient survival was 84%, but 25 recipients (6.9%) developed malignant tumors. Almost one-fourth of the cancers were skin tumors and 5 patients developed post-transplant lymphoproliferative disorders (PTLD) (106). According to the SRTR/Annual Data Report the cumulative incidence of PTLD at 4 years is 2.3% after PTA, 0.9% after SPK, and 1.1% after PAK. The higher frequency of PTLD in PTA patients is likely related to their increased immunosuppression and higher rates of acute rejection (104,116,117). The incidence of other cancers is 3- to 4-fold higher compared with the background population (115).

PATIENT AND GRAFT SURVIVAL

According to the International Pancreas Transplant Registry, 5- and 10-year graft function rates in 21,383 PTx, performed from 1984 to 2009, are 73 and 56%, respectively, for SPK; 64 and 38%, respectively, for PAK; and 53 and 36%, respectively, for PTA (1).

Cardiovascular and/or cerebrovascular events are the leading cause of recipient death either short- (<3 months post-transplant) and long-term (>1-year post-transplant) (118). In patients with type 1 diabetes, SPK has been shown in several studies to increase the observed versus expected lifespan, as compared with a kidney transplant alone (119,120). According to a large study of 13,467 patients, using data from the US Scientific Renal Transplant Registry and the US Renal Data System, the patient survival rate at 10 years post-transplant was significantly higher in recipients of a SPK than of a KTA from a deceased donor. In fact, recipients of a SPK had the greatest longevity (23.4 years), as compared with 20.9 years for recipients of a KTA from a living donor and 12.8 years for recipients of a KTA from a deceased donor (10,121).

In recipients of PAK, evidence shows that the PTx improves long-term patient and kidney graft survival rates. Also, glomerular filtration rates are significantly higher after PAK than after KTA (122). In recipients of PTA who have brittle diabetes mellitus, the mortality rate at 4 years is lower than that in the waiting list candidates (123). Earlier reports stating a survival disadvantage for recipients of solitary pancreas transplants (PTA and PAK) compared with patients on the waiting list for a transplant now seem to be unsubstantiated (54).

Pancreas graft survival rate is based on insulin independence. In the past decade, unadjusted graft survival rates at 1 year were 89% for SPK, 86% for PAK and 82% for PTA. Equivalent figures at 5 years were 71%, 65%, and 58%, respectively (118). More recently, 10-year actual insulin independence rates have been reported to exceed 80% in SPK and 60% in PTA (12,13).

The greatest improvements are seen in the gains over time in the estimated half-life (50% function) of pancreas grafts. The estimated half-life is now 14 years for SPK, and 7 years for both PAK and PTA. Moreover, the estimated half-life has increased to 10 years in recipients of PAK or PTA with a functioning pancreas graft at 1-year post-transplant. The longest pancreas graft survival time, by category, has been 26 years (SPK), 24 years (PAK) and 23 years (PTA) (124).

The leading cause of pancreas loss is rejection (125,126). Autoimmunity is also increasingly recognized as a cause of graft failure (127,128). The diagnosis of pancreatic rejection is based on laboratory markers and imaging techniques, but core biopsy remains the final diagnostic tool. In SPK, a rise in serum creatinine can be a surrogate for pancreas rejection suspicion; however, discordant kidney and pancreas rejection have been described (129). An increase in serum amylase and lipase, although not specific, can be an initial sign of pancreatic immune-activation. Hyperglycemia occurs only in cases of severe beta-cell dysfunction or destruction, and therefore it is a late marker of rejection. Guidelines for the diagnosis of PTx rejection have been recently updated with major implementation for the identification of antibody mediated rejection (130). Pancreatic antibody mediated rejection is a combination of serological and immunohistological findings consisting of donor specific antibody detection, morphological evidence of microvascular injury, and C4d staining in interacinar capillaries. The newest Banff schema recognizes different patterns of immunoactivation, including the recurrence of autoimmune diabetes that is characterized by insulitis and/or selective beta-cell destruction. Among the different causes of graft loss, recent studies have proven that despite immunosuppression, the recurrence of autoimmune disease is not a rare event (129). Historical experience with segmental PTx in identical twins showed that, without immunosuppression, autoimmune destruction of beta cells occurs early after PTx (131). Immunosuppression prevents such recurrence in most, but not in all, patients (127).

Graft failure of any organ has a negative impact on patient survival. In recipients of SPK, kidney graft loss increases the relative risk of death by a factor of 17.6 and pancreas graft loss by a factor of 3.1. In recipients of PAK, kidney graft loss increases the relative risk of death by a factor of 4.3 and pancreas graft loss by a factor of 4.1. In recipients of PTA, pancreas graft loss increases the relative risk of death by a factor of 4.1 (132).

EFFECTS OF PANCREAS TRANSPLANTATION ON ACUTE DIABETES COMPLICATIONS

The excess mortality seen in type 1 diabetes is largely related to diabetes and its comorbidities. Acute complications are represented by hyperglycemic syndromes (most commonly ketoacidosis, less frequently the hyperosmolar syndrome) and hypoglycemia induced by exogenous insulin therapy. They contribute to 80% of all early (<10-year diabetes duration) deaths, and for a 15% of deaths thereafter. Most early acute deaths result from diabetic ketoacidosis (often at diabetes onset or after an acute illness), whereas later acute deaths tend to result from hypoglycemic episodes (133,134). Successful PTx restores a regulated endogenous insulin production and eliminates the need for exogenous insulin administration. As such, no acute diabetic complication is seen in patients with fully functioning pancreatic graft. In addition, PTx improves hypoglycemia counter-regulation, by improving catecholamine and glucagon responses to glucose lowering. These improvements are stable and long-lasting, and have been shown up to 19 years from the grafting (135). Recently, the use of beta cell replacement therapy has been discussed for patient with problematic hypoglycemia, defined as two or more episodes per year of severe hypoglycemia or as one episode associated with impaired awareness of hypoglycemia (136). In such cases, if appropriate educational and technological interventions are not sufficient to improve the condition, PTx is indicated (136). It is therefore reasonable to consider PTx in patients with type 1 diabetes who are at proven risk for serious episodes of insulin-induced hypoglycemia and who demonstrate refractoriness to conventional medical management (135,136).

EFFECTS OF PANCREAS TRANSPLANTATION ON CHRONIC DIABETES COMPLICATIONS

Chronic diabetes complications are a major burden of the disease, dramatically contributing to deterioration of quality of life and reduced survival in the population with type 1 diabetes (137). They can be broadly separated into two categories: microvascular and macrovascular. The first ones are due to damage of small vessels involving eyes, kidneys and nerves, while the others are related to damage in larger blood vessels.

Diabetic Retinopathy

Diabetic retinopathy (DR) is the most common, highly specific microvascular complication of diabetes, with prevalence strongly related to duration of diabetes and the levels of glycemic control. Numerous studies have been performed to elucidate the role of PTx on the clinical course of this complication. Initial work (138,139) found that SPK with subsequent normalization of blood glucose concentrations did not play a role in preventing or reversing retinal damage, but more recent studies support the view that PTx has beneficial effects. In a study conducted on 48 successful SPK, a careful eye examination was performed before and up to 60 months after grafting, with standardized classification of DR (19). The results showed, compared with a group of non-transplanted, matched patients with type 1 diabetes, that SPK recipients had a significantly higher rate of improvement or stabilization of the retinal lesions, depending on the severity of retinopathy at the time of transplantation. A report describing 112 patients with functioning SPK showed an improvement and/or stabilization in 73.5% patients with non-proliferative retinopathy, with an important decrease in the number or ophthalmologic procedures after a period of 4 years (140). Regarding the role of PTA, the course of DR was studied prospectively in PTA recipients and in non-transplanted patients with type 1 diabetes, with a follow-up of almost 3 years (18). The PTA and non-PTA groups consisted respectively of 33 (follow-up: 30 +/- 11 months) and 35 patients (follow-up: 28 +/- 10 months). Best corrected visual acuity, slit lamp examination, intraocular pressure measurement, ophthalmoscopy, retinal photographs, and in selected cases angiography were performed by the authors. At baseline, 9% of PTA and 6% of non-PTA patients had no diabetic retinopathy, 24 and 29% had non-proliferative diabetic retinopathy (NPDR), whereas 67 and 66% had laser-treated and/or proliferative diabetic retinopathy (LT/PDR), respectively. No new case of diabetic retinopathy occurred in either group during follow-up. In the NPDR PTA group, 50% of patients improved by one grading, and 50% showed no change. In the LT/PDR PTA, stabilization was observed in 86% of cases, whereas worsening of retinopathy occurred in 14% of patients. In the NPDR non-PTA group, diabetic retinopathy improved in 20% of patients, remained unchanged in 10%, and worsened in the remaining 70%. In the LT/PDR non-PTA group, retinopathy did not change in 43% and deteriorated in 57% of patients. Overall, the percentage of patients with improved or stabilized diabetic retinopathy was significantly higher in the PTA group (18). Therefore, although cases of early deterioration of diabetic retinopathy have been reported after pancreas transplantation (141), current evidence indicates delay of development and/or increased rate of stabilization of this complication following functioning pancreatic graft (142,143).

Diabetic Kidney Disease

Type 1 diabetes mellitus patients present a high risk of developing renal complications. Diabetic kidney disease, or CKD attributed to diabetes, occurs in 20 – 40% of patients with diabetes and is the leading cause of end-stage renal disease (ESRD) (144). Progression to ESRD in this patient population has important prognostic implications (48,145) and proves to be resistant to most nephroprotective therapeutic measures (146). As discussed above, simultaneous pancreas-kidney transplantation (SPK) in T1D patients is associated with improved patient survival compared to solitary cadaveric renal transplantation (10,121,147,148). Regarding the survival of the grafted kidney, the SPK approach generally guarantees better results compared with the cadaveric donor kidney only transplant. In long-term results (>10 years), the kidney graft survival rate in SPK is equal or better compared to that observed with a living donor solitary renal transplantation (149). Successful long-term normoglycemia as obtained by a functioning pancreas can also prevent recurrence of diabetic glomerulopathy in the kidney graft, as shown histologically by comparing renal biopsies from SPK or PAK versus kidney transplant alone (follow-up 1 to 6 years, approximately). In addition, SPK has been reported to be associated with better creatinine levels and reduced urinary albumin excretion in SPK patients, compared to kidney alone grafted individuals (150). Along similar lines, in patients with type 1 diabetes and long-term normoglycemia after successful SPK transplantation, kidney graft ultrastructure and function were better preserved compared with LDK transplantation alone (151). Altogether, the available information indicates that pancreas transplantation plays a role in protecting the grafted kidney and preventing the recurrence of diabetic nephropathy in renal allografts.

In the case of PTA, the effects on the native kidneys are not fully established yet. Currently available immunosuppressive drugs are nephrotoxic, and this places pancreas transplantation recipients, like other solid organ recipients (152), at risk for post-transplant nephropathy (153,154). Gruessner et al. (155) showed that a serum creatinine level above 1.5 mg/dL, recipient age below 30 years and or tacrolimus levels > 12 mg/dl at 6 months were significantly associated with the development of overt renal failure after PTA. However, in another study (156) no significant deterioration of renal function was observed at 1 year after PTA in patients with glomerular filtration rate (GFR) of about 50 ml/min. Initial work from our group showed no significant change in creatinine concentration and clearance and an improvement in proteinuria at 1 year after PTA (22). More recently, we reported the results achieved in 71 PTA recipients 5 years after transplantation (13,20). In this series proteinuria improved significantly, and only one patient developed ESRD. In the 51 patients with sustained pancreas graft function, kidney function (serum creatinine and glomerular filtration rate) decreased over time with a slower decline in recipients with pretransplant eGFR less than 90 ml/min in comparison to those with pretransplant eGFR greater than 90 ml/min; this finding is possibly due to the correction of hyperfiltration following normalization of glucose metabolism. However, another study (157) reported an accelerated decline in renal function after PTA in the patient population with lower pretransplant GFR. Important information on this issue has been provided by a study conducted with 1135 adult recipient of first PTA (55). The authors have subdivided their series of recipients into three groups, depending on the eGFR (ml/min/1.73 m2): ≥ 90 (n: 528), 60-89 (n: 338) and < 60 (n: 269). The patients were followed up to 10 years and the outcome was ESRD, according to the need for maintenance dialysis or kidney transplantation. The results indicated that at 10 years the cumulative probability of ESRD was 21.8%, 29.9% and 52.2% in recipients with pre-transplant eGFR ≥ 90, 60-89 and < 60 ml/min/1.73 m2, respectively (55). Overall, data available indicates the renal function before PTA as a major factor affecting post-transplantation evolution of the function of the native kidneys. The course of diabetic nephropathy after pancreas transplantation has also been characterized histologically (158-160). Fioretto et al. (161) performed protocol biopsies in patients who had received a successful PTA and found that, whereas 5 years after transplant the histologic lesions of diabetic nephropathy were unaffected, at 10 years reversal of diabetic glomerular and tubular lesions was evident. The histologic reversibility of diabetic nephropathy was previously shown in the case of transplantation of human cadaveric kidneys into recipients without diabetes (162,163) and is supported by the current favorable outcome of deceased diabetic donor kidneys (164). Of interest, a recent study has shown that mortality in PTA recipients who develop ESRD is similar to that found in type 1 diabetic patients on dialysis (165). Therefore, current evidence indicates that normoglycemia ensuing after successful pancreas transplantation prevents and may even reverse diabetic nephropathy lesions in native kidneys and kidney grafts. This has to be balanced with the potential nephrotoxic effects of immunosuppression.

Diabetic Neuropathy

Diabetic neuropathy affects approximately 50% of T1D patients and is associated with reduced survival (166,167). All types of pancreas transplantation may have beneficial effects on diabetic neuropathy (sensory, motor, and autonomic) (168-172). Navarro et al. (171) compared the course of diabetic neuropathy in 115 patients with a functioning pancreas transplantation (31 SPK, 31 PAK, 43 PTA without and 10 PTA with subsequent kidney transplantation) and 92 control patients over 10 years of follow-up. Using clinical examination, nerve conduction studies, and autonomic function tests, the authors found significant improvements in the transplanted groups (similar across the different subgroups) (171). Allen et al. demonstrated a gradual, sustained, and late improvement in nerve action potential amplitudes, consistent with axonal regeneration and partial reversal of diabetic neuropathy, in SPK recipients. Two distinct patterns of neurological recovery were analyzed: conduction velocity improved in a biphasic pattern, with a rapid initial recovery followed by subsequent stabilization. In contrast, the recovery of nerve monophasic amplitude continued to improve for up to 8 years (170). Similarly, we found a significant improvement in Michigan Neuropathy Screening Instrument scores (173), vibration perception thresholds, nerve conduction studies, and autonomic function tests in a series of PTA patients with long-term follow-up (13,20). The beneficial effects of pancreas transplantation on cardiac autonomic neuropathy were also reported by Cashion et al. (174) using 24 h heart rate variability monitoring. However, spectral analysis of heart rate variation was performed by Boucek et al. (175), but without significant findings. Interestingly, Martinenghi et al. (172) monitored nerve conduction velocities in five patients who underwent SPK, reporting a significant improvement which was strictly dependent on pancreas graft function. Nerve regeneration is defective in patients with diabetes (166). In a case report, Beggs et al. (176) performed sequential sural nerve biopsies after PTA and found histologic evidence of nerve regeneration. Quantification of nerve fiber density in skin biopsies (177-179) or in gastric mucosal biopsies obtained during endoscopy (180) is an interesting tool to assess diabetic neuropathy. However, Boucek et al. (181,182) did not find any significant improvement in intraepidermal nerve fiber density after pancreas transplantation. In contrast, Mehra et al. used corneal confocal microscopy, a noninvasive and well validated imaging technique (183,184), and were able to find significant small nerve fiber repair within 6 months after pancreas transplantation. These latter findings have been recently confirmed (26). Lately, it has been observed that successful pancreas transplantation improved cardiovascular autonomic neuropathy (185). However, the impact of pancreas transplantation on late, serious autonomic neurological complications (gastroparesis, bladder dysfunction) is still unsettled.

Cardiovascular Disease

Patients with diabetes present an increased risk for cardiovascular morbidity and mortality, mainly due to diffuse coronary atherosclerosis and diabetic cardiomyopathy (132). After SPK, cardiovascular events remain a primary cause of morbidity and mortality (186), both in the immediate postoperative period (187) and in the long term (188). Preoperative cardiovascular assessment is mandatory to select patients who may maximally benefit from transplantation (189,190), which could also include myocardial perfusion scintigraphy (191).

In SPK recipients, improvement in macrovascular disease (including cerebral vasculopathy and morphology) and cardiac function has been generally observed. A retrospective study of cardiovascular outcomes after SPK and cadaveric kidney-alone transplantation (192) showed cardiovascular death rate (acute myocardial infarction, acute heart failure, lethal arrhythmias, acute pulmonary edema) of 7.6% in SPK, 20.0% in kidney alone and 16.1% in dialyzed patients. In the same study, SPK was associated with improved left ventricular ejection fraction, left ventricular diastolic function, blood pressure, peak filling rate to peak ejection rate ratio and endothelial dependent dilation of the brachial artery (193,194). A study by Biesenbach et al compared SPK and KTA: after 10 years from the procedure, in the SPK group the authors showed a significant lower frequency of vascular complications which included myocardial infarction (16% vs. 50%), stroke (16% vs. 40%) and amputations (16% vs. 30%). In addition, when the cardiovascular outcomes after SPK or living donor kidney-alone transplantation were compared, it was found that SPK was associated with reduced long-term cardiovascular mortality especially in a long term follow up (195). Less information is available regarding the effects of PTA on the cardiovascular system. In a single center experience with 71 consecutive PTA followed for 5 years, clinical cardiac evaluation and doppler echocardiographic examinations were performed. The authors observed that left ventricular ejection fraction increased significantly, and several parameters of diastolic function improved (13). Most of these findings were confirmed after 8 years from transplant (11). As for the effects of PTx on the peripheral arteries, the available information suggests that this type of transplantation neither aggravates nor improves peripheral vascular disease events or progression (196). However, some authors have reported that SPK is protective against atherosclerotic risk factor and progression, prothrombotic state, endothelial function and carotid intima media thickness independent of significant changes in other risk factor (197).

FIRST WORLD CONSENSUS CONFERENCE ON PANCREAS TRANSPLANTATION

The first WCCPTx was held in Pisa (Italy) October 18-19, 2019. Based on the analysis and discussion of 597 studies, an independent jury provided 49 jury deliberations concerning the impact of pancreas transplantation on the treatment of patients with diabetes, using the Zurich-Danish model, while a group of 51 experts, from 17 countries and 5 continents, provided 110 recommendations for the practice of PTx. Consensus was reached after two online Delphi rounds with a final voting at the consensus conference on Pisa. Each recommendation received a GRADE rating (Grading of Recommendations, Assessment, Development and Evaluations) and was validated using the AGREE II instrument (Appraisal of Guidelines for Research and Evaluation II). Quality of evidence was assessed using the SIGN methodology (Scottish Intercollegiate Guidelines Network).

The WCCPTx conveys several important messages. First, both SPK and PTA can improve long-term patient survival. Second, PAK increases the risk of mortality only in the early period after transplantation, but is associated with improved life expectancy thereafter. Third, all types of PTx dramatically improve of quality of life of recipients. Fourth, depending on severity at baseline, PTX has the potential to improve the course of chronic complications of diabetes. Fifth, SPK transplantation should be performed before initiation of dialysis or shortly thereafter, as time on dialysis has negative prognostic implications for patients with diabetes. As a consequence, kidney grafts should be preferentially allocated to patients listed for an SPK transplant (102-103).

CONCLUSIONS

As shown by the WCCPTx, PTx has a high therapeutic index, when correctly indicated and performed at proficient centers. Therefore, all possible efforts should be made to make this important treatment option available in a timely manner to all suitable recipients.

REFERENCES

1. Gruessner AC, Gruessner RW. Long-term outcome after pancreas transplantation: a registry analysis. Curr Opin Organ Transplant 2016;21:377-85.
2. Boggi U, Vistoli F, Egidi FM, Marchetti P, De Lio N, Perrone V, et al. Transplantation of the pancreas. Curr Diab Rep 2012;12:568-79.
3. Redfield RR, Rickels MR, Naji A, Odorico JS. Pancreas transplantation in the modern era. Gastroenterol Clin North Am 2016;45:145-66.
4. Othonos N, Choudhary P. Who should be considered for islet transplantation alone? Curr Diab Rep 2017;17:23.
5. Tatum JA, Meneveau MO, Brayman KL. Single-donor islet transplantation in type 1 diabetes: patient selection and special considerations. Diabetes Metab Syndr Obes 2017;10:73-8.
6. Moassesfar S, Masharani U, Frassetto LA, Szot GL, Tavakol M, Stock PG, et al. A comparative analysis of the safety, efficacy, and cost of islet versus pancreas transplantation in nonuremic patients with type 1 diabetes. Am J Transplant 2016;16:518-26.
7. Boggi U, Amorese G, Marchetti P. Surgical techniques for pancreas transplantation. Curr Opin Organ Transplant 2010;15:102-11.
8. Boggi U, Vistoli F, Coppelli A, Marchetti P, Rizzo G, Mosca F. Use of basiliximab in conjunction with either Neoral/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation. Transplant Proc 2001;33:3201-2.
9. Tydén G, Tollemar J, Bolinder J. Combined pancreas and kidney transplantation improves survival in patients with end-stage diabetic nephropathy. Clin Transplant 2000;14:505-8.
10. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman A, Magee JC, Cibrik D, et al. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation 2001;71:82-90.
11. Occhipinti M, Rondinini L, Mariotti R, Vistoli F, Baronti W, Barsotti M, et al. Amelioration of cardiac morphology and function in type 1 diabetic patients with sustained success of pancreas transplant alone. Diabetes Care 2014;37:e171-2.
12. Marchetti P, Occhipinti M, Rondinini L, Mariotti R, Amorese G, Barsotti M, et al Metabolic and cardiovascular effects of beta cell replacement in type 1 diabetes. Intern Emerg Med 2013;8 Suppl 1:S55-6.
13. Boggi U, Vistoli F, Amorese G, Giannarelli R, Coppelli A, Mariotti R, et al. Long-term (5 years) efficacy and safety of pancreas transplantation alone in type 1 diabetic patients. Transplantation 2012;93:842-6.
14. Boggi U, Mosca F, Vistoli F, Signori S, Del Chiaro M, Bartolo TV, et al. Ninety-five percent insulin independence rate 3 years after pancreas transplantation alone with portal-enteric drainage. Transplant Proc 2005;37:1274-7.
15. Coppelli A, Giannarelli R, Mariotti R, Rondinini L, Fossati N, Vistoli F, et al. Pancreas transplant alone determines early improvement of cardiovascular risk factors and cardiac function in type 1 diabetic patients. Transplantation 2003;76:974-6.
16. Coppelli A, Giannarelli R, Aragona M, Rizzo G, Boggi U, Paleologo G, et al. Cardiovascular risk factors in recipients of successful kidney-pancreas transplantation. Transplant Proc 2001;33:3681.
17. Boggi U, Rosati CM, Marchetti P. Follow-up of secondary diabetic complications after pancreas transplantation. Curr Opin Organ Transplant. 2013;18:102-10.
18. Giannarelli R, Coppelli A, Sartini MS, Del Chiaro M, Vistoli F, Rizzo G, et al. Pancreas transplant alone has beneficial effects on retinopathy in type 1 diabetic patients. Diabetologia 2006;49:2977-82.
19. Giannarelli R, Coppelli A, Sartini M, Aragona M, Boggi U, Vistoli F, et al. Effects of pancreas-kidney transplantation on diabetic retinopathy. Transpl Int 2005;18:619-22.
20. Boggi U, Vistoli F, Amorese G, Giannarelli R, Coppelli A, Mariotti R, et al. Results of pancreas transplantation alone with special attention to native kidney function and proteinuria in type 1 diabetes patients. Rev Diabet Stud 2011;8:259-67.
21. Coppelli A, Giannarelli R, Boggi U, Del Prato S, Amorese G, Vistoli F, et al Disappearance of nephrotic syndrome in type 1 diabetic patients following pancreas transplant alone. Transplantation 2006;81:1067-8.
22. Coppelli A, Giannarelli R, Vistoli F, Del Prato S, Rizzo G, Mosca F, et al. The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care 2005;28:1366-70.
23. Piccoli GB, Mezza E, Picciotto G, Burdese M, Marchetti P, Rossetti M, et al. The grafted kidney takes over: disappearance of the nephrotic syndrome after preemptive pancreas-kidney and kidney transplantation in diabetic nephropathy. Transplantation 2004;78:627-30.
24. Paleologo G, Tregnaghi C, Bianchi AM, Barsotti M, Nerucci B, Marchetti P, et al. Solitary pancreas transplantation: preliminary findings about early reduction of proteinuria in incipient or evident diabetic type I nephropathy. Transplant Proc 2004;36:591-6.
25. Piccoli GB, Rossetti M, Marchetti P, Grassi G, Picciotto G, Barsotti M, et al. Complete reversal of the nephrotic syndrome after preemptive pancreas-kidney transplantation: a case report. Transplant Proc 2004;36:589-90.
26. Tavakoli M, Mitu-Pretorian M, Petropoulos IN, Fadavi H, Asghar O, Alam U, et al. Corneal confocal microscopy detects early nerve regeneration in diabetic neuropathy after simultaneous pancreas and kidney transplantation. Diabetes 2013; 62:254-60.
27. Martins LS, Outerelo C, Malheiro J, Fonseca IM, Henriques AC, Dias LS, et al. Health-related quality of life may improve after transplantation in pancreas-kidney recipients. Clin Transplant 2015;29:242-51.
28. Boggi U, Vistoli F, Del Chiaro M, Signori S, Coletti L, Morelli L, et al. Pietrabissa A, Moretto C, Barsotti M, Marchetti P, Rizzo G, Mosca F. Simultaneous cadaver pancreas-living donor kidney transplantation. Transplant Proc 2004;36:577-9.
29. Boggi U, Amorese G, Marchetti P, Mosca F. Segmental live donor pancreas transplantation: review and critique of rationale, outcomes, and current recommendations. Clin Transplant 2011;25:4-12.
30. Klassen DK, Hoen-Saric EW, Weir MR, Papadimitriou JC, Drachenberg CB, Johnson L, et al. Isolated pancreas rejection in combined kidney pancreas tranplantation. Transplantation 1996;61:974-7.
31. Mangus RS, Tector AJ, Kubal CA, Fridell JA, Vianna RM. Multivisceral transplantation: expanding indications and improving outcomes. J Gastrointest Surg 2013;17:179-86; discussion 186-7.
32. Swan EJ, Salem RM, Sandholm N, Tarnow L, Rossing P, Lajer M, et al. Genetic risk factors affecting mitochondrial function are associated with kidney disease in people with type 1 diabetes. Diabet Med 2015;32:1104-9.
33. Singh K, Kant S, Singh VK, Agrawal NK, Gupta SK, Singh K. Toll-like receptor 4 polymorphisms and their haplotypes modulate the risk of developing diabetic retinopathy in type 2 diabetes patients. Mol Vis 2014;20:704-13.
34. Rogus JJ, Poznik GD, Pezzolesi MG, Smiles AM, Dunn J, Walker W, et al. High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach. Diabetes 2008;57:2519-26.
35. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35(Suppl 1):S11-63 .
36. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
37. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.
38. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35(Supp 1):S64-71.
39. Assogba FG, Couchoud C, Hannedouche T, Villar E, Frimat L, Fagot-Campagna A, et al. Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011. Diabetologia 2014;57:718-28.
40. Narres M, Claessen H, Droste S, Kvitkina T, Koch M, Kuss O, et al. The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: a systematic review. PLoS One 2016;11:e0147329.
41. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.
42. DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365(25):2366-76.
43. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-89.
44. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364(9):818-28.
45. Orlando G, Stratta RJ, Light J. Pancreas transplantation for type 2 diabetes mellitus. Curr Opin Organ Transplant 2011;16(1):110-5.
46. Sutherland DER. Pancreas and islet transplant population. In: Gruessner RWG, Sutherland DE, editors. Transplantation of the pancreas. New York (USA): Springer Verlag; 2004. p. 91-102.
47. Allen KV, Walker JD. Microalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care 2003;26(8):2389-91.
48. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J 1987;294(6588):1651-54.
49. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341(23):1725-30
50. White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet 2009;373(9677):1808-17.
51. Stratta RJ, Gruessner AC, Odorico JS, Fridell JA, Gruessner RW. Pancreas transplantation: an alarming crisis in confidence. Am J Transplant. 2016;16:2556-62.
52. Robertson RP, Davis C, Larsen J, Stratta R, Sutherland DE; American Diabetes Association. Pancreas and islet transplantation in type 1 diabetes. Diabetes Care 2006;29:935.
53. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998;339:69-75.
54. Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA 2003;290:2817-23.
55. Kim SJ, Smail N, Paraskevas S, Schiff J, Cantarovich M. Kidney function before pancreas transplant alone predicts subsequent risk of end-stage renal disease. Transplantation 2014;97:675-80.
56. Kandaswamy R, Stock PG, Miller J, et al. OPTN/SRTR 2019 Annual Data Report: Pancreas. Am J Transplant 2021; 21 Suppl 2: 138–207.
57. Pham PH, Stalter LN, Martinez EJ, Wang JF, Welch BM, Leverson G, Marka N, Al-Qaoud T, Mandelbrot D, Parajuli S, Sollinger HW, Kaufman D, Redfield RR, Odorico JS. Large single center results of simultaneous pancreas-kidney transplantation in patients with type 2 diabetes. Am J Transplant. 2021; 00:1–14
58. Alhamad T, Malone AF, Brennan DC, Stratta RJ, Chang SH, Wellen JR, et al. Transplant center volume and the risk of pancreas allograft failure. Transplantation 2017. doi: 10.1097/TP.0000000000001628.
59. Wiseman AC, Wainright JL, Sleeman E, McBride MA, Baker T, Samana C, et al. An analysis of the lack of donor pancreas utilization from younger adult organ donors. Transplantation 2010 15;90:475-80.
60. Lam HD, Schaapherder AF, Kopp WH, Putter H, Braat AE, Baranski AG. Professionalization of surgical abdominal organ recovery leading to an increase in pancreatic allografts accepted for transplantation in the Netherlands: a serial analysis. Transpl Int 2017;30:117-123.
61. Escudero D, Valentín MO, Escalante JL, Sanmartín A, Perez-Basterrechea M, de Gea J, et al. Intensive care practices in brain death diagnosis and organ donation. Anaesthesia 2015;70:1130-9.
62. Fridell JA, Mangus RS, Taber TE, Goble ML, Milgrom ML, Good J, et al. Growth of a nation part I: impact of organ donor obesity on whole-organ pancreas transplantation. Clin Transplant 2011;25:E225-32.
63. Axelrod DA, Sung RS, Meyer KH, Wolfe RA, Kaufman DB. Systematic evaluation of pancreas allograft quality, outcomes and geographic variation in utilization. Am J Transplant 2010;10:837-45.
64. Kootstra G, Daemen JH, Oomen AP. Categories of non-heartbeating donors. Transplant Proc 1995;27:2893–4.
65. Giannini A, Abelli M, Azzoni G, Biancofiore G, Citterio F, Geraci P, et al. "Why can't I give you my organs after my heart has stopped beating?" An overview of the main clinical, organisational, ethical and legal issues concerning organ donation after circulatory death in Italy. Minerva Anestesiol 2016;82:359-68.
66. Boggi U, Del Chiaro M, Vistoli F, Signori S, Vanadia Bartolo T, Gremmo F, et al. Pancreas transplantation from marginal donors. Transplant Proc 2004;36:566-8.
67. World Pancreas Transplant Covid-19 Collaborative Group. Impact of SARS-CoV-2 on pancreas transplant activity: survey of international surgeons. Br J Surg. 2021 Apr 5;108(3):e109-e110. doi: 10.1093/bjs/znaa105.
68. Barros N, Sharfuddin AA, Powelson J, et al. Rabbit anti-thymocyte globulin administration to treat rejection in simultaneous pancreas and kidney transplant recipients with recent COVID-19 infection. Clin Transplant. 2021;35:e14149.
69. Babel N, Anft M, Blazquez-Navarro A, et al. Immune monitoring facilitates the clinical decision in multifocal COVID-19 of a pancreas-kidney transplant patient. Am J Transplant. 2020;20:3210-3215.
70. Dube GK, Husain SA, McCune KR, et al. COVID-19 in pancreas transplant recipients. Transpl Infect Dis. 2020;22:e13359.
71. Kates OS, Haydel BM, Florman SS, et al; UW COVID-19 SOT Study Team. COVID-19 in solid organ transplant: A multi-center cohort study. Clin Infect Dis. 2020:ciaa1097.
72. Mamode N, Ahmed Z, Jones G, et al. Mortality rates in transplant recipients and transplantation candidates in a high-prevalence COVID-19 environment. Transplantation. 2021;105:212-215.
73. Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, et al.; Spanish Group for the Study of COVID-19 in Transplant Recipients. COVID-19 in transplant recipients: The Spanish experience. Am J Transplant. 2021;21:1825-1837.
74. Vistoli F, Kauffmann EF, Boggi U. Pancreas transplantation. Curr Opin Organ Transplant. 2021 Aug 1;26(4):381-389. doi: 10.1097/MOT.0000000000000900.
75. Qureshi MS, Callaghan CJ, Bradley JA, Watson CJ, Pettigrew GJ. Outcomes of simultaneous pancreas-kidney transplantation from brain-dead and controlled circulatory death donors. Br J Surg 2012;99:831-8.
76. Van Loo ES, Krikke C, Hofker HS, Berger SP, Leuvenink HG, Pol RA. Outcome of pancreas transplantation from donation after circulatory death compared to donation after brain death. Pancreatology 2017;17:13-18.
77. Muthusamy AS, Mumford L, Hudson A, Fuggle SV, Friend PJ. Pancreas transplantation from donors after circulatory death from the United Kingdom. Am J Transplant 2012;12:2150-6.
78. Shahrestani S, Webster AC, Lam VW, Yuen L, Ryan B, Pleass HC, et al. Outcomes from pancreatic transplantation in donation after cardiac death: a systematic review and meta-analysis. Transplantation 2017;101:122-130.
79. Stratta RJ, Farney AC, Rogers J, Orlando G. Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective. Expert Rev Clin Immunol 2014;10:117-32.
80. Boggi U, Vistoli F, Del Chiaro M, Signori S, Pietrabissa A, Costa A, et al. A simplified technique for the en bloc procurement of abdominal organs that is suitable for pancreas and small-bowel transplantation. Surgery 2004;135:629-41.
81. Humar A, Kandaswamy R, Drangstveit MB, Parr E, Gruessner AG, Sutherland DE. Prolonged preservation increases surgical complications after pancreas transplants. Surgery 2000;127:545-51.
82. Vrakas G, Arantes RM, Gerlach U, Reddy S, Friend P, Vaidya A. Solitary pancreas transplantation: a review of the UK experience over a period of 10 yr. Clin Transplant 2015;29:1195-202.
83. Parsons RF, Guarrera JV. Preservation solutions for static cold storage of abdominal allografts: which is best? Curr Opin Organ Transplant 2014;19:100-7.
84. Boggi U, Vistoli F, Del Chiaro M, Signori S, Croce C, Pietrabissa A, et al. Pancreas preservation with University of Wisconsin and Celsior solutions: a single-center, prospective, randomized pilot study. Transplantation 2004;77:1186-90.
85. Fridell JA, Mangus RS, Powelson JA. Histidine-tryptophan-ketoglutarate for pancreas allograft preservation: the Indiana University experience. Am J Transplant 2010;10:1284-9.
86. Alonso D, Dunn TB, Rigley T, Skorupa JY, Schriner ME, Wrenshall LE, et al. Increased pancreatitis in allografts flushed with histidine-tryptophan-ketoglutarate solution: a cautionary tale. Am J Transplant 2008;8:1942-5.
87. Chedid MF, Grezzana-Filho TJ, Montenegro RM, Leipnitz I, Hadi RA, Chedid AD, et al. First report of human pancreas transplantation using IGL-1 preservation solution: a case series. Transplantation 2016;100:e46-7.
88. Kuan KG, Wee MN, Chung WY, Kumar R, Mees ST, Dennison A, et al. Extracorporeal machine perfusion of the pancreas: technical aspects and its clinical implications--a systematic review of experimental models. Transplant Rev (Orlando) 2016;30:31-47.
89. Demartines N, Schiesser M, Clavien PA. An evidence-based analysis of simultaneous pancreas-kidney and pancres transplantation alone. Am J Transplant 2005;5:2688-97.
90. El-Hennawy H, Stratta RJ, Smith F.Exocrine drainage in vascularized pancreas transplantation in the new millennium. World J Transplant 2016;6:255-71.
91. De Roover A, Coimbra C, Detry O, Van Kemseke C, Squifflet JP, Honore P, et al. Pancreas graft drainage in recipient duodenum: preliminary experience. Transplantation 2007;84:795-7.
92. De Roover A, Detry O, Coimbra C, Squifflet J-P, Honoré P, Meurisse M. Exocrine pancreas graft drainage in recipient duodenum through side-to-side duodeno-duodenostomy. Transpl Int 2008;21:707.
93. Hummel R, Langer M, Wolters HH, Senninger N, Brockmann JG. Exocrine drainage into the duodenum: a novel technique for pancreas transplantation. Transpl Int 2008;21:178-81.
94. Gunasekaran G, Wee A, Rabets J, Winans C, Krishnamurthi V. Duodenoduodenostomy in pancreas Transplantation. Clin Transplant 2012;26:550-7.
95. Shokouh-Amiri H, Zakhary JM, Zibari GB. A novel technique of portal-endocrine and gastric-exocrine drainage in pancreatic transplantation. J Am Coll Surg 2011;212:730-9.
96. Petruzzo P, Laville M, Badet L, Lefrançois N, Bin-Dorel S, Chapuis F, et al. Effect of venous drainage site on insulin action after simultaneous pancreas-kidney transplantation. Transplantation 2004;77:1875-9.
97. Nghiem DD, Corry RJ. Technique of simultaneous renal pancreatoduodenal transplantation with urinary drainage of pancreatic secretion. Am J Surg 1987;153:405-6.
98. Boggi U, Signori S, Vistoli F, D'Imporzano S, Amorese G, Consani G, et al. Laparoscopic robot-assisted pancreas transplantation: first world experience. Transplantation 2012;93:201-6.
99. Boggi U, Signori S, Vistoli F, Amorese G, Consani G, De Lio N, et al. Current perspectives on laparoscopic robot-assisted pancreas and pancreas-kidney transplantation. Rev Diabet Stud 2011;8:28-34.
100. Yeh CC, Spaggiari M, Tzvetanov I, Oberholzer J. Robotic pancreas transplantation in a type 1 diabetic patient with morbid obesity: A case report. Medicine (Baltimore) 2017;96(6):e5847.
101. Amorese G, Lombardo C, Tudisco A, Iacopi S, Menonna F, Marchetti P, Vistoli F, Boggi U. Induction and Immunosuppressive Management of Pancreas Transplant Recipients. Curr Pharm Des. 2020;26(28):3425-3439
102. Boggi U, Vistoli F, Marchetti P, Kandaswamy R, Berney T; World Consensus Group on Pancreas Transplantation. First World Consensus Conference on Pancreas Transplantation: Part I - methods and results of literature search. Am J Transplant. 2021 Jul 9. doi: 10.1111/ajt.16738.
103. Boggi U, Vistoli F, Andres A, Arbogast H, Badet L, Baronti W, Bartlett ST, Benedetti E, Branchereau J, W Rd Burke G, Buron F, Caldara R, Cardillo M, Casanova D, Cipriani F, Cooper M, Cupisti A, Davide J, Drachenberg C, de Koning EJ, Ettorre GM, Fernandez Cruz L, Fridell J, Friend PJ, Furian L, Gaber O, Gruessner AC, Gruessner RW, Gunton J, Han DJ, Iacopi S, Kauffmann EF, Kaufman D, Kenmochi T, Khambalia HA, Lai Q, Langer RM, Maffi P, Marselli L, Menichetti F, Miccoli M, Mittal S, Morelon E, Napoli N, Neri F, Oberholzer J, Odorico J, Öllinger R, Oniscu G, Orlando G, Ortenzi M, Perosa M, Perrone VG, Pleass H, Redfield RR, Ricci C, Rigotti P, Robertson PR, Ross L, Rossi M, Saudek F, Scalea J, Schenker P, Secchi A, Socci C, Sousa Silva D, Squifflet JP, Stock P, Stratta R, Terrenzio C, Uva P, Watson C, White SA, Marchetti P, Kandaswamy R, Berney T. First World Consensus Conference on Pancreas Transplantation: Part II - recommendations. Am J Transplant. 2021 Jul 10. doi: 10.1111/ajt.16750.
104. OPTN/SRTR Annual Data Report 2010/Pancreas p 34-52.
105. Heilman RL, Mazur MJ, Reddy KS. Immunosuppression in simultaneous pancreas-kidney transplantation: progress to date. Drugs 2010;70:793-804.
106. Singh RP, Stratta RJ. Advances in immunosuppression for pancreas transplantation. Curr Opin Organ Transplant 2008;13:79-84.
107. Matias P, Araujo MR, Romao JE, Abensur H, Noronha IL. Conversion to sirolimus in kidney-pancreas and pancreas transplantation. Transplant Proc 2008;40:3601-5.
108. Cantarovich D, Vistoli F. Minimization protocols in pancreas transplantation. Transpl Int 2009;22:61-8.
109. Fridell JA, Agarwal A, Powelson JA, Goggins WC, Milgrom M, Pescovitz MD, et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. Transplantation 2006;82:389-92.
110. Cantarovich D, De Amicis S, Akl A, Devys A, Vistoli F, Karam G, et al. Posttransplant donor-specific- anti-HLA antibodies negatively impact pancreas transplantation outcome. Am J Transplant 2011;11:2737-46.
111. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med 2016;374:333–43.
112. Mujtaba MA, Sharfuddin AA, Taber T, Chen J, Phillips CL, Goble M, et al. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. Am J Transplant 2014;14:2657-61.
113. Banga N, Hadjianastassiou VG, Mamode N, Calder F, Olsburgh J, Drage M, et al. Outcome of surgical complications following simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2012;27:1658-63.
114. Fridell JA, Johnson MS, Goggins WC, Beduschi T, Mujtaba MA, Goble ML, et al. Vascular catastrophes following pancreas transplantation: an evolution in strategy at a single center. Clin Transplant 2012;26:164-72.
115. Girman P, Lipar K, KocikM, Kriz J, Marada T, Saudek F. Neoplasm incidence in simultaneous pancreas and kidney transplantation: a single-center analysis. Transplant Proc 2011;43:3288-91.
116. Caillard S, Lamy FX, Quelen C, Dantal J, Lebranchu Y, Lang P, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 2012;12:682-93.
117. Issa N, Amer H, Dean PG, Kremers WK, Kudva YC, Rostambeigi N, et al. Posttransplant lymphoproliferative disorder following pancreas transplantation. Am J Transplant 2009;9:1894-902.
118. Gruessner AC, Gruessner RW. Pancreas transplant outcomes for United States and non United States cases as reported to the United Network for Organ Sharing and the International Pancreas Transplant Registry as of December 2011. Clin Transpl 2012:23-40.
119. Smets YF, Westendorp RG, van der Pijl JW, de Charro FT, Ringers J, de Fijter JW, et al. Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type 1 diabetes mellitus and end-stage renal failure. Lancet. 1999;353(9168):1915-9.
120. Becker BN, Brazy PC, Becker YT, Odorico JS, Pintar TJ, Collins BH, Pirsch JD, et al. Simultaneous pancreas-kidney transplantation reduces excess mortality in type-1 diabetic patients with end-stage renal disease. Kidney Int 2000;57:2129-35.
121. Reddy KS, Stablein D, Taranto S, Stratta RJ, Johnston TD, Waid TH, et al. Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure. Am J Kidney Dis 2003;41:464-70.
122. Kleinclauss F, Fauda M, Sutherland DE, Kleinclauss C, Gruessner RW, Matas AJ, et al. Pancreas after living donor kidney transplants in diabetic patients: impact on long-term kidney graft function. Clin Transplant 2009;23:437-46.
123. 54. Gruessner RW, Sutherland DE, Gruessner AC. Mortality assessment for pancreas transplants. Am J Transplant 2004;4:2018-26
124. Boggi U, Amorese G, Occhipinti M, Marchetti P. Transplantation of the pancreas. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-2014 Oct 6.
125. Oberholzer J, Tzvetanov G, Benedetti E. Surgical complication of pancreas transplantation. In: Hakim NS, Stratta RJ, Gray D, Friend P, Colman A, editors. Pancreas, islet, and stem cell transplantation for diabetes. New York: Oxford University Press; 2010. p. 179-89.
126. Troxell ML, Koslin DB, Norman D, Rayill S, Mittalhenkle A. Pancreas allograft rejection: analysis of concurrent renal allograft biopsies and posttherapy follow-up biopsies. Transplantation 2010;90:75-84.
127. Burke GW 3rd, Vendrame F, Pileggi A, Ciancio G, Reijonen H, Pugliese A. Recurrence of autoimmunity following pancreas transplantation. Curr Diabet Rep 2011;11:413-9.
128. Occhipinti M, Lampasona V, Vistoli F, Bazzigaluppi E, Scavini M, Boggi U, et al. Zinc transporter 8 autoantibodies increase the predictive value of islet autoantibodies for function loss of technically successful solitary pancreas transplant. Transplantation 2011;92:674-7.
129. Shapiro R, Jordan ML, Scantlebury VP, Vivas CA, Jain A, McCauley J, et al. Renal allograft rejection with normal renal function in simultaneous kidney/pancreas recipients: does dissynchronous rejection really exist? Transplantation 2000;69:440-1.
130. Drachemberg CB, Torrealba JR, Nankivell BJ, Rangel EB, Bajema IM, Kim DU, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated banff grading schema. Am J Transplant 2011;11:1792-802.
131. Sutherland DE, Sibley R, Xu XZ, Michael A, Srikanta AM, Taub F, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Phys 1984;97:80-7.
132. Gruessner RW, Gruessner AC. The current state of pancreas transplantation. Nat Rev Endocrinol 2013;9:555-62.
133. Nishimura R , LaPorte RE, Dorman JS, Tajima N, Becker D, Orchard TJ. Mortality trends in type 1 diabetes. The Allegheny County (Pennsylvania) Registry 1965-1999. Diabetes Care 2001;24:823-7.
134. Dagogo-Jack S Hypoglycemia in type 1 diabetes mellitus: pathophysiology and prevention. Treat Endocrinol 2004;3:91–103.
135. Diem,J B Redmon, M Abid, A Moran, D E Sutherland, J B Halter, et al. Glucagon, catecholamine and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts.J Clin Invest 1990; 86:2008–13.
136. Paty BW, Lanz K, Kendall DM, Sutherland DE, Robertson RP. Restored hypoglycemic counterregulation is stable in successful pancreas transplant recipients for up to 19 years after transplantation. Transplantation 2001;72:1103-7.
137. Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry. Diabetes Care 2010;33:2573-9.
138. Scheider A, Meyer-Schwickerath E, Nusser J, Land W, Landgraf R. Diabetic retinopathy and pancreas transplantation: a 3-year follow-up. Diabetologia 1991;34:S95-6.
139. Zech JC, Trepsat D, Gain-Gueugnon M, Lefrancois N, Martin X, Dubernard JM. Ophthalmological follow-up of type 1 (insulin dependent) diabetic patients after kidney and pancreas transplantation. Diabetologia 1991;34 (Suppl 1):S89-91.
140. De Sá JR, Monteagudo PT, Rangel EB, Melaragno CS, Gonzalez AM, Linhares MM, et al. The evolution of diabetic chronic complications after pancreas transplantation. Diabetol Metab Syndr 2009; 1: 11.
141. Kim YJ, Shin S, Han DJ, Kim YH, Lee JY, Yoon YH, Kim JG. Long-term Effects of Pancreas Transplantation on Diabetic Retinopathy and Incidence and Predictive Risk Factors for Early Worsening. Transplantation. 2018 Jan;102(1): e30-e38
142. Voglová B, Hladíková Z, Nemétová L, Zahradnická M, Kesslerová K, Sosna T, Lipár K, Kožnarová R, Girman P, Saudek F. Early worsening of diabetic retinopathy after simultaneous pancreas and kidney transplantation-Myth or reality?. Am J Transplant. 2020 Oct;20(10): 2832-2841
143. Jenssen T, Hartmann A, Birkeland KI. Long-term diabetes complications after pancreas transplantation. Curr Opin Organ Transplant. 2017 Aug;22(4): 382-388.
144. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014;37:2864–2883
145. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987;59(8):750-5.
146. Rosolowsky ET, Skupien J, Smiles AM, Niewczas M, Roshan B, Stanton R, Eckfeldt JH, Warram JH, Krolewski ASl. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol. 2011;22(3):545-3
147. Morath C, Zeier M, Dohler B, Schmidt J, Nawroth PP, Schwenger V, et al. Transplantation of the type 1 diabetic patient: the long-term benefit of a functioning pancreas allograft. Clin J Am Soc Nephrol 2010;5(3):549–52.
148. Lindahl JP, Hartmann A, Horneland R, Holdaas H, Reisaeter AV, Midtvedt K, et al. Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease. Diabetologia 2013;56(6):1364–71
149. Lindahl JP, Jenssen T, Hartmann A. Long-term outcomes after organ transplantation in diabetic end-stage renal disease. Diabetes Res Clin Pract. 2014;105(1):14-21
150. Fiorina P, Venturini M, Folli F, Losio C, Maffi P, Placidi C, La Rosa S, Orsenigo E, Socci C, Capella C, Del Maschio A, Secchi A. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care. 2005;28(6):1303-10.
151. Lindahl JP, Reinholt FP, Eide IA, Hartmann A, Midtvedt K, Holdaas H, Dorg LT, Reine TM, Kolset SO, Horneland R, Øyen O, Brabrand K, Jenssen T. In patients with type 1 diabetes simultaneous pancreas and kidney transplantation preserves long-term kidney graft ultrastructure and function better than transplantation of kidney alone. Diabetologia. 2014 Nov;57(11):2357-65.
152. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931-40
153. Fioretto P, Najafian B, Sutherland DE, Mauer M. Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients. Clin J Am Soc Nephrol. 2011;6(1):101-6
154. Scalea JR, Butler CC, Munivenkatappa RB, Nogueira JM, Campos L, Haririan A, Barth RN, Philosophe B, Bartlett ST, Cooper M. Pancreas transplant alone as an independent risk factor for the development of renal failure: a retrospective study. Transplantation. 2008;86(12):1789-94
155. Gruessner RW, Sutherland DE, Kandaswamy R, Gruessner AC. Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. Transplantation. 2008;85(1):42-7
156. Chatzizacharias NA, Vaidya A, Sinha S, Smith R, Jones G, Sharples E, Friend PJ. Renal function in type 1 diabetics one year after successful pancreas transplantation. Clin Transplant. 2011;25(5):e509-15
157. Genzini T, Marchini GS, Chang AJ, Antunes I, Hayashi A, Abensur H, Kataoka L, Crescentini F, Romão JE Jr, Rangel EB, Perosa M. Influence of pancreas transplantation alone on native renal function. Transplant Proc. 2006;38(6):1939-40
158. Fioretto P, Caramori ML, Mauer M. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia. 2008;51(8):1347-55
159. Steinke JM. The natural progression of kidney injury in young type 1 diabetic patients. Curr Diab Rep. 2009;9(6):473-9
160. Fornoni A. Proteinuria, the podocyte, and insulin resistance. N Engl J Med. 2010;363(21):2068-69
161. Fioretto P, Mauer SM, Bilious RW, Goetz FC, Sutherland DE, Steffes MW. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet. 1993;342(8881):1193-6
162. Abouna GM, Al-Adnani MS, Kremer GD, Kumar SA, Daddah SK, Kusma G. Reversal of diabetic nephropathy in human cadaveric kidneys after transplantation into nondiabetic recipients. Lancet. 1983;2(8362):1274-6
163. Abouna GM, Adnani MS, Kumar MS, Samhan SA. Fate of transplanted kidneys with diabetic nephropathy. Lancet. 1986;1(8481):622-3
164. Mohan S, Tanriover B, Ali N, Crew RJ, Dube GK, Radhakrishnan J, Hardy MA, Ratner LE, McClellan W, Cohen D. Availability, utilization and outcomes of deceased diabetic donor kidneys: analysis based on the UNOS registry. Am J Transplant. 2012;12(8):2098-105
165. Singh SK, Kim SJ, Smail N, Schiff J, Paraskevas S, Cantarovich M. Outcomes of Recipients With Pancreas Transplant Alone Who Develop End-Stage Renal Disease. Am J Transplant. 2016;16(2):535-40
166. Boucek P. Advanced diabetic neuropathy: a point of no return? Rev Diabet Stud. 2006;3(3):143-50
167. Shakher J, Stevens MJ. Update on the management of diabetic polyneuropathies. Diabetes Metab Syndr Obes. 2011;4:289-305
168. Kennedy WR, Navarro X, Goetz FC, Sutherland DE, Najarian JS. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med. 1990;322(15):1031-7
169. Hathaway DK, Abell T, Cardoso S, Hartwig MS, el Gebely S, Gaber AO. Improvement in autonomic and gastric function following pancreas-kidney versus kidney-alone transplantation and the correlation with quality of life. Transplantation. 1994;57(6):816-22
170. Allen RD, Al Harbi IS, Morris JG, Clouston PD, O'Connell PJ, Chapman JR, Nankivell BJ. Diabetic neuropathy after pancreas transplantation: determinants of recovery. Transplantation. 1997;63(6):830-8
171. Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol. 1997;42(5):727-36
172. Martinenghi S, Comi G, Galardi G, Di Carlo V, Pozza G, Secchi A. Amelioration of nerve conduction velocity following simultaneous kidney/pancreas transplantation is due to the glycemic control provided by the pancreas. Diabetologia. 1997;40(9):1110-2
173. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281-9
174. Cashion AK, Hathaway DK, Milstead EJ, Reed L, Gaber AO. Changes in patterns of 24-hr heart rate variability after kidney and kidney-pancreas transplant. Transplantation. 1999;68(12):1846-50
175. Boucek P, Saudek F, Adamec M, Janousek L, Koznarova R, Havrdova T, Skibova J. Spectral analysis of heart rate variation following simultaneous pancreas and kidney transplantation. Transplant Proc. 2003;35(4):1494-8
176. Beggs JL, Johnson PC, Olafsen AG, Cleary CP, Watkins CJ, Targovnik JH. Signs of nerve regeneration and repair following pancreas transplantation in an insulin-dependent diabetic with neuropathy. Clin Transplant. 1990;4:133-41
177. Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology. 1996;47(4):1042-8
178. Beiswenger KK, Calcutt NA, Mizisin AP. Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem. 2008;110(5):351-62
179. Nolano M, Provitera V, Caporaso G, Stancanelli A, Vitale DF, Santoro L. Quantification of pilomotor nerves: a new tool to evaluate autonomic involvement in diabetes. Neurology. 2010;75(12):1089-97
180. Selim MM, Wendelschafer-Crabb G, Redmon JB, Khoruts A, Hodges JS, Koch K, Walk D, Kennedy WR. Gastric mucosal nerve density: a biomarker for diabetic autonomic neuropathy? Neurology. 2010;75(12):973-81
181. Boucek P, Havrdova T, Voska L, Lodererova A, Saudek F, Lipar K, Janousek L, Adamec M, Sommer Cl. Severe depletion of intraepidermal nerve fibers in skin biopsies of pancreas transplant recipients. Transplant Proc. 2005;37(8):3574-5
182. Boucek P, Havrdova T, Voska L, Lodererova A, He L, Saudek F, Lipar K, Adamec M, Sommer C. Epidermal innervation in type 1 diabetic patients: a 2.5-year prospective study after simultaneous pancreas/kidney transplantation. Diabetes Care. 2008;31(8):1611-2
183. Malik RA, Kallinikos P, Abbott CA, van Schie CH, Morgan P, Efron N, Boulton AJ. Corneal confocal microscopy: a noninvasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia. 2003;46(5):683-8
184. Tavakoli M, Hossain P, Malik RA. Clinical applications of corneal confocal microscopy. Clin Ophthalmol. 2008;2(2):435-45
185. Argente-Pla M, Pérez-Lázaro A, Martinez-Millana A, Del Olmo-García MI, Espí-Reig J, Beneyto-Castello I, López-Andújar R, Merino-Torres JF. Simultaneous Pancreas Kidney Transplantation Improves Cardiovascular Autonomic Neuropathy with Improved Valsalva Ratio as the Most Precocious Test. J Diabetes Res. 2020 Apr 6;2020:7574628.
186. Sollinger HW, Odorico JS, Becker YT, D'Alessandro AM, Pirsch JD. One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg 2009;250:618-30.
187. Medina-Polo J, Domínguez-Esteban M, Morales JM, Pamplona M, Andrés A, Jiménez C, et al. Cardiovascular events after simultaneous pancreas-kidney transplantation. Transplant Proc. 2010;42:2981-3.
188. Näf S, José Ricart M, Recasens M, Astudillo E, Fernández-Cruz L, Esmatjes E. Macrovascular events after kidneypancreas transplantation in type 1 diabetic patients. Transplant Proc 2003;35:2019-20.
189. Fossati N, Meacci L, Amorese G, Bellissima G, Pieri M, Nardi S, et al. Cardiac evaluation for simultaneous pancreas-kidney transplantation and incidence of cardiac perioperative complications: preliminary study. Transplant Proc 2004;36:582-5.
190. Rondinini L, Mariotti R, Cortese B, Rizzo G, Marchetti P, Giannarelli R, et al. Echocardiographic evaluation in type 1 diabetic patients on waiting list for isolated pancreas or kidney-pancreas transplantation. Transplant Proc 2004;36:457-9.
191. Ruparelia N, Bhindi R, Sabharwal N, Mason P, Klucniks A, Sinha S, et al. Myocardial perfusion is a useful screening test for the evaluation of cardiovascular risk in patients undergoing simultaneous pancreas kidney transplantation. Transplant Proc 2011;43:1797-800.
192. La Rocca E, Fiorina P, Di Carlo V, Astorri E, Rossetti C, Lucignani G, et al. Cardiovascular outcomes after kidney–pancreas and kidney–alone transplantation. Kidney Int 2001; 60:1964-71.
193. Fiorina P, La Rocca E, Astorri E, Lucignani G, Rossetti C, Fazio F, et al. Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients. Diabetes Care 2000;23:1804-10.
194. Fiorina P, La Rocca E, Venturini M, Minicucci F, Fermo I, Paroni R, et al. Effects of kidney-pancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes. Diabetes 2001;50:496-501.
195. Biesenbach G, Königsrainer A, Gross C, Margreiter R. Progression of macrovascular diseases is reduced in type 1 diabetic patients after more than 5 years successful combined pancreas-kidney transplantation in comparison to kidney transplantation alone. Transpl Int 2005;18:1054-60.
196. Biesenbach G, Margreiter R, Königsrainer A, Bösmüller C, Janko O, Brücke P. Comparison of progression of macrovascular diseases after kidney or pancreas and kidney transplantation in diabetic patients with end-stage renal disease. Diabetologia 2000;43:231-4.
197. Larsen JL, Ratanasuwan T, Burkman T, Lynch T, Erickson J, Colling C, et al. Carotid intima media thickness is decreased after pancreas transplantation. Transplantation 2002;73:936-40.